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The Wisdom of a Bad Memory
Always remember to forget
The things that made you sad.
But never forget to remember
The things that made you glad.
Always remember to forget
The friends that proved untrue.
But never forget to remember
Those that have stuck by you.
Always remember to forget
The troubles that passed away.
But never forget to remember
The blessings that come each day.
 Anonymous
Aan mijn ouders
Voor Vivian
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1. INTRODUCTION
The term immunity is derived from the Latin word immunitas, which referred to the 
exemption from various civic duties and legal prosecution offered to Roman senators 
during their tenures in offi ce. Since Roman times immunity had been taken to mean 
freedom from infections, which connoted the ability to resist infection. The immune 
system is a complex assemblage of cells and molecules, which allow the body to 
function in a habitat crowded with pathogens.
The immune system can be divided in natural or innate immunity and acquired, 
adaptive or specifi c immunity. This general and crude division is based on the abil-
ity of the adaptive immune system to increase defense mechanisms in magnitude 
and specifi city following exposure to infectious agents, enabling a more rigorous 
immune response after a second infection. The innate immunity differs from adap-
tive immunity as it recognizes a restricted array of structures on a broad range 
of microorganisms, the so-called pathogen-associated molecular patterns. Repeated 
contact with pathogens always results in a constant innate immune reaction, which 
is not amplifi ed.
The ability to vastly counteract a great variety of pathogenic microorganisms is of 
eminent importance for homeostasis. However, profl igate functioning of the immune 
system is disadvantageous under specifi c circumstances. Two situations in which 
excessive immunological response is unwanted are autoimmunity and transplanta-
tion. The inability of the immune system to distinguish self-tissue and self-proteins 
from non-self pathogens (i.e. to maintain of self-tolerance) can result in autoim-
mune disease causing tissue and organ damage. Traditionally, it is assumed that the 
recognition of self-determinants in autoimmune diseases is confi ned to the adaptive 
immune system, ignoring the role of the innate immune system in auto-immunity. 
More recently it has been argued that, in order to initiate an (auto)immune response, 
additional signals generated by the innate immune system (i.e. danger signals) are 
required (1). Evidence is growing that (auto) antigen recognition by the innate im-
mune system, in a certain context, could lead to autoimmunity, either by priming 
or promoting aggressive immune responses. In transplantation, disproportionate im-
mune responses can cause both acute and chronic graft rejection as the adaptive 
immune system may consider the graft hazardous.
The present thesis underscores the current concept of collaboration between the 
innate and adaptive immune system by showing close interactions between both im-
mune systems. This thesis shows that several constituents of the complement system, 
a core component of innate immunity, are highly allied with the adaptive immune 
system. Furthermore the involvement of innate immunity in type 1 diabetes, generally 
accepted as an adaptive immune system-mediated autoimmune disease is addressed.
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In the following paragraphs, a general overview will be given of a specifi c com-
ponent of the innate immune system, the complement system. The most recently 
discovered pathway of the complement system, the lectin pathway and particularly 
its activating molecule mannose binding lectin (MBL) will be discussed in greater 
detail. After having outlined the current view on association between MBL and vari-
ous diseases and disease complications, the role of MBL in transplantation will be 
addressed. Subsequently, the role of the adaptive immune system will be discussed 
in pancreatic islet transplantation. Finally, the aim and content of the studies in this 
thesis will be presented.
2. THE COMPLEMENT SYSTEM
The complement system consists of a variety of functionally linked proteins, includ-
ing complement factors classifi ed as C1 to C9, which act in conjunction and result 
in many effects in humoral immunity and infl ammation. The fi ve principal biologi-
cal functions of the complement system are: 1) complement-mediated cytolysis; 2) 
opsonisation of foreign organisms; 3) activation of infl ammation; 4) clearance of self 
and non-self debris; and 5) amplifi cation of adaptive immunity.
The complement system consists of three pathways, the classical, the alternative 
and the lectin pathway. All pathways are activated differently, however they con-
verge in a shared terminal pathway and result in the same basic effects. The classical 
pathway is activated when the fi rst classical pathway component C1, binds to the 
fragment crystalline (Fc) portion of an immune complex. Activation of the alternative 
pathway occurs when complement factor C3b binds to various activating surfaces, 
like microbial cell walls. Finally the lectin pathway, a recently discovered comple-
ment activation pathway, is triggered when MBL binds to common carbohydrate 
structures of a variety of microorganisms (including bacteria, viruses and fungi) 
(2-6).
Central in the complement system is the complement factor C3. All activated path-
ways result in generation of a C3 convertase, facilitating the proteolytic cleavage of 
complement factor C3 into C3a and C3b. Subsequent binding of C3b to C3 conver-
tase enzymes allow the formation of C5 convertase, enabling proteolytic cleavage of 
the complement factor C5. Upon C5 cleavage, all pathways converge and enter the 
terminal pathway of complement activation, eventually resulting in the formation of 
a so-called membrane attack complex (MAC), a lipid-soluble pore structure which 
causes osmotic lysis of cells (fi gure 1). Cleavage products C3a and C5a are potent 
chemotactic products amplifying infl ammation. C3b facilitates both opsonisation of 
foreign organisms and clearance of immune complexes.
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As the MBL forms a major topic of the present thesis, the lectin pathway will be 
discussed in greater detail in the next section.
3. MANNOSE BINDING LECTIN
THE PLURIPOTENT MOLECULE OF THE INNATE IMMUNE SYSTEM
Mannose binding lectin, also referred to as mannan binding lectin or mannan bind-
ing protein, is believed to be a central player in the innate immune response. The 
fi rst case of an association of MBL defi ciency and infectious disease dates back to 
1968. A small girl, suffering from severe dermatitis, consisting diarrhea and recur-
rent bacterial infections indifferent to antibiotic and steroid therapy, was reported. 
Hematological examination revealed a defect in the phagocytosis of yeast particles 
from Saccharomyces cerevisiae, rice starch and Staphylococcus aureus in polymor-
phonuclear leukocytes. This defect was serum-dependent. Infusion of fresh plasma 
corrected the phagocytic defi ciency. As the same phagocytic defect was observed 
in several direct relatives of the patient, it was concluded that this condition had a 
genetic origin (7).
C3MBL
Membrane Attack Complex
(MAC)
Lectin
pathway
Classical
pathway
Alternative
pathway
C1q
C4b2a
C3H2O
C3bBb
C3b
Opsonisation
Immune complex clearance
Chemotaxis
C5 C6 C7 C8 C9
+C3a C5a
Figure 1: A bird’s eye view of the complement system.
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In order to fully appreciate the implication of MBL in clinical settings, biological 
characteristics of MBL will be discussed prior to focusing on the association of MBL 
with various diseases.
3a. MBL Characteristics
Mannose binding lectin is a C-type serum lectin and is presumed to be produced by 
the liver. MBL is build up out of 96 kDa structural units, which in turn are composed 
of three identical 32 kDa primary subunits. The subunits consist of an N-terminal 
cross-linking region, a collagen-like domain and a C-terminal carbohydrate-recogni-
tion (CRD) domain (8). Circulating MBL is comprised of higher-order oligomeric 
structures, which include dimers, trimers, tetramers, pentamers and hexamers of the 
structural homotrimeric unit. The oligomeric confi guration of the structural units al-
lows the MBL molecule to have multiple CRDs facilitating multivalent ligand binding 
(fi gure 2). Each CRD of MBL is structurally identical and is able to bind a wide range 
of oligosaccharides including N-acetylglucosamine, mannose, N-acetylmannosamine 
and fucose (5). Although the various sugars are bound with different affi nities, the 
cluster-like array of multiple binding sites allows activation of the complement acti-
vation to be most effective. MBL is considered to play its major role in innate defense 
against pathogens, involving recognition of arrays of MBL-binding carbohydrates 
on microbial surfaces. However, more recent studies have shown that MBL is also 
involved in the recognition of self-targets, such as apoptotic and necrotic cells.
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Figure 2: Mannose binding lectin (MBL) structural build-up.
MBL is composed of 32 kDa subunits. The primary subunits combine to form a trimeric MBL structural unit, which in term 
forms high-order oligomers. (ﬁ gure modiﬁ ed from D.P. Eisen and R.M. Minchinton (22)).
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In plasma, MBL is associated with MBL-associated serine proteases (MASP) (9). 
Currently, three MASPs have been identifi ed, MASP-1, MASP-2 and MASP-3 (10-12). 
Although the function of MASP-1 and MASP-3 remains subject to debate, there is a 
general consensus of the role of MASP-2, which is responsible for cleavage of C4 and 
C2, generation of the C3 convertase C4b2a and subsequent complement activation.
Exon 1 of the mbl-2 gene, which is located at chromosome 10, contains three 
known single nucleotide polymorphisms (SNPs) at codons 52 (CGT to TGT; Arg 
→ Cys), referred to as allele 'D', codon 54 (GGC to GAC; Gly → Asp, allele 'B') 
and codon 57 (GGA to GAA; Gly → Glu, allele 'C') (8). All SNPs of exon 1 result in 
altered collagenous regions and as a consequence, interfere with the formation of 
high-order oligomers. This impairment of polymerization causes low serum levels of 
high molecular weight MBL and impaired MBL function. Dependent on ethnicity, the 
allele frequency of variant alleles B, C and D, commonly referred to as O-alleles, may 
be above 40% (wildtype = A/A) (13). In addition to the three SNPs in exon 1, there 
are several other polymorphic sites located in the MBL promoter region, including 
SNPs located at positions -550 (H/L variant), and -221 (X/Y variant), both G to C 
nucleotide substitutions. Furthermore a polymorphic site is located at position +4 of 
the 5'-untranslated portion of the mbl-2 gene (P/Q variant, C→T) (14-16) (fi gure 3). 
The common allele A of exon 1 is associated with the following haplotypes: HYPA, 
~~~      ~~~N CDR] ] ]
Exon 15'UTR
52 54
Promoter
57-221-550
start 
transcription
H/L Y/X A/D A/B A/C
~~~~~~~~~~~~~~~~
~~~~~~~
~~
~~~~~
Non-functional
MBL structural unit
Aberrant MBL subunit
+4
P/Q
Figure 3: Location of single nucleotide polymorphisms located in the promoter and exon 1 of the mbl-2 gene.
Promoter SNPs are located at positions -550 (H/L variant), and -221 (X/Y variant), both G to C nucleotide substitutions. 
Another SNP is located in the 5’-untranslated portion of the MBL gene, at position +4 (P/Q variant). Exon 1 SNPs are located 
at codon 52 (Arg→Cys; allele 'D'), codon 54 (Gly→Asp, allele 'B') and codon 57 (Gly→Glu, allele 'C').
The SNPs of exon 1 result in aberrant formation of MBL subunits, which are unable to form functional MBL structural units 
and high-order oligomers.
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LYPA, LYQA and LXPA with high, high-intermediate, intermediate and low promoter 
activity (17). Although there is great variety of MBL levels between the different hap-
lotypes, it has been advocated in order to ease interpretation, to only show the most 
signifi cant promoter allele in position –221 (X/Y), which is only found in normal 
A haplotype background (YA or XA) exhibiting high and low promoter activity and 
serum MBL levels (14). The structural alleles carry the following haplotypes: LYPB, 
LYQC and HYPD.
3b. MBL and associated diseases
MBL has been studied in a great diversity of diseases. Both decreased and elevated 
serum levels of MBL and different SNPs of the mbl2 gene and its promoter have been 
associated with a variety of diseases, indicating the Jekyll-and-Hyde character of MBL. 
In order to structure the discussion of this double-edged sword phenomenon, in-
volvement of MBL in different diseases will be discussed according to the aetiology.
MBL and infectious diseases
When the adaptive immune response is either immature or compromised, the innate 
immune system constitutes the principle defense against infection. A logical conse-
quence of impaired MBL function would be an enlarged susceptibility to infectious 
disease. The phenomenon of an increased incidence of infectious disease in MBL-
defi cient patients has been shown in pediatric patients and in immune compromised 
patients. However it also has been shown that adult patients with recurrent infec-
tious disease are more likely to have insuffi cient serum MBL levels.
MBL and bacterial infections
Pediatric patients are still in the developmental stage of the adaptive immune system 
and rely to a great extent on their innate immune system to counteract infectious 
pathogens. In support of the theory that MBL has an important protective role in 
early childhood is a British study amongst 266 pediatric patients (mean age 3.5 years) 
suffering from meningococcal disease (18). Showing a clinical association between 
MBL variant alleles and meningococcal disease, the authors of this study suggested 
that genetic variants of MBL gene might account for a third of all meningococcal 
disease cases.
Patients undergoing myeloablative bone marrow transplantation or cytotoxic che-
motherapy are severely immune-compromised. MBL defi ciency has been shown to 
be associated with severe bacterial infections after chemotherapy and major infec-
tions following allogeneic hemopoietic stem cell transplantation (19-21).
In immune-competent Caucasians, it has been suggested that homozygotes for 
MBL exon 1 codon variants could have an increased risk of invasive pneumococcal 
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disease (22; 23). Considering post-operative infections a surgical complication, low 
MBL levels are associated with signifi cantly increased infection rates (24).
In vast contrast to the protective properties of MBL against extracellular bacterial 
infections is the observation that mycobacterial infections (Mycobacterium tuber-
culosis and M. leprae) occur more frequently in patients with increased serum MBL 
levels. Complement-mediated enhanced phagocytosis as a result of opsonization has 
been suggested to facilitate these intracellular infections (25).
MBL and virus infections
MBL has been studied in relation to various viruses. Persistent hepatitis B virus infec-
tion has been reported to be associated with the variant alleles located at codons 52 
and 54 of the MBL gene, responsible for low MBL serum levels (26; 27). Furthermore 
it has been suggested that high MBL serum levels are associated with increased sur-
vival rates among Japanese patients with hepatitis B (28). MBL in hepatitis C has been 
studied to lesser extent and appears to be somewhat contradictive (22; 29-31) .
The role of MBL in HIV infection and progression has been a confl ict of debate 
over the last years. The envelope protein gp120 of the HIV-1 virus is highly glyco-
sylated with N-linked carbohydrates, enabling MBL to bind (32; 33). Although it is 
conceivable that MBL-mediated complement activation could facilitate the immune 
response directed against HIV infection, reports on the effects of MBL on HIV infec-
tion and progression are contradictory.
Although common pediatric virus infection, including RSV and EBV, lack associa-
tion with MBL (34-36), it has been shown that MBL is able to neutralize the infl uenza 
A virus and inhibit the spread of this virus (37; 38).
MBL and autoimmunity
It is generally assumed that the recognition of self-determinants is confi ned to the 
adaptive immune system, neglecting the role of the innate immune system in auto-
immunity. However, evidence is growing that the innate immune system could lead 
to autoimmunity, either by priming or promoting aggressive immune responses (39; 
40). Low MBL serum levels and genetic polymorphisms associated with impaired 
MBL function have been shown to be associated with different autoimmune diseases 
including celiac disease and systemic lupus erythematosis (41; 42). A major current 
pathophysiological concept of autoimmunity is impaired apoptotic cell clearance. 
MBL has been shown to facilitate the clearance of apoptotic cells (43; 44). A result 
of cells going into apoptosis is alteration of membrane carbohydrates leading to 
increased expression of fucose and N-acetyl-glucosamine (45; 46). Redistribution 
or clustering of glycoproteins has been suggested to enable MBL to bind to these 
carbohydrates expressed on apoptotic cells, thereby facilitating clearance (47; 48).
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When studying the association between MBL and Rheumatoid arthritis, it has been 
shown that MBL is able to bind to rheumatoid factor (RF) complexes and as a 
consequence could assist RF clearance by the reticuloendothelial system (49; 50). 
Although several other studies have not yet been able to reproduce these fi ndings 
(51), the observations that MBL insuffi ciency is associated with both elevated IgM RF 
and increased joint erosions, infl ammation and early disease onset are in support of 
the MBL RF clearance theory (52-56). 
MBL and transplantation
Tissue damage and impaired organ function as a result of ischemia/reperfusion (I/R) 
injury still remain enormous predicaments in solid organ transplantation. The hypoxic 
state to which an organ is subjected during organ harvesting, transport and implanta-
tion, result in activation of various immunological events (57-60). The complement 
system plays an important role in mediating tissue injury after oxidative stress. Activa-
tion and deposition of complement on the vascular endothelium following oxidative 
stress has been shown (61-63) and more interestingly, tissue injury after I/R is sig-
nifi cantly reduced by complement inhibition (64; 65). Complement activation via the 
lectin pathway has been shown following oxidative stress, indicating that inhibition 
of MBL could be a novel approach in reducing ischemia/reperfusion damage (66; 
Impaired 
MBL-mediated
Defence
Exogenous
Factor 
(for ex. virus infection)
Beta cell 
damage
Initial 
Tissue
Damage
Hyperglycaemia
Lectin Pathway
Complement  Activation
Aberrant
Glycosylation
Insulitis
1. Genetic
predisposition
3. Diabetic
Complications
2. Immunopathogenesis
MBL mutation
Diabetic
Complications
Figure 4: Theoretical association between MBL and type 1 diabetes.
The genetic predisposition (1) of low MBL serum levels could result in an impaired clearance and inactivation of pathogens 
responsible for beta cell destruction. Contrarily, high MBL serum levels during insulitis could facilitating further beta cell 
damage and fulminant insulitis (2). Finally, aberrantly glycosylated proteins could result in MBL mediated complement 
activation and result in subsequent tissue damage (i.e. diabetic complications) (3).
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67). In support of the involvement of MBL in I/R injury is the fact that MBL-deposi-
tions were observed early after transplantation of ischemically injured kidneys (68). 
Furthermore, it has been suggested that high MBL levels are associated with a more 
severe form of rejection leading to graft loss in kidney transplantation (69).
MBL and diabetes
A major source of mortality and morbidity in diabetes is caused by microvascular com-
plications, as a substantial portion of diabetic patients develop diabetic nephropathy 
and retinopathy. MBL has been associated with diabetic microvasular complications. 
Several studies have shown the association between an increased risk of developing 
renal failure and high MBL producing genotypes in diabetic patients (70-72). The 
involvement of MBL in the pathogenesis of diabetic nephropathy now appears to be 
appreciated, however the exact immunological process remains to be studied (fi gure 
4). Controversially, it has been suggested that high MBL serum levels may predict a 
decreased likelihood of myocardial infarction in diabetic patients (73).
4. ADAPTIVE IMMUNITY IN ISLET TRANSPLANTATION
Type 1 (Insulin Dependent) Diabetes Mellitus (T1D) is an autoimmune disease char-
acterized by the specifi c destruction of beta cells in the pancreas resulting in the 
loss insulin production. The aetiology of T1D is multifactorial, consisting of genetic 
predisposition and environmental factors possibly including a variety of viruses and 
dietary components (74-78). Currently insulin substitution is the most common ther-
apy for patients with T1D. A potential novel therapy for diabetes is transplantation of 
insulin-producing beta-cells of isolated pancreatic islets. Two major immunological 
hurdles have to be tackled in order to obtain successful islet transplantation. As the 
autoimmune response of T1D potentially can destroy the transplanted islets, the 
recurrence of T-cell autoreactivity against islet determinants, needs to be prevented. 
In addition, induction of alloimmunity to donor antigens, has to be inhibited (79-
81). The attractive and recently successful therapy of transplanting pancreatic islets 
in T1D is overshadowed by the need for permanent immune suppression. Without 
the administration of these non-specifi c and potentially harmful immunosuppressive 
drugs, graft failure seems inevitable. Islet transplantation is thus limited to diabetic 
patients already receiving immune suppression for a previous organ transplant, or 
to patients with severe hypoglycemia unawareness or uncontrollable hyperglyce-
mia. The introduction of a new glucocorticoïd-free immunosuppressive regime, the 
so-called Edmonton protocol, has improved the outcome of islet transplantation 
considerably (82). This protocol includes sirolimus, tacrolimus and dacluzimab. All 
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these immunosuppressive drugs share the same basic quality that they all inhibit 
T-cell stimulation and proliferation, identifying once again T-cells as key-players in 
this rejection process (83).
Prediction and prevention of ongoing beta-cell destruction after islet transplanta-
tion, resulting in long-term graft survival is of utmost importance. In order to be able 
to optimise the current islet transplantation, it is essential to study the reaction of 
T-cells to islets. 
5. SCOPE OF THE THESIS
The scope of the current thesis is to obtain insight in immunological aspects of 
transplantation and diabetes. As previously stated, the present thesis underscores the 
current concept collaboration between the innate and adaptive immune system by 
showing close interactions between both immune systems. Mannose binding lectin 
as a major recognition molecule of the lectin pathway and as a key protein of the 
immune system was studied in relation to its functional characteristics. Appreciating 
the Jekyll-and-Hyde character of MBL and the fact that MBL serum levels and func-
tionality are under strict genetic control, MBL was studied under distinct pathologi-
cal conditions. Chapter 2 describes molecular and biological aspects of mannose 
binding lectin and the interaction of MBL with the adaptive immune system. The fi rst 
part focuses on functional characterizion of the lectin pathway of complement. The 
second part discusses the possible compensation of MBL defi ciency by antibodies 
and the classical complement pathway as an example of interaction between adap-
tive and innate immunity. Furthermore, it describes the functional consequences 
of genetic MBL polymorphisms for the activation of the lectin pathway in serum 
of healthy individuals. In the last part of this chapter, lectin pathway complement 
activation via human IgA is described, presenting a novel linkage between innate 
and adaptive immunity. Chapter 3 focuses on the involvement of MBL in autoim-
munity, by studying juvenile type 1 diabetic patients at disease onset. Prior to starting 
the study, it was hypothesized that MBL could be associated with type 1 diabetes 
in three different manners, as shown in fi gure 4. The genetic predisposition of low 
MBL serum levels could result in an impaired clearance and inactivation of patho-
gens responsible for beta cell destruction. Contrarily, high MBL serum levels could 
contribute to complement activation and infl ammation via the recognition of injured 
tissue, facilitating further beta cell damage and aggravating insulitis progression. Fi-
nally, aberrantly glycosylated proteins, as a consequence of the diabetic state, could 
result in MBL-mediated complement activation resulting in subsequent tissue dam-
age in eyes, kidneys and in various vascular structures (i.e. diabetic complications). 
Introduction 21
The last theory has been shown in several different studies during the completion 
of this thesis (70-72; 84). Chapter 4 addresses the role of the liver in production of 
serum MBL and to evaluates the effect of MBL variant alleles on the susceptibility to 
infection after liver transplantation.
Having studied the role of innate immunity in new onset diabetic patients and 
transplantation, chapter 5 focuses on the effect of the adaptive immune system on 
islet transplantation, a novel treatment of type 1 diabetes. The aspects of HLA in-
compatibility in human pancreatic islet transplantation and the subsequent adaptive 
allogeneic immune response are discussed. Finally, the results and conclusions of all 
studies will be summarized and discussed in chapter 6. 
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Functional characterization of the lectin pathway of 
complement in human serum
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ABSTRACT
Mannan-binding lectin (MBL) is a major initiator of the lectin pathway (LP) of com-
plement. Polymorphisms in exon 1 of the MBL gene are associated with impaired 
MBL function and infections. Functional assays to assess the activity of the classical 
pathway (CP) and the alternative pathway of complement in serum are broadly used 
in patient diagnostics. We have now developed a functional LP assay that enables 
the specifi c quantifi cation of autologous MBL-dependent complement activation in 
human serum. 
Complement activation was assessed by ELISA using coated mannan to assess the 
LP and coated IgM to assess the CP. Normal human serum contains IgG, IgA and 
IgM antibodies against mannan, as shown by ELISA. These antibodies are likely to 
induce CP activation. Using C1q-blocking and MBL-blocking mAb, it was confi rmed 
that both the LP and the CP contribute to complement activation by mannan. In 
order to quantify LP activity without interference of the CP, LP activity was measured 
in serum in the presence of C1q-blocking Ab. Activation of serum on coated IgM 
via the CP resulted in a dose-dependent deposition of C1q, C4, C3, and C5b-9. This 
activation and subsequent complement deposition was completely inhibited by the 
C1q-blocking mAb 2204 and by polyclonal Fab anti-C1q Ab. Evaluation of the LP in 
the presence of mAb 2204 showed a strong dose-dependent deposition of C4, C3, 
and C5b-9 using serum from MBL-wildtype (AA) but not MBL-mutant donors (AB 
or BB genotype), indicating that complement activation under these conditions is 
MBL-dependent and C1q-independent. Donors with different MBL genotypes were 
identifi ed using a newly developed oligonucleotide ligation assay for detection of 
MBL exon 1 polymorphisms. 
We describe a novel functional assay that enables quantifi cation of autologous 
complement activation via the LP in full human serum up to the formation of the 
membrane attack complex. This assay offers novel possibilities for patient diagnos-
tics as well as for the study of disease association with the LP.
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INTRODUCTION
Activation of the complement system is an important component of host defense. 
Following infection, triggering of the complement activation cascade via direct bind-
ing of complement components to microbial surfaces may lead to opsonization and 
pathogen elimination via humoral and cellular mechanisms. Furthermore, comple-
ment activation may trigger and amplify the acquired immune system. Until now, 
three different pathways of complement activation have been described, i.e. the 
classical pathway, the alternative pathway, and the lectin pathway. These pathways 
converge at the level of C3, leading to activation of the common terminal comple-
ment pathway and fi nally formation of the membrane attack complex (1; 2). 
Defects in the complement system may lead to a partial or complete blockade of 
the complement activation cascade. Depending on the level of the defect, either the 
induction phase or the effector phase of complement activation may be hampered, 
and the defect may affect more than one pathway. Impaired function of the comple-
ment system may occur due to genetic defects, or due to acquired defi ciencies of 
complement components. Acquired complement defi ciencies may occur due to for-
mation of autoantibodies to complement components or due to excessive comple-
ment consumption (1-3). Genetic complement defi ciencies have been described at 
all levels of the system, i.e., in the classical pathway, in the alternative pathway, in 
the lectin pathway, and in the terminal pathway from C3 to C9 (4). 
Most complement defects are associated with disease, ranging from a relatively 
mild increase in the susceptibility to infections to the occurrence of a severe systemic 
autoimmune syndrome. Furthermore, impaired complement function is associated 
with the occurrence of fl ares in patients with systemic lupus erythematosus (SLE) (1; 
2; 4). Therefore, functional assays to measure complement activity in human serum 
have a clear diagnostic and prognostic value. 
Complement function in serum is mostly measured using hemolytic assays that 
enable the functional assessment of the classical complement pathway and the alter-
native complement pathway, respectively. In these hemolytic assays, the function of 
the complement pathways is expressed as its ability to generate the C5b-9 complex 
upon activation. However, such an assay is currently not available for the evaluation 
of the lectin pathway of complement in serum. 
The lectin pathway of complement (LP) is mainly driven by binding of mannan-
binding lectin (MBL) to one of its carbohydrate ligands (5). Binding will induce 
activation of the MBL-associated serine proteases (MASP) leading to formation of the 
C3 convertase C4b2a (6-8). The MBL-MASP complex, being the recognition complex 
of the LP, has a strong structural and functional similarity to the C1 complex, the 
recognition unit of the classical complement pathway (CP). The C1 complex, consist-
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ing of C1q and the serine proteases C1r and C1s, is mainly activated by binding of 
C1q to immune complexes comprising IgG or IgM, also leading to the generation 
of C4b2a.
The gene encoding human MBL is characterized by a high degree of polymor-
phisms, both in the promoter region and in exon 1 (9). In the promoter region, vari-
ous single nucleotide polymorphisms (SNP) have been described that are involved 
in quantitative gene expression and hence determine the MBL plasma concentration. 
Furthermore, at least fi ve different SNPs have been discovered in exon 1 of the MBL 
gene, encoding the collagenous region of MBL (10-13). At codon 52 (D genotype), 
codon 54 (B genotype) and codon 57 (C genotype), SNPs are frequently present: the 
allele frequency in the Caucasian population is 5% (D allele), 13% (B allele) and 2% 
(C allele), respectively (9). These SNPs induce amino acid substitutions that affect 
the polymerization of the MBL molecule in a dominant way. Accordingly, small-sized 
MBL molecules are generated with impaired functional properties (14-16). 
The presence of MBL-mutant alleles is associated with increased susceptibility to 
infections, mainly in childhood and in immune-compromised individuals (17-20). 
Furthermore, the above-described SNPs confer an increased progression of severe 
chronic diseases such as cystic fi brosis, rheumatoid arthritis, and SLE (21-23). There-
fore, since there is such a high inter-individual variability in expression of (func-
tional) MBL, which is determined by multiple variables, functional assessment of 
LP activity in human serum generates novel and most likely clinically more relevant 
possibilities for risk assessment for individual patients. 
We have now developed an ELISA-based LP assay that enables the functional 
evaluation of successive steps of autologous complement activation in full human 
serum without any interference of the CP. Measurement of the activity of the CP and 
the alternative complement pathway (AP) in a similar ELISA system provides the 
possibility of parallel quantifi cation of all three complement activation pathways in 
patient serum using one assay system. 
MATERIALS AND METHODS
Human materials
Human serum was obtained from 70 healthy adult volunteers and immediately fro-
zen at -80°C in aliquots. Genomic DNA was isolated from heparinized blood as 
described below. Human DNA samples with known MBL gene polymorphisms were 
kindly provided by Dr. P. Garred, (Copenhagen, Denmark). Outdated healthy donor 
plasma was obtained from the Bloodbank Leiden-Haaglanden, Leiden, the Nether-
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lands. From a patient with Waldenström’s macroglobulinemia, plasma was obtained 
that became available after a plasmapheresis treatment. 
Anti-C1q and anti-MBL antibodies
Monoclonal antibodies directed against C1q were produced in mice as described 
before (24). The anti-C1q mAb 2204 (IgG1) is directed against the globular head 
domain of C1q and is able to inhibit the binding of C1q to IgG, as well as C1q-
dependent hemolysis (25). For the purifi cation of mAb 2204, gamma globulins were 
precipitated from ascites using 50% (NH
4
)
2
SO
4
. The precipitate was dialyzed against 
10 mM Tris containing 2 mM EDTA (pH 7.8) and subjected to anion exchange chro-
matography using DEAE-Sephacel (Pharmacia, Uppsala, Sweden). Proteins were 
eluted using a salt gradient and the fractions that showed binding of mouse IgG to 
C1q-coated ELISA plates in the presence of 1 M NaCl were pooled, concentrated, 
dialyzed against PBS and stored at -80°C.
Polyclonal anti-C1q antibodies were produced in rabbits. New Zealand White 
rabbits were immunized (weekly for four weeks) with 180 µg C1q dissolved in 
complete Freunds adjuvant, resulting in antisera with a positive titer on C1q-coated 
ELISA plates beyond 1/25,000. IgG was precipitated from rabbit serum using 40% 
(NH
4
)
2
SO
4
 and purifi ed using DEAE-Sephacel as described above. 
Starting from purifi ed rabbit IgG anti-C1q, Fab fragments were generated using pa-
pain. IgG was dialyzed against 10 mM phosphate buffer containing 10 mM L-cysteine 
and 2 mM EDTA (pH 7.0). Subsequently, mercuripapaine (from Sigma, St. Louis, MO) 
was added (1% w/w of the protein content) followed by incubation for 16 hours 
at 37°C. After dialysis against PBS, the sample was applied to Sepharose-coupled 
protein G (from Pharmacia), and the fall through fractions, containing Fab fragments, 
were pooled, concentrated, and used for experiments. Analysis by non-reducing 
SDS-PAGE showed a prominent band at approximately 45 kD. 
A mouse mAb directed against the lectin domain of human MBL (mAb 3F8) was 
kindly provided by Dr. G.L. Stahl (Harvard Medical School, Boston, Massachusetts, 
USA) (26).
Preparation of human C1q and C1q-depleted serum
Human C1q was isolated from human donor plasma exactly as described previously 
and was stored at -80°C (25). Isolated C1q was able to completely restore the lysis of 
antibody-coated erythrocytes in the presence of C1q-depleted human serum. 
For the preparation of C1q-depleted serum, undiluted normal human EDTA-plasma 
(obtained from a donor with the MBL/AA genotype) was applied on column consist-
ing of rabbit IgG anti-human C1q coupled to Biogel A5 (from Biorad). The column 
was washed using Veronal-buffered saline (VBS; 1.8 mM Na-5,5-diethylbarbital, 
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0.2 mM 5,5-diethylbarbituric acid, 145 mM NaCl) containing 10 mM EDTA. Fractions 
were tested in a C1q-dependent hemolytic assay in the absence or presence of 
purifi ed C1q, as previously described (25). Fractions that showed complete erythro-
cyte lysis in the presence of C1q, but not in the absence of C1q, were pooled and 
concentrated until the original volume. After recalcifi cation, C1q-depleted serum was 
stored at -80°C.
Isolation of human IgM
Plasma containing an IgM paraprotein was dialyzed against 10 mM sodium acetate 
containing 2 mM EDTA (pH 5.0). The precipitated proteins were recovered by cen-
trifugation, dissolved in PBS, dialyzed against Tris/EDTA buffer (10 mM Tris, 2mM 
EDTA, pH 7.8 and conductivity 5.0 mS), and subjected to anion exchange chroma-
tography using DEAE-Sephacel. IgM that eluted in the salt gradient was pooled, 
dialyzed against 10 mM sodium acetate (6.0 mS, pH 7.0) and applied to a CM-C-50 
Sephadex anionic exchange column (from Pharmacia). Following elution with a 
salt gradient, fractions containing IgM were pooled, concentrated, and applied to a 
Superdex 300 gel fi ltration column. Peak fractions containing IgM and free of IgG 
were pooled, concentrated, and stored at -80°C.
Assessment of functional lectin pathway activity by ELISA
Functional activity of the lectin pathway was assessed by ELISA using immobilized 
mannan as a ligand. Mannan was obtained from Sigma (from Saccharomyces Cerevi-
siae; M7504), dissolved in PBS (10 mg/ml) and stored at -20°C. Nunc Maxisorb plates 
(Nunc, Roskilde, Denmark) were coated with mannan (100 µg/ml; 100 µl per well) in 
coating buffer (100 mM Na
2
CO
3
/ NaHCO
3
, pH 9.6), for 16 hours at room temperature 
or for 2 hours at 37°C. After each step, plates were washed three times with PBS 
containing 0.05% Tween 20. All incubation volumes were 100 µl. Residual binding 
sites were blocked by incubation with PBS containing 1% BSA for one hour at 37°C. 
Serum samples were diluted in GVB++ (VBS containing 0.5 mM MgCl
2
, 2 mM CaCl
2
, 
0.05% Tween-20, and 0.1% gelatin; pH 7.5) in the presence of mAb 2204 (20 µg/ml) 
as an inhibitor of C1q, unless otherwise indicated. This mixture was pre-incubated 
for 15 minutes on ice, before addition to the plates. The plates were then sequen-
tially incubated for 1 hour at 4°C and for 1 hour at 37°C, followed by washing. 
Complement binding was detected using mouse mAb conjugated to digoxygenin 
(dig) using digoxygenin-3-O-methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccin-
imide ester (from Boehringer Mannheim, Mannheim, Germany) according to instruc-
tions provided by the manufacturer. Detection of MBL, C1q, C4, C3, and C5b-9 was 
performed using mAb 3E7 (anti-human MBL, kindly provided by Dr. T. Fujita, Fu-
kushima, Japan), mAb 2214 (anti-human C1q), mAb C4-4a (anti-human C4d), RFK22 
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(anti-human C3) and AE11 (anti-human C5b-9, kindly provided by Dr. T.E. Mollnes, 
Oslo, Norway), respectively. Binding of mAb was detected using dig-conjugated 
sheep anti-mouse antibodies (Fab fragments) followed by HRP-conjugated sheep 
anti-dig antibodies (Fab fragments, both from Boehringer Mannheim). All detection 
antibodies were diluted in PBS containing 1% BSA and 0.05% Tween 20. Enzyme 
activity of HRP was detected following incubation with 2,2’-azino-bis(3-ethylbenz-
thiazoline-6-sulfonic acid) (from Sigma; 2.5 mg/ml in 0.1 M Citrate/Na
2
HPO
4
 buffer, 
pH 4.2) in the presence of 0.01% H
2
O
2
, for 30-60 min. at room temperature. The OD 
at 415 nm was measured using a microplate biokinetics reader (EL312e, from Biotek 
Instruments, Winooski, Vermont, USA).
Assessment of functional classical pathway activity by ELISA
The protocol for the functional activity of the classical pathway was similar to the 
protocol for the LP assay, as described above, with important modifi cations. As 
a ligand for CP activation, human IgM was coated at 2 µg/ml. After blocking of 
residual binding sites, serum samples, diluted in GVB++, were added to the plate 
and incubated for 1 hour at 37°C. Complement binding was assessed using dig-con-
jugated mAb directed against C1q, C4, C3, and C5b-9, followed by the detection of 
mAb binding using HRP-conjugated sheep anti-dig antibodies.
Assessment of functional alternative pathway activity by ELISA
The protocol for the functional activity of the alternative pathway was similar to the 
protocol for the LP assay, as described above, with important modifi cations. As a 
ligand for AP activation, LPS was coated at 10 µg/ml. LPS from Salmonella Typhosa 
was obtained from Sigma (L-6386), dissolved in PBS at 1.6 mg/ml and stored at 
-20°C. Plates were blocked using 1% BSA in PBS. Serum samples were diluted in 
GVB/MgEGTA (VBS containing 10 mM EGTA, 5 mM MgCl
2
, 0.05% Tween-20, and 
0.1% gelatin; pH 7.5) and incubated in the plate for 1 hour at 37°C. Complement 
binding was assessed using dig-conjugated mAb directed against C4 and C3, followed 
by the detection of mAb binding using HRP-conjugated sheep anti-dig antibodies.
Quantiﬁ cation of anti-mannan antibodies in human serum
For the quantifi cation of anti-mannan antibodies in human serum, ELISA plates were 
coated with mannan and blocked with 1% BSA in PBS. Serum samples were diluted 
1/100 for detection of IgG anti-mannan Ab, 1/10 for detection of IgA anti-mannan 
Ab, and 1/40 for detection of IgM anti-mannan Ab, respectively, unless otherwise 
indicated. For quantifi cation, pooled human IgG (48 mg/ml IgG), pooled human IgA 
(41 mg/ml IgA), and pooled human IgM (35 mg/ml IgM) were used as a standard for 
detection of IgG, IgA and IgM anti-mannan antibodies, respectively (kindly provided 
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by Biotest Pharma GmbH, Dreieich, Germany). The concentration of anti-mannan 
antibodies in these preparations was arbitrarily set at 1000 U/ml. All samples were 
diluted in PBS containing 0.05% Tween 20 and 1% BSA. Antibody binding was 
detected using biotinylated HB43 (mouse mAb anti-human IgG), biotinylated HB57 
(mouse mAb anti-human IgM) and dig-conjugated 4E8 (mouse mAb anti-human 
IgA), respectively, followed by either HRP-conjugated streptavidin or HRP-conju-
gated sheep anti-dig antibodies (both from Boehringer). 
DNA isolation
Genomic DNA was isolated from heparinized blood according to standard proce-
dures (27). Briefl y, 10 ml blood was diluted with 40 ml EL buffer (erythrocyte lysis 
buffer: 155 mM NH
4
Cl, 10 mM KHCO
3
, 1 mM EDTA, pH 7.4) and incubated on ice for 
20 minutes. After centrifugation (10 minutes at 500 g), the pellet was washed with 25 
ml EL buffer, and resuspended in 3 ml of KL buffer (10 mM Tris, 2mM EDTA, 400 mM 
NaCl, pH 8.4), followed by thoroughly shaking. After addition of 25 µl pronase (20 
mg/ml in water, Boehringer Mannheim, Germany) and 150 µl SDS (20% in water), 
the mixture was incubated in a shaking water bath at 37°C for 18 hours. Finally, the 
DNA was precipitated with ethanol, dissolved in 0.5 ml TE buffer (10 mM Tris, 0.1 
mM EDTA, pH 7.4), heated for 5 minutes at 65°C, and kept at 4°C.
PCR ampliﬁ cation of exon 1 of the MBL gene
Exon 1 of the MBL gene was amplifi ed from genomic DNA by PCR. Starting from 
1 µl of genomic DNA (approximately 0.7 µg), a 40 µl PCR reaction was performed, 
using 0.25 mM dNTP (from Pharmacia Biotech), 0.8 U Amplitaq (from Perkin Elmer, 
Table 1. Oligonucleotides used for MBL genotyping
Oligonucleotide Sequence
PCR forward 5’-ACCCAGATTGTAGGACAGAG-3’
PCR reverse 5’-GTTGTTGTTCTCCTGTCCAG-3’
OLA 52-common 5’-P-CCCATCTTTGCCTGG-bio-3’
OLA 52-wildtype 5’-dig-CCTTGGTGCCATCACG-OH-3’
OLA 52-mutant 5’-dig-CCCTTGGTGCCATCACA-OH-3’
OLA 54-common 5’-P-CATCACGCCCATCTTTG-bio-3’
OLA 54-wildtype 5’-dig-CTTTTCTCCCTTGGTGC-OH-3’
OLA 54-mutant 5’-dig-CCTTTTCTCCCTTGGTGT-OH-3’
OLA 57-common 5’-P-CCTTGGTGCCATCACG-bio-3’
OLA 57-wildtype 5’-dig-TGGTTCCCCCTTTTCTC-OH-3’
OLA 57-mutant 5’-dig-CTGGTTCCCCCTTTTCTT-OH-3’
PCR primers were derived from (9) with slight modiﬁ cations. OLA primers are labelled with either biotin (bio) or digoxygenin (dig). 
All primers were obtained from Eurogentec (Seraing, Belgium).
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Wellesley, MA), and 12.5 pmol of both PCR primers (from Eurogentec, Seraing, Bel-
gium; Table 1) in PCR buffer (10 mM Tris HCl, 50 mM KCl, 2.5 mM MgCl
2
, 0.6 mg/ml 
BSA, pH 8.3). The PCR reaction was performed in a Peltier Thermal Cycler (PTC200, 
from MJ Research, Waltham, MA) using the following program: denaturation for 5 
min at 95°C, followed by 36 cycles of 1 min. 95°C, 1 min. 57°C, and 1 min. 72°C, 
and a fi nal elongation period for 7 min. at 72°C. Evaluation of the PCR products by 
agarose electrophoresis showed one specifi c band of the expected molecular weight 
(679 bp) with an estimated concentration of about 30 ng/µl.
Oligonucleotide Ligation Assay (OLA) for MBL genotyping
For detection of MBL mutant alleles at codon 52, 54, and 57, three different OLA 
protocols were developed. For each OLA, two reactions were performed in parallel, 
using either the wildtype or the mutant primer, both in combination with a common 
primer (Table 1). PCR products were fi rst heated for 5 min at 99°C. The OLA reac-
tion was performed in a 20 µl reaction mixture consisting of 2 µl of PCR product, 
5 pmol common primer, 5 pmol of either the wildtype or the mutant primer (Table 
1), and 1.2 U Taq DNA ligase, using the buffer supplied by the manufacturer (from 
New England Biolabs, Beverly, MA). The following program was run in a PTC 200 
Thermal Cycler: denaturation for 2 min. at 94°C, 10 cycles of 10 sec. 94°C and 3 min. 
60°C, followed by a fi nal incubation of 5 min. at 99°C. For OLA detection of codon 
57 polymorphisms, probe anealing was performed at 54°C instead of 60°C.
For detection of OLA products, ELISA plates were coated with avidin (20 µg/ml, 
from ICN Biomedicals inc., Aurora, Ohio, USA) and aspecifi c binding sites were 
blocked with PBS containing 3% BSA. The OLA reaction mixture was 1/5 diluted in 
PBS containing 1% BSA, added to the plate, and incubated for 1 hour at 37°C. Plates 
were washed and dig-conjugated reaction products were detected using HRP-conju-
gated sheep anti-dig antibodies as described above. 
RESULTS
Anti-mannan antibodies in human serum
Mannan is a major ligand of MBL that can effi ciently activate the LP of comple-
ment. Human serum contains anti-carbohydrate antibodies, probably resulting from 
previous microbial contacts. Such anti-carbohydrate antibodies may bind to mannan 
and the resulting immune complex may contribute to complement activation by 
mannan via activation of the classical complement pathway (28; 29). Mannan-bind-
ing antibodies are clearly detectable in human serum as assessed by ELISA (Fig. 1). 
Incubation of pooled human IgG (Fig. 1A), IgA (Fig. 1B) and IgM (Fig. 1C) on 
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immobilized mannan resulted in a dose-dependent binding of IgG, IgA, and IgM as 
detected by isotype-specifi c mAb. As a control, parallel incubations were performed 
on immobilized BSA, resulting in low or undetectable background binding of pooled 
Ig. Incubation of three sera from healthy donors on mannan-coated plates resulted 
in strong dose-dependent IgG binding in all three sera. In donor 1, IgA and IgM 
anti-mannan Ab were undetectable, serum from donor 2 contained IgG, IgA and IgM 
anti-mannan antibodies, whereas in donor 3 some IgM binding was observed but 
no IgA binding (Fig. 1A-C). Binding of Ig was undetectable following incubation of 
serum on BSA-coated plates (Fig. 1A-C). Quantifi cation of anti-mannan antibodies in 
serum from 70 healthy donors is presented in fi g. 1D. IgG and IgM anti-mannan Ab 
were present in nearly all donors, with a large interindividual variation, whereas IgA 
anti-mannan Ab were detected in 63% of the donors. No signifi cant correlation was 
observed between the three major isotypes of anti-mannan antibodies, or between 
anti-mannan antibodies and MBL concentrations (not shown). 
Figure 1. Anti-mannan-antibodies in human serum. A-C: Diﬀ erent concentrations of pooled immunoglobulin, as indicated, or 
human serum from three diﬀ erent healthy donors were incubated on plates coated with either mannan (closed symbols, solid 
lines) or BSA (open symbols, dashed lines). Binding of IgG (A), IgA (B) or IgM (C) was detected. D: Anti-mannan antibodies of 
the three major Ig classes were quantiﬁ ed in healthy donor serum (N = 70). Solid lines indicate the median concentrations, 
dashed lines indicate the detection limits. 
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Functional characterization of the lectin pathway in the presence of C1q-inhibitory Ab
Both the LP and the CP are calcium-dependent and lead to activation of C4. A dis-
tinction between both pathways can be made by selection of a specifi c ligand that 
induces activation of either the LP or the CP. In view of the presence of anti-mannan 
Ab in human serum, mannan is likely to activate both the LP, via MBL, and the CP, 
via anti-mannan Ab. Therefore, a strategy was developed to inhibit activation of the 
CP in order to allow solely the activation of the LP by immobilized mannan, by using 
inhibitory anti-C1q antibodies.
Anti-C1q antibodies were tested for their ability to inhibit the CP of complement 
using immobilized IgM as a specifi c activator of the CP. Incubation of 1% normal 
human serum (NHS) on immobilized IgM induces deposition of C4, which could be 
dose-dependently inhibited by the anti-C1q mAb 2204, by rabbit IgG anti-C1q anti-
bodies and by Fab fragments prepared from this rabbit anti-C1q antibody prepara-
tion (Fig. 2A). Complete inhibition was reached when the antibodies were applied at 
5 µg/ml. In contrast, rabbit IgG prepared from non-immunized rabbits did not have 
an effect on C4 activation via the CP. These antibodies were tested for their effect 
on complement activation induced by immobilized mannan. Incubation of NHS on 
mannan induced a dose-dependent deposition of C4, with a maximal activation at a 
serum concentration of 1% (Fig. 2B). Addition of a fi xed concentration of mAb 2204, 
Fab anti-C1q fragments, or normal rabbit IgG as a control had a slight inhibitory 
effect on C4 activation. In contrast, rabbit IgG anti-C1q Ab induced complete inhibi-
tion of C4 activation by mannan, most likely due to complement consumption via 
C1q-anti-C1q complexes (Fig. 2B). These data show that C1q-inhibitory antibodies 
can block CP activation completely whereas mannan-induced activation of the LP 
can proceed in a C1q-independent way. 
To further examine the role of C1q in complement activation by mannan and by 
IgM, NHS was depleted of C1q. Depletion of C1q from NHS resulted in a complete 
inhibition of C4 activation by immobilized IgM (Fig. 3A), as previously described 
(30), whereas C4 activation by immobilized mannan was slightly inhibited by de-
pletion of C1q (Fig. 3B). Reconstitution of C1q-depleted serum with purifi ed C1q 
resulted in a complete restoration of C4 activation by IgM (Fig. 3C). In contrast, 
C4 activation by mannan was slightly inhibited by addition of purifi ed C1q to C1q-
depleted serum, possibly due to the presence of an inhibitory protein co-isolated 
with C1q. The contribution of C1q and MBL to C4 activation by IgM and mannan was 
further studied using blocking mAb against C1q and MBL, respectively (Fig. 3D). C4 
activation on IgM-coated plates was completely inhibited by mAb anti-C1q and no 
inhibition occurred with a blocking anti-MBL mAb. In contrast, C4 activation induced 
by mannan was partially inhibited by mAb anti-C1q and strongly inhibited by mAb 
anti-MBL. Complete inhibition of mannan-induced C4 activation was achieved when 
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a combination of mAb anti-C1q and mAb anti-MBL was used (Fig. 3D). Together, 
these data indicate that IgM-mediated activation of C4 is completely dependent on 
C1q and does not involve MBL. In contrast, mannan-induced activation of C4 is 
mainly mediated by the LP but comprises a minor contribution of the CP. The latter 
contribution of the CP can be inhibited by C1q-blocking Ab, thus allowing activation 
of the LP only. 
Complement activation and formation of C5b-9 via the CP and via the LP
The complement activation cascade was further studied using mAb to detect binding 
of specifi c complement components upon their activation via the CP and the LP, 
respectively. Incubation of NHS on immobilized IgM resulted in a dose-dependent 
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Figure 2. The eﬀ ect of C1q inhibitory antibodies on complement activation via the CP and the LP. A: Normal human serum 
(diluted 1/100) was pre-incubated in the presence or absence of diﬀ erent antibody preparations (rabbit IgG anti-C1q, rabbit 
Fab anti-C1q, normal rabbit IgG or mAb 2204 in concentrations as indicated), and added to IgM-coated plates to assess CP 
activation. Activation of C4 was detected. B: Normal human serum in diﬀ erent concentrations was pre-incubated in the 
presence or absence of a ﬁ xed concentration of antibodies (rabbit IgG anti-C1q, rabbit Fab anti-C1q, normal rabbit IgG (10 µg/
ml) or mAb 2204 (20 µg/ml)). Activation of C4 via the LP was assessed following addition of the mixture to mannan-coated 
plates. Results represent mean ± SD from one out of three similar experiments. 
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deposition of C1q, C4, C3, and C5b-9 to the plate (Fig. 4A). Binding of C1q and 
subsequent complement activation induced by IgM could be completely inhibited by 
mAb 2204. Incubation of NHS on immobilized mannan resulted in dose-dependent 
binding of C4, C3 and C5b-9, whereas binding of C1q was hardly detectable (Fig. 
4B). Complement activation by mannan was only slightly inhibited by addition of 
mAb 2204. Therefore, addition of mAb 2204 in serum allows the specifi c detection of 
LP activation using mannan as a ligand, without interference of the CP. 
Activation of the alternative pathway
To enable the detection of all complement activation pathways in one assay system, 
we also studied activation of the alternative pathway in an ELISA system. In contrast 
to the LP and the CP, activation of the AP is calcium-independent. Therefore, a 
calcium-free buffer was used, thus excluding involvement of the CP and the LP. As 
previously described (30), incubation of NHS in a buffer containing EGTA and Mg++ 
on plates coated with LPS resulted in a dose-dependent deposition of C3 (Fig. 5A). 
Figure 3. The role of C1q in activation of the CP and the LP. A, B: Normal human serum or C1q-depleted serum (C1qD-NHS), 
diluted in GVB++, was incubated on plates coated with IgM (A) and mannan (B), respectively, followed by detection of C4 
binding. C: NHS and C1q-depleted NHS (diluted 1/400) were incubated on plates coated with IgM or mannan in the presence 
or absence of puriﬁ ed C1q (0.5 µg/ml), as indicated. D: NHS was incubated on IgM- or mannan-coated plates in the presence 
or absence of blocking mAb directed against MBL (mAb 3F8, 10 µg/ml) or C1q (mAb 2204, 20 µg/ml), or both (combination). 
Results represent mean ± SD from one of at least two experiments
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Figure 4. Complement activation via the LP and the CP. Complement activation was induced by incubation of diﬀ erent 
concentrations of NHS on plates coated with IgM for CP activation (A) or with mannan for LP activation (B), in the presence or 
absence of mAb 2204 (20 µg/ml). Activation and binding of complement was demonstrated by detection of C1q, C4, C3, and 
C5b-9 using speciﬁ c mAb. Results represent mean ± SD from one out of at least three experiments.
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Some activation of C3 was also observed on plates coated with BSA only. Sur-
prisingly, strong activation of C3 was also observed when NHS was incubated on 
mannan-coated plates using the same conditions, suggesting that mannan may also 
support activation of the AP (Fig. 5A). Detection of C3 was reduced until background 
levels when EDTA was present in the complement source (not shown). As expected 
from an AP-dependent mechanism, C3 activation in calcium-free buffers required a 
serum concentration that is about 10-fold higher than that required for C3 activation 
by mannan in a calcium-containing buffer via the LP (compare fi g. 5A with fi g. 4B). 
Although C3 activation was clearly detectable in a calcium-free buffer, no activation 
of C4 could be established (Fig. 5B), suggesting that under these conditions activa-
tion of C3 is independent of MBL binding and C4 activation. 
MBL genotyping by oligonucleotide ligation assay
Single nucleotide polymorphisms in exon 1 of the MBL gene are the most important 
genetic modifi ers of MBL function. We developed three oligonucleotide ligation as-
says (OLA) for the detection of MBL exon 1 SNPs at codon 52, codon 54, and codon 
57, respectively. Using this technique, the presence of B (codon 54), C (codon 57), 
and D alleles (codon 52), as indicated by formation of double-labeled DNA products 
using the mutant oligonucleotides, can be easily detected with a standard laboratory 
equipment, both in homozygous and in heterozygous patterns (Fig. 6). 
Lectin pathway activation is dependent on the MBL genotype
In the Caucasian population, the B allele is the most frequent exon 1 polymorphism 
in the MBL gene. It has been previously reported that recombinant MBL with the 
BB genotype has a strongly reduced ability to support complement activation (14)). 
Figure 5. Activation of the alternative pathway. NHS was incubated on plates coated with mannan, LPS, or BSA, in a calcium-free 
buﬀ er (GVB/MgEGTA) to block activation of the CP and the LP. Binding of C3 (A) and C4 (B) was subsequently assessed. Results are 
shown as the mean ± SD from a representative experiment; similar data were obtained in at least two experiments. 
0
0
1
2
3 Mannan
BSA
1 10 20
LPS
Serum (%)
C
3 
bi
nd
in
g 
(O
D
41
5)
0
0
1
2
3 Mannan
BSA
1 10 20
LPS
Serum (%)
C
4 
bi
nd
in
g 
(O
D
41
5)
A B
44
C
ha
p
te
r 2
.1
Using MBL genotyping by OLA, sera from individuals with different MBL genotypes 
were identifi ed. We compared activity of the CP and the LP in serum obtained from 
an MBL wildtype donor (AA genotype) with serum from donors with a heterozygous 
Figure 6. Detection of MBL mutant alleles by oligonucleotide ligation assay. DNA from individuals with diﬀ erent MBL 
genotypes was used for detection of wildtype or mutant alleles in an OLA for codon 54, codon 57 and codon 52. Results 
are expressed as the OD at 415 nm of the detection of biotin and dig-labeled OLA products upon ligation using either the 
wildtype or the mutant allelic probes, and represent mean ± SD of one out of three experiments performed in duplicate. MBL 
genotypes were conﬁ rmed by DNA sequencing. 
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and a homozygous mutation at codon 54 (AB and BB genotype, respectively). Serum 
from all three donors showed binding of C1q and strong activation of C4, C3 and 
C5b-9 via the CP upon incubation on immobilized IgM, in a similar dose-response 
relationship (Fig. 7A). Upon serum incubation on immobilized mannan, strong dose-
dependent binding of MBL to mannan was observed in AA serum, whereas MBL 
binding in AB serum was about 8-fold less and no binding of MBL to mannan could 
be established in BB serum (Fig. 7B, upper panel). In parallel, LP activity was as-
sessed in the same sera by their incubation on immobilized mannan, in the presence 
of mAb 2204 to block the CP. In sharp contrast to the results obtained on coated 
IgM, only AA serum, but not BB serum nor AB serum, was able to induce detectable 
activation of C4, C3 and C5b-9 via the LP (Fig. 7B). These results indicate that LP 
activity is dependent on the presence of functionally active MBL. 
DISCUSSION
In the present study, we describe a novel assay for the detection of functional activ-
ity of the LP of complement. The assay is based on the detection of various stages 
of complement activation induced by binding of MBL to immobilized mannan, and 
involves the addition of inhibitory anti-C1q antibodies to prevent interference of 
activation of the CP. We demonstrate that in this novel assay system activation of 
autologous C4, C3, and C5b-9 in full human serum is totally dependent on the pres-
ence of functionally active MBL. 
Our results show the broad presence of anti-mannan antibodies in the human pop-
ulation. These antibodies may be produced in response to a previous yeast contact 
and/or may belong to the so-called natural antibodies. Increased levels of antibodies 
binding to mannan from Saccharomyces Cerevisiae have been described in patients 
with infl ammatory bowel disease (31; 32). Certain anti-carbohydrate antibodies can 
be present in extremely high levels, as is the case for antibodies directed against the 
major xenoantigen Galα1-3Gal (33). IgG and IgM anti-carbohydrate antibodies can 
activate the classical complement pathway, and this mechanism is likely to contrib-
ute to anti-microbial defense, in addition to lectin-mediated mechanisms. Indeed it 
has been described that IgG anti-mannan antibodies contribute to opsonization of 
Candida albicans with C3 (34). Such a mechanism may especially be important in 
cases where the function of the lectin pathway of complement is impaired. In our 
study, we were not able to detect any signifi cant difference in levels of anti-mannan 
Ab between MBL-wildtype and MBL-mutant individuals (not shown). 
The presence of highly variable amounts of anti-mannan Ab in human serum 
necessitates a special strategy to prevent involvement of CP activity in mannan-based 
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Figure 7. Lectin pathway activity is impaired in serum from MBL-mutant donors. Serum was obtained from three diﬀ erent 
donors with a wildtype MBL genotype (AA), a heterozygous mutation (AB) or a homozygous mutation (BB) at codon 54, 
respectively. Diﬀ erent concentrations were applied to plates coated with IgM to assess CP activity, in the absence of mAb 2204 
(A), or with mannan to assess LP activity, in the presence of mAb 2204 (B). Deposition of C4, C3, and C5b-9 was assessed. 
Results represent mean ± SD from one out of at least two similar experiments. 
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assays for LP activation. The present study therefore includes a specifi c inhibitor of 
C1q in the assay, which prevents any activation of the CP in serum. Until now, at 
least two other groups reported a functional assay for the MBL pathway activity that 
excluded the interference of the CP. Petersen et al. reported an elegant assay that 
detects the functional activity of the MBL-MASP complex in serum (28). This assay 
is based on the difference between the C1 complex and the MBL-MASP complex 
with respect to its sensitivity to ionic strength. By addition of 1 M NaCl to the serum 
dilution buffer, C1q binding and CP activation can be completely prevented whereas 
MBL binding can proceed. In the assay described by Petersen et al. (28), the se-
rum incubation step is performed at 4 ºC, thus allowing binding of the MBL-MASP 
complex but not the subsequent complement activation. Activity of the complex is 
subsequently assessed by addition of exogenous purifi ed C4. The advantage of this 
technique is that activity of the MBL-MASP complex is directly detected, without any 
interference of other variables in donor serum. The major difference with the tech-
nique as described in the present study is that we now describe a LP assay that as-
sesses activation of autologous complement, which is more representative for the in 
vivo situation. Furthermore, our assay enables the detection of the complete comple-
ment activaton cascade, up to the formation of the membrane attack complex. In this 
respect, our assay is comparable to hemolytic assays (CH50, AP50) generally used 
in clinical practice for the evaluation of CP and AP activity. The functional analysis 
of all three complement activation pathways in parallel by ELISA, as described in 
the present study, is potentially useful in routine diagnostic laboratories for a more 
complete diagnostic evaluation of complement defects.
An alternative functional MBL pathway assay was recently described by Zimmer-
man-Nielsen et al. (35). This assay also includes 1 M NaCl in the incubation buffer, 
but analyzes autologous C4 activation. However, activation of C4 in the presence of 
1M NaCl is highly ineffi cient ((28) and our own unpublished observations), which is 
apparent from the low serum dilutions used in this study. These suboptimal condi-
tions may have a differential effect on C4 activation in serum from various donors, 
and therefore the C4 activation assessed in this respect is diffi cult to interpret. Fur-
thermore, also in this assay it is not possible to assess complement activation at a 
later stage than C4, since formation of C4b2a is strongly dependent on ionic strength 
(36), and accordingly C3 activation is undetectable in 1 M NaCl (our unpublished 
observations).
An alternative approach for the analysis of LP activity in serum is the quantifi cation 
of serum-induced hemolysis of mannan-coated sheep erythrocytes (6; 37). MBL is 
able to bind to these coated erythocytes (37), leading to complement activation and 
erythrocyte lysis. Also in such an hemolytic assay, it is important to prevent interfer-
ence of the classical complement pathway, which may occur both by anti-mannan 
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antibodies and by anti-erythrocyte antibodies. Suankratay et al. described a method 
in which mannan-coated erythrocytes were pre-sensitized with purifi ed MBL, fol-
lowed by incubation with serum in the presence of MgEGTA (37). This hemolytic 
assay analyzes the activity of the lectin pathway of complement most likely from 
C4 until C9, and hence does not provide information about the activity of the MBL-
MASP complex in the serum source. Therefore, this assay can not be used to detect 
a functional impairment of LP activity at the level of MBL. We did not succeed to set 
up an hemolytic assay with mannan-coated erythocytes using full serum and a C1q 
inhibitor, probably due to unsuffi cient sensitivity (data not shown). 
We show in the present study that both C1q and MBL have a contribution in the 
activation of complement by mannan-coated ELISA plates, using inhibitory antibod-
ies directed against C1q and MBL. It is likely that the relative contribution of C1q is 
strongly increased in donor serum containing high levels of IgG and IgM anti-man-
nan antibodies in combination with low levels of functional MBL. In such a situation, 
the contribution of C1q may mask the detection of defi ciency of the LP unless CP 
activation is prevented. Therefore, inhibition of CP is crucial for a reliable functional 
LP assay. 
Different strategies are conceivable for the inhibition of C1q-mediated complement 
activation in human serum. In the present study, we show C1q inhibition with mAb 
2204, an anti-C1q monoclonal antibody that binds to the globular heads of C1q 
and blocks the interaction with immunoglobulins. Furthermore, Fab fragments from 
polyclonal rabbit anti-C1q antibodies, but not complete IgG, can be used to specifi -
cally inhibit CP activation. An alternative option is the use of C1q-inhibitory peptides 
(25). This option is under investigation in our laboratory. 
Our studies indicate that incubation of low serum concentrations on immobilized 
mannan may also activate the alternative pathway. This may involve stabilization of 
spontaneously activated C3, in a complex with activated factor B and properdin, by 
its binding to mannan, in a similar way as is effected with other heavily glycosylated 
microbial products that activate the AP, such as LPS and zymosan. Activation of C3 
in the absence of calcium, as well as the lack of detectable C4 activation, strongly 
suggest an MBL-independent mechanism. Additional studies indicated that binding 
of MBL in the presence of EGTA was undetectable (38). However, we can not totally 
exclude that small amounts of MBL binding under these conditions may trigger 
complement activation, which is subsequently strongly amplifi ed by the alternative 
pathway at the level of C3. Since activation of the AP requires a high serum concen-
tration, it is highly unlikely that similar MBL-independent complement activation is 
involved in the LP activity assay when serum is diluted at least 50-fold. This is clearly 
demonstrated in experiments showing that activation of C4, C3, and C5b-9 was 
completely undetectable in serum from an individual with a homozygous mutation 
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at codon 54 of the MBL-gene (BB genotype), although this serum had an intact AP 
activity. 
Two members of the fi colin family, L-fi colin and H-fi colin (Hakata antigen) have 
been recently shown to interact with MASP proteins, and thereby activate comple-
ment via the lectin pathway (39; 40). Ficolins are multimeric proteins with a carbo-
hydrate-binding fi brinogen-like domain. L-fi colin does not bind to mannan and is 
therefore not likely to be involved in complement activation induced by mannan. 
Both L-fi colin and H-fi colin are present in human serum. At present, there is no 
information available about the activity of fi colin-mediated complement activation 
in full serum. Development of such an assay is dependent on the identifi cation of 
fi colin-specifi c ligands that are able to activate fi colin-MASP complexes. 
The activity of the LP in human serum is determined by a number of variables, 
including the concentration and molecular structure of MBL and MASP proteins, the 
activity of complement proteins from C4 until C9, as well as the presence and activity 
of serum inhibitors of complement activation (41; 42). The assay we now describe 
enables the functional detection of important consequences of LP activation, i.e. 
opsonization of the target with complement components, and formation of the mem-
brane attack complex. Studies using recombinant MBL molecules clearly showed 
that structural mutations of the MBL gene lead to an impaired functional activity 
(14). In agreement with these data, we demonstrate that serum from donors with a 
mutation at codon 54 of the MBL gene (B genotype) has a defect in activation of the 
LP, which is in the homozygous mutant serum accompanied by a apparent failure of 
MBL to bind to the activating ligand mannan. Primarily in heterozygous individuals, 
the consequences of structural mutations may be highly variable, depending on 
the relative expression of the mutated and the wildtype gene. Therefore, functional 
assessment of LP activity most likely provides a more relevant marker for LP defects 
than analysis of mutations in the MBL gene and promoter region. Further studies are 
now underway to examine the relation between the different parameters involved in 
LP function and the resulting LP-mediated complement activation. 
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Antibody-mediated activation of the classical 
pathway of complement may compensate for 
mannose-binding lectin deﬁ ciency
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ABSTRACT
Defi ciency of mannose-binding lectin (MBL), a recognition molecule of the lectin 
pathway of complement, is associated with increased susceptibility to infections. 
The high frequency of MBL defi ciency suggests that defective MBL-mediated innate 
immunity can be compensated by alternative defense strategies. To examine this 
hypothesis, complement activation by MBL-binding ligands was studied.
The results show that the prototypic MBL-ligand mannan can induce complement 
activation via both the lectin pathway and the classical pathway. Furthermore, an-
tibody binding to mannan restored complement activation in MBL-defi cient serum 
in a C1q-dependent manner. Cooperation between the classical pathway and the 
lectin pathway was also observed for complement activation by p60 from Listeria 
monocytogenes. 
MBL pathway analysis at the levels of C4 and C5b-9 in the presence of classical 
pathway inhibition revealed a large variation of MBL pathway activity, depending 
on mbl2 gene polymorphisms. MBL pathway dysfunction in variant allele carriers is 
associated with reduced MBL-ligand binding and a relative increase of low molecular 
weight MBL. 
These fi ndings indicate that antibody-mediated classical pathway activation can 
compensate for impaired target opsonization via the MBL pathway in MBL-defi cient 
individuals and imply that MBL defi ciency may become clinically relevant in absence 
of a concomitant adaptive immune response.
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INTRODUCTION
Recognition of pathogen-associated molecular patterns by molecules of innate im-
munity can lead to direct and early target elimination as well as to antigen presenta-
tion resulting into clearance via adaptive immunity. A number of pattern recognition 
molecules have been identifi ed, such as lectin receptors, Toll-like receptors, and 
soluble opsonins including complement factors. The importance of the comple-
ment system in innate immune defense is clearly illustrated by a number of genetic 
complement defi ciencies described both in humans and mice. 
Activation of the complement cascade can take place via at least three pathways 
identifi ed until now: the classical pathway (CP), the alternative pathway (AP), and 
the lectin pathway (LP). Whereas the LP and the AP primarily use a direct target 
recognition mechanism, the CP is mainly activated via binding of the initiating factor 
C1q to e.g. antigen-bound IgG or IgM antibodies. The LP can be initiated by man-
nose-binding lectin (MBL), which in a calcium-dependent way binds to carbohydrate 
ligands present on a large number of pathogens (reviewed in (1; 2)). Both MBL and 
C1q are composed of trimers that are assembled into larger structures. The collag-
enous domains of C1q and MBL bind to related serine proteases, being the serine 
proteases C1r and C1s for the C1 complex and the MBL-associated proteases MASP-1, 
MASP-2 and/or MASP-3 for the MBL complex (2; 3). Activation of both pathways 
leads to formation of the C3 convertase C4b2a. Recently, two members of the fi colin 
family, i.e. L-fi colin and H-fi colin, have also been shown to bind MASPs and to 
activate the LP of complement (2). In the present study, therefore, MBL-dependent 
activation of the LP is called the MBL pathway (MP). 
Three MBL gene (mbl2) polymorphisms have been identifi ed that are associated 
with MBL defi ciency. These single nucleotide polymorphisms (SNP) are located in 
codon 54 (B genotype), codon 57 (C genotype), and codon 52 (D genotype) of the 
fi rst exon, encoding the collagenous region of the MBL molecule (reviewed in (4; 
5)). Experiments with recombinant MBL confi rmed that these SNP affect the struc-
ture and function of MBL (6-8). Furthermore, SNP in the promoter and untranslated 
region of the mbl2 gene modify the basal serum level of MBL (9). 
MBL defi ciency has been identifi ed as the basis of a common defect in opsonization 
of yeast-derived mannan (10), which is associated with decreased pathogen resistance 
(11; 12), particularly during early childhood (13). Among the complement defi cien-
cies described in humans, defi ciency of MBL has the highest frequency. Depending 
on ethnicity, the total allele frequency of the B, C and D allele may be above 40% 
(9). Since apparently these polymorphisms are not subject to a high negative selec-
tion pressure, it has been proposed that the polymorphisms are associated with host 
protection in certain situations (14). Furthermore, the clinical effect of MBL defi ciency 
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is strongly dependent on the immune status of the individuals tested, and most MBL-
defi cient individuals are apparently healthy. Together, the data suggest that although 
MBL gene polymorphisms do have important functional consequences for activation 
of the MP of complement, most affected persons have alternative mechanisms for 
target recognition to reach a suffi cient level of anti-microbial protection. 
Recently, assays became available that allow detailed functional evaluation of 
the MP, thus allowing a thorough examination into the mechanisms involved in 
complement activation by the prototypic MBL-ligand mannan (15; 16). The present 
study shows that, although the function of the MP of complement activation can 
be strongly hampered by MBL gene polymorphisms, recognition of mannan by the 
complement system may still proceed in an MBL-independent but C1q-dependent 
manner. Similarly, we show that p60, a protein derived from Listeria monocytogenes, 
can activate the complement system via both MBL-dependent and MBL-independent 
mechanisms. 
RESULTS
Both C1q and MBL can support complement activation by mannan in human serum
To characterize the mechanisms of complement activation by mannan in full human 
serum, serum samples from healthy donors who were genotyped for SNP of the 
mbl2 gene were investigated for their capacity to activate C4 by mannan. C4 activa-
tion was observed in all sera examined, with a high inter-individual variability (Fig. 
1A). Activation of C4 in A/B donors was signifi cantly lower than in wildtype (A/A) 
donors (p < 0.01). 
In order to assess complement activation by mannan via the MP only, activation 
of C4 by mannan was assessed in human serum in the presence of a C1q-blocking 
mAb, as recently described (16). The activation of autologous C4 via the MP was 
strongly dependent on the MBL genotype (Fig. 1B, p = 0.0002 in ANOVA), and was 
signifi cantly hampered in A/B donors (p < 0.001) but not in A/D donors, as compared 
to A/A donors (Fig. 1B). 
Initial strong activation of C4 by mannan could in a number of sera be inhibited 
to an undetectable level by inhibition of C1q (compare fi g. 1A with 1B, for example 
donor A/C and donor B/D), indicating a clear contribution of C1q and the CP in 
complement activation by mannan. The relative contribution of C1q is signifi cantly 
higher in sera with low activity of the MP than in sera with high activity of the MP 
(Fig. 1C, ANOVA p < 0.0001).
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The activity of the CP, based on the activation of C4 induced by immobilized IgM 
(16), was high in all donor sera, with a low variation, and no difference between the 
sera of different MBL genotypes (ANOVA: p = 0.87) (Fig. 1D). 
Since activation of C4 by mannan in a number of cases was C1q-dependent, the 
role of anti-mannan antibodies in complement activation by mannan was further 
studied. Serum levels of IgG and IgM anti-mannan antibodies are highly variable (16) 
and did not signifi cantly differ between the MBL genotypes (not shown). Pre-incuba-
tion of mannan-coated plates with purifi ed IgG (Fig. 2A) or IgM (Fig. 2B) induced a 
dose-dependent deposition of C4 on mannan upon addition of MBL-defi cient serum. 
This activation of C4 was completely inhibited by a C1q-inhibitory mAb (Fig. 2), 
clearly indicating that mannan-binding IgG and IgM can restore complement activa-
Figure 1. Complement activation via MBL pathway and classical pathway in human serum. 
A. Activation of C4 by mannan in sera from donors with diﬀ erent MBL genotypes (serum dilutions starting from 1/100). No 
C1q inhibition was applied. Horizontal solid lines indicate the median. ANOVA: p = 0.0066, A/A versus A/B p < 0.01. 
B. MP activity at the level of C4 assessed in the presence of mAb 2204 for C1q inhibition (dilutions starting from 1/100). 
ANOVA: p = 0.0002, A/A versus A/B p < 0.001. The horizontal dashed line indicates the detection limit. 
C. The relative contribution of C1q, expressed as the ratio between the activation of C4 without C1q inhibition (Fig. 1A) and 
with C1q inhibition (Fig. 1B). Values below the detection limit were set at 75 U/ml. The results are shown for 4 quartiles, 
based on MP activity. ANOVA: p < 0.0001.
D. CP activity assessed at the level of C4 (dilutions starting from 1/1500). ANOVA: p = 0.87. 
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tion by mannan in MBL-defi cient serum via activation of the CP, in the absence of 
functional MBL. 
C1q and MBL cooperate in complement activation by p60 of Listeria monocytogenes
Data presented above indicate that mannan, a major yeast antigen, can support acti-
vation of the complement system via both the CP and the MP. To extend these obser-
vations towards another microbial target, we examined activation of the complement 
system by protein p60 from Listeria monocytogenes. Purifi ed human MBL showed a 
strong and dose-dependent binding to p60, which was completely inhibited by D-
mannose but not L-mannose (Fig. 3A), indicating involvement of the lectin domain 
of MBL. Interestingly, also purifi ed C1q showed a strong binding to immobilized p60 
(Fig. 3B) but not to mannan (not shown). Complement activation was further studied 
using two groups of sera that were either suffi cient or defi cient for MP activity. C4 
activation by listerial p60 was signifi cantly higher in MBL-suffi cient sera than in the 
MBL-defi cient sera (Fig. 3C). In the presence of mAb 2204 for C1q inhibition, only 
sera with a functional MP activity showed activation of C4 (Fig. 3C). When C1q is 
inhibited, activation of C4 by p60 is completely blocked by D-mannose, strongly 
suggesting a complete dependence on MBL under these conditions (Fig. 3D). These 
data support an important role for both C1q and MBL in complement activation by 
Listeria p60. 
Together, these results provide evidence for a contribution of the CP to comple-
ment activation by two different ligands for MBL, which can compensate for MBL 
dysfunction. In studies presented below the basis of MP dysfunction is further exam-
ined using MBL-specifi c assays that exclude participation of the CP. 
Figure 2. Cooperation between the classical pathway and the MBL pathway in complement activation by mannan. 
Puriﬁ ed IgG (A) and IgM (B) were incubated on mannan-coated plates followed by incubation with MBL-deﬁ cient serum (B/B 
genotype, 1/100), in the absence or presence of mAb 2204 anti-C1q, and assessment of C4 activation. 
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Factors involved in the variability of MBL pathway activity in serum 
Activation of the MP by mannan was subsequently assessed at its fi nal stage. Forma-
tion of C5b-9 via the MP, as assessed in the presence of a C1q inhibitor, is strongly 
dependent on the MBL genotype (Fig. 4A). A signifi cantly lower activity was ob-
served in A/B donors (p < 0.001) but not in A/D donors, as compared to A/A donors. 
MP-mediated activation of C4 and activation of C5b-9 was strongly correlated (R = 
0.89, P < 0.0001).
Next to MBL exon 1 polymorphisms, other factors considered to be involved in 
the extreme variation of MP activation by mannan in human serum were the MBL 
serum concentration, the capability of MBL to bind to mannan, the activity of the 
Figure 3. Contribution of the classical pathway and the MBL pathway to complement activation by p60 from Listeria 
monocytogenes.
A. Plates were coated with Listeria p60 and incubated with puriﬁ ed MBL in the presence or absence of D-mannose or L-
mannose. Binding of MBL was assessed. 
B. Plates were coated with Listeria p60 or BSA and incubated with puriﬁ ed C1q. Binding of C1q was assessed.
C. Sera were selected on basis of MP activity (lo < 135, hi > 880 U/ml (N = 12)) and incubated (1/50) on p60-coated wells in 
the presence or absence of mAb 2204 for C1q inhibition. Activation of C4 was assessed.
D. Serum (A/A genotype) was incubated on p60 in the presence of mAb 2204 as well as D-mannose or L-mannose. Activation 
of C4 was assessed.
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Figure 4. Functional characterization of the MBL pathway
MP activity assessed at the level of C5b-9 in the presence of mAb 2204 (A, dilutions starting from 1/100), MBL concentration 
(B), MBL binding to mannan (C, dilutions starting from 1/10), and MBL complex activity (D, dilutions starting from 1/50) in 
diﬀ erent sera. ANOVA: p < 0.001, A/A versus A/B p < 0.001
MBL-MASP complex, MBL promoter polymorphisms and MASP-2 polymorphisms. 
The MBL serum concentration (Fig. 4B), the capacity of MBL to bind to mannan 
(Fig. 4C) as well as the C4-cleaving activity of the MBL complex, as determined by 
exogenously added C4 (15) (Fig. 4D), were strongly decreased in carriers of MBL 
variant alleles. For all three parameters, A/B donors but not A/D donors showed a 
signifi cant difference as compared to A/A donors. 
Both in wildtype and variant serum, MP activity assessed at the level of C5b-9 
correlated highly signifi cantly with the MBL concentration (Fig. 5A), the MBL ligand 
binding activity (Fig. 5B), and the MBL complex activity (Fig. 5C), demonstrating that 
the availability of functionally active MBL is the major determinant of the activity of 
the MP in full human serum. Furthermore, MBL complex activity was strongly cor-
related to both the MBL concentration (Fig. 6A), and the capacity of MBL to bind to 
mannan (Fig. 6B), suggesting that impaired ligand binding is an important cause of 
low MBL complex activity in carriers of variant alleles.
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Since our data indicate a functional MP defect in carriers of the A/B genotype, we 
further characterized the functional properties of MBL in serum from A/B donors. Se-
rum samples from A/B donors were compared with serum samples from A/A donors 
having a comparable MBL concentration (Table 1). The MBL ligand binding capacity 
and the MBL complex activity of circulating MBL were signifi cantly decreased in 
A/B donors as compared to A/A donors. This difference in MBL complex activity 
between wildtype and variant MBL is also illustrated in fi g. 6A.
MBL promoter polymorphisms have been identifi ed that control the MBL serum 
concentration. Accordingly, A/A donors with the H/H promoter genotype show 
higher MBL levels than A/A donors with the L/L promoter genotype (Fig. 7A). Fur-
thermore, MBL complex activity and MP activity were signifi cantly higher in sera 
obtained from H/H donors than in sera obtained from L/L donors (Fig. 7A). These 
functional effects are presumably directly related to the effects of the promoter 
polymorphisms on MBL gene expression. 
MBL promoter polymorphisms are in strong linkage disequilibrium with exon 1 
polymorphisms. In this respect, the B genotype is always found in haplotypes car-
Figure 5. MBL pathway activity is dependent on the presence of functional MBL. 
MP activity is plotted against the MBL concentration (A; R = 0.74 (wildtype); R = 0.90 (variant)), MBL binding to mannan 
(B; R = 0.67 (wildtype); R = 0.90 (variant)) and MBL complex activity (C; R = 0.76 (wildtype); R = 0.91 (variant)), for sera 
obtained from MBL wildtype and variant individuals, as indicated. P < 0.0001 for all correlations. 
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rying the LYP allele, and the D genotype is found on the HYP haplotype (9). In 
donors with heterozygous exon 1 SNP, MBL promoter polymorphisms present in 
the wildtype allele will determine the relative expression of the wildtype and the 
variant allele. To directly assess the impact of the B and the D allele, sera from A/B 
donors and from A/D donors were compared with serum from A/A donors with 
the same promoter genotype, respectively. Sera from LYQA/LYPB donors have a 
signifi cantly lower MBL concentration and MP activity as compared to LYQA/LYPA 
donors. Furthermore, sera from HYPA/HYPD donors have a signifi cantly lower MBL 
concentration than sera from HYPA/HYPA donors (Fig. 7B). 
Recently, a SNP in the MASP-2 gene was identifi ed that can cause MASP-2 defi -
ciency (17). Although the frequency of this variant allele was described to be 5.5%, 
all donors included in our study were homozygous carriers of the wildtype allele 
(assessed by PCR-RFLP, data not shown).
Impaired MBL function is related to impaired MBL polymerization
The molecular structure of MBL was examined in whole human serum from indi-
viduals with different genotypes by Western blotting (Fig. 8). Both wildtype and 
variant MBL showed a doublet between approximately 160 and 200 kDa, at variable 
amounts correlating with the MBL serum concentration. A number of high molecu-
lar weight bands (above ± 200 kDa) were observed only in those sera that show 
detectable MBL complex activity, also following prolonged exposure. In contrast, a 
double band was observed around 90 kDa that is predominantly present in carriers 
of variant alleles. Carriers of two variant alleles contained only low molecular weight 
MBL (up to ± 200 kDa), whereas a mixture of low and high molecular weight MBL 
was detected in heterozygous carriers of variant alleles.
Table 1. Functional activity of circulating MBL in A/A and A/B serum
Parameter MBL 
genotype
Median (range) p 
MBL concentration (ng/ml)
A/A 342 (99-607)
0.41
A/B 287 (126-571)
MBL ligand binding capacity of circulating MBL (U/ng)
A/A 1.09 (0.34-2.49)
0.008
A/B 0.25 (0.15-1.5)
MBL complex activity of circulating MBL (U/ng)
A/A 1.36 (0.99-1.98)
0.003
A/B 0.83 (0.29-1.77)
A/B donors (n = 12) were compared to A/A donors (n = 11) matched on basis of similar MBL serum concentrations. The 
parameters given were calculated by dividing the MBL binding to mannan (U/ml) or the MBL complex activity (U/ml), by the MBL 
concentration (ng/ml), as indicated. Data were analyzed by using the Mann-Whitney U test. 
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Figure 6. MBL complex activity is determined by the availability of MBL binding to mannan. 
MBL complex activity is plotted against the MBL concentration (A; R = 0.88 (wildtype); R = 0.94 (variant)) and the level 
of MBL binding to mannan (B; R = 0.86 (wildtype); R = 0.96 (variant)) for sera obtained from MBL wildtype and variant 
individuals. P < 0.0001 for all correlations.
Figure 7. Functional eﬀ ects of MBL promoter 
variants. 
Sera from A/A donors homozygous for the 
H or L promoter variant (A) and sera from 
A/B donors, A/D donors and A/A donors with 
identical promoter haplotype (B) are compared 
for diﬀ erent parameters of MBL function, as 
indicated. 
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DISCUSSION
The present study demonstrates that, although the MP of complement can be se-
verely hampered by MBL defi ciency, activation of the CP of complement via C1q and 
anti-carbohydrate antibodies can compensate for such a defect. 
Epidemiological studies clearly indicated that MBL is an important factor of innate 
immune defense, both as a primary opsonin and as an activator of the complement 
cascade. In case of MBL defi ciency, hampering the opsonization of targets with MBL 
and complement components, other molecules may support phagocytosis and pre-
sentation of carbohydrate antigens to the acquired immune system, thereby compen-
sating for the lack of functional MBL. In this respect, recognition of carbohydrates on 
pathogens may also involve lectin receptors expressed on phagocytes, other soluble 
lectins, including collectins and fi colins (1; 18), and anti-carbohydrate antibodies. 
Certain anti-carbohydrate antibodies are present at high levels in human serum, 
such as antibodies directed against the ABO blood group antigens and antibodies 
against the major xenoantigen, Galα1-3Gal. These anti-carbohydrate antibodies most 
likely originate from the continuous immune stimulation by bacteria of the gut fl ora. 
It is likely that similar mechanisms are responsible for the production of anti-mannan 
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Figure 8. Impaired MBL function is related to the presence of low molecular weight MBL. 
Total serum (1.5 µl) was subjected to SDS-PAGE followed by Western blotting and detection of MBL. The position of markers is 
indicated. For each donor, the MBL exon 1 genotype, the MBL concentration and the MBL complex activity are indicated. The 
same blot is shown after short exposure (5 minutes, top) and long exposure (30 minutes, bottom) of the ﬁ lm.
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antibodies in humans, in response to the high mannose structures commonly found 
on microbial surfaces. In the current study we show that anti-mannan antibodies 
are able to induce the CP of complement, thereby inducing complement activation 
in MBL-defi cient serum until a level that is comparable to that of MBL-suffi cient 
serum. 
The presented data indicate that human sera display a high variability when tested 
for the activation of C4 by mannan, which is in agreement with fi ndings of Super and 
Minchinton (19; 20). Our study indicates signifi cant MBL-independent complement 
activation by mannan, which is dependent on C1q. In case of MBL dysfunction, C4 
activation by mannan is dominated by activation of the CP, as is illustrated by an 
increasing relative contribution of C1q with decreasing MP activity. The contribution 
of the CP is most likely explained by the presence of anti-carbohydrate antibodies, 
which are present in human serum with a high inter-individual variation (16). Anti-
carbohydrate antibodies may contribute to early host defense, and, when produced 
at a suffi cient level, may compensate for the lack of functional MBL in the protection 
against at least part of the pathogens recognized by MBL. This could also explain 
why MBL-defi cient young children, who do not yet produce suffi cient levels of anti-
bodies, are more prone to acquire infections than MBL-defi cient adults (13).
In the present study we investigate the role of MBL and C1q in opsonization of 
mannan, a component of Saccharomyces Cerevisiae, as well as p60, a protein from 
Listeria monocytogenes. The latter microorganism is a facultative intracellular bacte-
rium that can cause severe systemic infections, associated with e.g. septicemia and 
meningitis, in humans. Previous studies have shown binding of purifi ed MBL (21) 
and C1q (22) to this microorganism, and C1q binding was shown to be involved in 
the uptake of L. monocytogenes by macrophages. We now show that the p60 protein 
of L. monocytogenes is able to activate the LP of complement via a direct interaction 
with MBL. Furthermore, C1q is also able to directly bind to this protein, activating the 
CP. Activation of the CP may be further promoted by antibodies against p60 which 
are present in human serum (23). In case of MBL defi ciency, activation via the CP 
only results into a signifi cantly lower level of opsonization. Interestingly, the p60 
molecule has been implicated in host cell invasion, as well as in the phagocytosis of 
L. monocytogenes by dendritic cells (23). Our data indicate cooperation between the 
CP and the LP in complement activation by p60 from L. monocytogenes, thereby most 
likely promoting phagocytosis and bacterial killing. However, a role for complement 
and complement receptors in the invasion of this bacterium into non-phagocytic host 
cells can not be excluded. 
The difference that we noticed between complement activation by mannan in 
the absence or in the presence of C1q inhibition confi rms previous suggestions 
that the CP is likely to be involved in complement activation assays using mannan. 
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Therefore, assays have been developed, which are used in the present study, in 
which the CP was inhibited, either by the use of high ionic strength buffer (15), or by 
including a blocking mAb directed against C1q (16). Previous studies have assessed 
complement activation by mannan without excluding interference of the CP (19; 
20). Minchinton et al. recently presented a detailed study concerning the capacity 
of serum from healthy donors with different MBL genotypes to activate C4 by man-
nan, using incubation of serum samples at physiologic ionic strength, followed by 
a second incubation with an MBL-defi cient complement source (20). In agreement 
with our study, this method also revealed that C4 activating capacity was severely 
hampered in carriers of MBL variant alleles. 
In the present study we evaluate specifi c MP activation of the whole complement 
cascade, up to C5b-9 formation, using autologous complement components and an 
inhibitor of C1q. Our results indicate that heterozygous and homozygous expression 
of the B allele is associated with low MBL serum concentrations, low MBL binding to 
mannan and low MBL complex activity, resulting into hampered activation of C4 and 
C5b-9 via the MP. These fi ndings raise the question of the primary cause of impaired 
MBL function in individuals with structural MBL polymorphisms. 
The serum level of MBL is a strong determinant of both MBL complex activity (15) 
and MP activity. In our study, decreased serum concentrations of MBL were observed 
in donors with two structural mutations as well as in both A/D and A/B donors, when 
compared to wildtype donors with the same promoter haplotype. 
MBL in serum shows a wide range of molecular weights, and MBL gene mutations 
are associated with low molecular weight MBL (24). We show that low molecular 
weight MBL, which may represent MBL oligomers consisting of up to two trimers (8), 
is present in variant serum and virtually absent in wildtype serum. Furthermore, the 
presence of MBL with a molecular weight above 200 kDa, presumably representing 
molecules consisting of at least three trimers, is required for MBL complex activity 
and activation of the MP of complement in serum, and these bands are lacking in 
serum from carriers of two variant alleles. These results agree with recently obtained 
data with human recombinant MBL (8). Furthermore, the MASP-2 content and the 
ability to cleave C4 were reported to be highest in human MBL complexes of about 
345 kDa (3).
Experiments with recombinant human and rat MBL also point to functional defects 
of the variant molecules, showing impaired complement activation and MASP bind-
ing (6-8). Our data show that MBL binding to mannan and MBL-MASP complex activ-
ity of circulating MBL are strongly decreased in carriers of MBL variant alleles. This 
difference is apparent in A/B donors and in donors with a double MBL mutation (B/B 
and B/D) but not in A/D donors, which is in agreement with data from Minchinton et 
al. (20), and which was also suggested by data obtained with recombinant rat MBL 
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(7). Taken together, the intrinsic defects that we detect in circulating variant MBL are 
a relative increase in low molecular weight MBL and an impaired ability to bind to 
mannan, resulting into reduced MBL complex activity and hampered activation of C4 
and C5b-9. Impaired ligand binding most likely results from a lower avidity that is 
inherent to smaller MBL molecules with less ligand-binding domains. Low molecular 
weight MBL in carriers of variant alleles, in association with impaired ligand binding, 
was also recently shown by gel fi ltration (24; 25).
Associations between MBL defi ciency and increased susceptibility to infectious dis-
eases have been frequently reported, in otherwise healthy subjects (10-12) and, more 
strongly, in patients with additional immunological defects or chronic diseases (26-28). 
In these studies, MBL defi ciency was always defi ned on basis of the MBL genotype, 
the MBL concentration, or both, and genetic associations could be observed both for 
homozygous and heterozygous carriers of MBL variant alleles (10; 11; 28). 
The present study shows that, also when the MBL haplotype is taken into ac-
count, MP activity shows a much larger variation than CP activity. Sera from healthy 
donors with an identical MBL haplotype can have a 10-fold difference in MP activity 
(Fig. 7 and unpublished results). Additional polymorphisms in the genes of MBL 
and/or MBL-associated molecules could play a role in this variation. The recently 
characterized variant allele of MASP-2 (17) was not present in the donors examined 
in our study, suggesting that this variant may be more prevalent in the Scandinavian 
population. 
In conclusion, activation of the complement cascade via the MP is critically de-
pendent on the availability of MBL that is able to bind to its ligands. However, MP 
dysfunction is not necessarily associated with inadequate opsonization, since anti-
carbohydrate antibodies and the CP of complement can take over this function. Anti-
bodies, C1q and MBL can cooperate in early host defense by simultaneous activation 
of parallel pathways of the complement system. Therefore, MBL defi ciency primarily 
may become clinically relevant in situations without a concomitant adaptive immune 
response. 
MATERIALS AND METHODS
Human materials
Blood was taken from 70 healthy donors. Serum was immediately aliquotted and 
frozen at -80°C. Heparinized blood was used for genomic DNA isolation (16).
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MBL genotyping
MBL exon 1 SNP were identifi ed using an oligunucleotide ligation assay (16) and con-
fi rmed by PCR using sequence-specifi c priming (29). Furthermore, the regulatory ge-
netic variants H/L (-550), X/Y (-221), and P/Q (+4) (9) were typed as described (29). 
Functional assessment of complement activation
Functional activity of the MP and the CP were assessed using methods that were 
previously described in detail (16), using plates coated with mannan and human IgM 
to assess MP and CP activity, respectively. MP function was assessed in the pres-
ence of a blocking mAb directed against C1q (mAb 2204, 20 µg/ml; kindly provided 
by Dr. C.E. Hack, Sanquin Research, Amsterdam). In some experiments, comple-
ment activation on mannan was assessed in the absence of mAb 2204, as indicated. 
Complement activation was detected using monoclonal antibodies directed against 
C4 and C5b-9, as described (16). For specifi c experiments, mannan-coated plates 
were pre-incubated with IgG and IgM purifi ed from human donor plasma, diluted in 
PBS containing 1% BSA, 0.05% Tween 20, and 10 mM EDTA.
Binding of MBL to mannan was assessed following incubation with human se-
rum diluted in a Calcium-containing buffer (GVB++), using dig-conjugated mAb 3E7 
(anti-human MBL) as described (16).
Complement activation by p60 from Listeria monocytogenes
ELISA plates were coated with p60 (5 µg/ml), a protein from Listeria monocyto-
genes expressed as described before ((30), kindly provided by Dr. S.H.E. Kaufmann, 
Berlin, Germany) in coating buffer (100 mM Na
2
CO
3
/ NaHCO
3
, pH 9.6). Binding 
sites were saturated with 1% BSA in PBS. Binding of MBL (diluted in GVB++) and 
C1q (diluted in PBS/ 1% BSA / 0.05% Tween 20) (both purifi ed from normal donor 
plasma), was assessed using mAb 3E7 and mAb 2214 (anti-human C1q, from Dr. C.E. 
Hack), respectively, both conjugated to dig. Deposition of C4 in the presence or 
absence of mAb 2204, D-mannose or L-mannose (both used at 100 mM, from Sigma) 
was assessed. 
MBL concentration
The concentration of MBL in serum was assessed by sandwich ELISA. Plates were 
coated with 3E7 (mAb anti-MBL) at 5 µg/ml. Sera were diluted in PBS containing 
0.05% Tween-20 and 1% BSA. MBL was detected using rabbit IgG anti-MBL (20 
µg/ml, prepared by immunization of rabbits with purifi ed human MBL), followed by 
HRP-conjugated goat anti-rabbit IgG (from Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA). 
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MBL complex activity
MBL complex activity was assessed using the method described by Petersen et al. 
(15) with slight modifi cations. Mannan-coated plates were incubated with serum, di-
luted in GVB++ containing 1 M of NaCl, during 16 hours at 4°C. Plates were washed 
with PBS/Tween containing 5 mM CaCl
2
, followed by incubation with purifi ed C4 (1 
µg/ml), diluted in GVB++, for 1 hour at 37°C. Activation of C4 was assessed. 
Western blotting
Human serum (1.5 µl) was subjected to SDS-PAGE using a 4 to 15% polyacrylamide 
gradient gel (Criterion Pre-cast gel, Tris-HCl, from Bio-Rad Laboratories, Richmond, 
CA, USA) under non-reducing conditions. Proteins were transferred to polyvinyldene 
fl uoride membranes (Immobilon, Millipore, Bedford, USA) using a semi-dry blotting 
procedure. Membranes were blocked with PBS/0.05% Tween 20/ 2% Casein followed 
by incubation with mAb 3E7 (1 µg/ml) for 16 hours at 4°C and HRP-conjugated goat 
anti-mouse IgG (Dako, Glostrup, Denmark) for 2 hours at room temperature. Devel-
opment of blots was performed with Supersignal (Pierce Chemical Co., Rockford, IL, 
USA) and exposure to Hyperfi lms (Amersham Pharmacia Biotech). 
Calculations and statistical analysis
All sera were analyzed in at least two dilutions in duplicates. Functional activity was 
expressed in units per ml, based on serial dilutions of a human pool serum used as 
a standard (set at 1000 U/ml). The activity was calculated using parameters of linear 
regression following log-transformation of arbitrary units and logit-transformation 
of OD values. Statistical analysis was performed with GraphPad Prism 3.03 using 
non-parametric tests. Differences were evaluated by the Mann Whitney U test or by 
analysis of variance (ANOVA), using the Kruskal Wallis test and Dunn’s correction for 
multiple comparisons. Correlation was evaluated using the Spearman Rank correla-
tion coeffi cient (R). Results were considered as statistically signifi cant when p values 
were below 0.05.
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ABSTRACT
The recently identifi ed lectin pathway of the complement system, initiated by bind-
ing of mannan-binding lectin (MBL) to its ligands, is a key component of innate 
immunity. MBL-defi cient individuals show an increased susceptibility for infections, 
especially of the mucosal system. We examined whether IgA, an important mediator 
of mucosal immunity, activates the complement system via the lectin pathway. Our 
results indicate a dose-dependent binding of MBL to polymeric but not monomeric 
IgA coated in microtiter plates. This interaction involves the carbohydrate recogni-
tion domain of MBL, since it was calcium-dependent and inhibited by mannose and 
by mAb against this domain of MBL. Binding of MBL to IgA induces complement 
activation, as demonstrated by a dose-dependent deposition of C4 and C3 upon 
addition of a complement source. The MBL concentrations required for IgA-induced 
C4 and C3 activation are well below the normal MBL plasma concentrations. In line 
with these experiments, serum from individuals having mutations in the MBL-gene 
showed signifi cantly less activation of C4 by IgA and mannan than serum from 
“wildtype” individuals. We conclude that MBL binding to IgA results in complement 
activation, which is proposed to lead to a synergistic action of MBL and IgA in anti-
microbial defense. Furthermore, our results may explain glomerular complement 
deposition in IgA nephropathy.
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INTRODUCTION
The complement system is an important component of host defense. Activation 
of the complement cascade takes place upon the interaction of complement com-
ponents with a variety of pathogens, either directly or via antibodies bound to 
pathogen antigens. Three different pathways for complement activation have been 
described, the classical pathway, the alternative pathway and the lectin pathway, of 
which the latter is most recently identifi ed. The lectin pathway is mainly driven by 
mannan-binding lectin (MBL). 
MBL, a member of the collectin family (1), is a C-type lectin present in serum as 
a part of a large pro-enzymatic complex. The MBL protein consists of three to six 
identical homotrimeric subunits. Each trimer is composed of a collagen-like tail part 
and a globular head part containing a carbohydrate recognition domain (CRD). The 
collagen-like part of MBL interacts with the MBL-associated serine proteases MASP-1 
(2), MASP-2 (3), and MASP-3 (4). These enzymes are responsible for the comple-
ment-activating properties of the MBL complex, by the cleavage of C4, C2 and C3 
(5). The CRD of MBL is able to bind in a calcium-dependent way to a number of 
saccharides, such as D-mannose, L-fucose, and N-acetyl-glucosamine (1). MBL bind-
ing to a ligand induces activation of the MASP enzymes, leading to complement 
activation up to the terminal pathway. Both the structural and functional properties 
of MBL are strikingly similar to those of C1q, the recognition unit of the classical 
complement pathway.
Genetic mutations in the MBL gene are present with a high frequency in the hu-
man population (6). Until now, three different point mutations have been described 
which lead to the production of MBL with structural aberrations and impaired 
complement-activating properties (6; 7). Heterozygous and homozygous expression 
of these mutant alleles is associated with an enhanced incidence of a range of 
infections, in both children and adults (8; 9). In this spectrum of diseases, mucosal 
infections, occurring in the respiratory tract and the gastrointestinal tract, are com-
mon. Furthermore, mutations in the MBL gene have a signifi cant negative impact on 
chronic diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE) 
and cystic fi brosis, resulting in an increased incidence of complicating infections 
and/or a worse outcome (10-12). These studies indicate the importance of the lectin 
pathway of complement activation in anti-microbial defense. In line of this function 
of the lectin pathway, MBL is able to bind directly to a number of microorganisms, 
via the carbohydrates expressed on their surface (1; 13). Upon binding, complement 
activation takes place, leading to either direct elimination via the terminal comple-
ment pathway, or opsonization and phagocytosis.
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In the mucosal immune system, a major factor of defense is immunoglobulin A. 
It is present in plasma at a concentration of about 2 mg/ml, and it is secreted at 
mucosal surfaces throughout the body where it is postulated to play an important 
role as a defense mechanism against invading microorganisms (14; 15). Upon inter-
action of IgA with pathogens, the IgA molecule can have diverse effector functions, 
including the direct prevention of invasion of microorganisms, the interaction with 
the phagocytic IgA Fc receptor CD89, and complement activation.
Complement activation by IgA has been previously shown to involve the alterna-
tive but not the classical complement pathway (16; 17). No data are available con-
cerning the possible involvement of the lectin pathway. A classical disease involving 
IgA and complement activation is primary IgA nephropathy, a common renal disease 
involving mesangial deposition of IgA and complement components, resulting in 
end stage renal failure in about 30% of the patients (18). Recent studies indicate the 
presence of MBL in association with IgA in the mesangial area of patients with IgA 
nephropathy (19; 20). 
Therefore, we examined whether IgA induces complement activation via a pos-
sible interaction with MBL. Our results demonstrate activation of the lectin pathway 
by IgA. This novel interaction in the immune system is proposed to contribute to 
the roles of MBL and IgA in host defense, as well as to the pathogenesis of IgA 
nephropathy. 
MATERIALS AND METHODS
Puriﬁ cation of MBL/MASP complexes
MBL and its associated proteases were purifi ed from pooled plasma obtained from 
healthy human donors, essentially as described by Tan et al. (21). In brief, a pre-
cipitation step was performed using polyethylene glycol 3350 (Sigma, St. Louis, 
MO; 7% (w/v)). The precipitate was dissolved in TBS-T/Ca2+ (50 mM Tris, 0.15 M 
NaCl, 0.05% Tween 20, 20 mM CaCl
2
, pH 7.8) and incubated for 18 hours at 4°C 
with mannan-agarose (Sigma; equilibrated with TBS-T/Ca2+). After extensive wash-
ing with TBS-T/Ca2+/1M NaCl, bound proteins were eluted using TBS-T containing 
10 mM EDTA. Fractions containing MBL, as determined by ELISA, were pooled and 
concentrated. To remove contaminating immunoglobulins, the MBL preparation was 
absorbed using a mixed absorbent consisting of 4E8 (mAb anti-IgA, produced in the 
laboratory of Nephrology, Leiden, the Netherlands) coupled to Biogel A5 (Biorad, 
Richmond, CA, USA), HB57 (mAb anti-IgM, hybridoma obtained from the American 
Type Culture Collection (ATCC)) coupled to Biogel A5, and protein G coupled to 
Sepharose (from Pharmacia, Uppsala, Sweden). The resulting MBL preparation con-
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tained negligible amounts of IgA (< 0.5%) whereas IgG and IgM were undetectable. 
Furthermore, the MBL preparation did not contain any detectable C1q, as determined 
by singe radial immunodiffusion and by a sensitive C1q-specifi c hemolytic assay. 
This purifi cation method results in co-purifi cation of MASP proteins, as shown by 
Western blotting using rabbit anti-MASP-1 antibodies, prepared as described (3), and 
rabbit anti-MASP-2 antibodies (kindly provided by Dr. R. Sim, Oxford, UK) as well as 
by a C4 consumption assays (not shown). The resulting MBL-MASP preparation was 
subjected to ELISA to determine the MBL concentration (as described below) and 
subsequently used in all experiments.
Puriﬁ cation of human IgA
IgA was purifi ed from pooled normal human serum (NHS) or recalcifi ed donor 
plasma as described by Hiemstra et al. (16) with minor modifi cations. In brief, the 
majority of serum proteins were removed by dialysis against H
2
O, and precipita-
tion by ZnSO
4
. Proteins in the supernatant were precipitated using glycine and 
(NH
4
)
2
SO
4
, dialyzed against TE buffer (10 mM Tris, 2 mM EDTA, pH 7.8) and loaded 
on a DEAE-Sephacel column (Pharmacia). IgA was eluted with a linear salt gradi-
ent (conductivity 1-20 mS). IgA-containing fractions, as determined by ELISA, were 
pooled, concentrated and further purifi ed by gelfi ltration, using a Sephacryl S-300 
column (Pharmacia). Veronal-buffered saline (VBS, 1.8 mM Na-5,5-diethylbarbital, 
0.2 mM 5,5-diethylbarbituric acid, 145 mM NaCl) containing 2 mM EDTA was used as 
a running buffer. Fractions were tested for IgA by ELISA; IgA of different molecular 
sizes, i.e. monomeric, dimeric, and polymeric IgA were pooled separately on basis 
of its position in the elution profi le. Reanalysis of these different IgA preparations 
indicated that this molecular size is stable: typically > 90% runs at the same position 
in the elution profi le. Contamination with IgG and IgM was below 0.4% on a weight 
basis, as determined by ELISA. Experiments were performed with polymeric IgA 
unless otherwise indicated. 
Puriﬁ cation of human IgG and IgM
Human IgG was purifi ed from outdated plasma obtained from healthy donors as de-
scribed previously (22). Human IgM was purifi ed from human serum by euglobulin 
precipitation and anion exchange chromatography, as described (22), followed by 
cation exchange chromatography, using CM-Sephadex C-50 (Pharmacia), and gelfi l-
tration, using a Sephacryl S-300 column (Pharmacia). The IgG preparation was free 
of any detectable IgA and IgM, and the IgM preparation was free of any detectable 
IgA and IgG. 
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Puriﬁ cation of functionally active C4
Freshly obtained NHS (120 ml) was adjusted with TEB-buffer (10 mM Tris, 2 mM 
EDTA, 1 mM benzamidine hydrochloride hydrate (Sigma)) to pH 7.8 and conductiv-
ity of 4.0 mS. This sample was loaded on a DEAE-sephacel column (5 x 10 cm) 
which was previously equilibrated with TEB buffer at pH 7.8 and mS 4.0. The col-
umn was extensively washed with the same buffer, followed by elution with a linear 
salt gradient with a conductivity from 4.0 mS to 25 mS. Fractions were tested for the 
presence of C4 using a hemolytic assay. In this assay, serum from C4-defi cient guinea 
pig is used as a complement source and sheep red blood cells (SRBC) sensitized with 
rabbit anti-SRBC antibodies as targets. Lytic activity of an excess amount of C4-defi -
cient serum can be restored by addition of a limiting amount of C4. Peak fractions 
containing C4 (at 15 mS) were pooled and concentrated. The concentration of C4 
was determined by single radial immunodiffusion.
Human serum containing wildtype or mutated MBL
Serum samples were obtained from 5 healthy donors having the wildtype genotype 
at codon 52, 54, and 57 from the fi rst exon of the MBL gene (A-genotype) as well as 
from 6 healthy donors with a homozygous (n = 2) or heterozygous (n = 4) mutation 
at codon 54 (B-genotype) (6). These genotypes were identifi ed by an oligonucle-
otide ligation assay (A. Roos et al., manuscript in preparation) and were confi rmed 
by DNA sequencing. 
ELISA protocol
For all ELISA assays, Nunc Maxisorb plates (Nunc, Roskilde, Denmark) were coated 
using coatingbuffer (100 mM Na
2
CO
3
/ NaHCO
3
, pH 9.6), for 16 hours at room tem-
perature or for 2 hours at 37°C. After each step, plates were washed three times with 
PBS containing 0.05% Tween 20. Residual binding sites were blocked by incubation 
with PBS containing 1% BSA. Unless otherwise indicated, all subsequent steps were 
incubated in PBS containing 0.05% Tween 20 and 1% BSA, for one hour at 37°C. 
Detection antibodies were conjugated to digoxygenin (dig) using digoxygenin-3-O-
methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester (from Boehringer 
Mannheim, Mannheim, Germany) according to instructions provided by the manu-
facturer. Detection of binding of antibodies conjugated to dig was performed by HRP-
conjugated rabbit anti-dig antibodies (Fab fragments, from Boehringer Mannheim). 
Enzyme activity of HRP was detected using 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (Sigma). The OD at 415 nm was measured using a microplate biokinet-
ics reader (EL312e, from Biotek Instruments, Winooski, Vermont, USA).
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MBL detection ELISA
Plates were coated with 3E7 (mAb anti-MBL (mouse IgG1, kindly provided by Dr. 
T. Fujita, Fukushima, Japan) at 5 µg/ml. Samples containing MBL were incubated, 
followed by detection with dig-conjugated 3E7. A calibration line was produced us-
ing pooled human serum from healthy donors with a known concentration of MBL 
(kindly provided by Dr. P. Garred, Copenhagen, Denmark). 
MBL binding to IgA or mannan
IgA was coated at 5 µg/ml, unless otherwise indicated. Mannan (from Saccharo-
myces Cerevisiae; Sigma (M7504)) was coated at 100 µg/ml. As a negative control, 
BSA (Sigma) was coated at 10 µg/ml. After blocking with BSA, MBL was incubated 
in BVB++ (VBS, 0.5 mM MgCl
2
, 1 mM CaCl
2
, 0.05% Tween-20, 1% BSA, pH 7.5) for 
one hour at 37°C. MBL binding was detected using dig-conjugated 3E7. In some 
experiments, MBL was pre-incubated (30 minutes, 20°C) in a calcium-free buffer 
(BVB/MgEGTA: VBS, 5 mM MgCl
2
, 0.05% Tween-20, 1% BSA, 10 mM EGTA) or in 
BVB++ containing D-mannose, L-fucose, N-acetyl-glucosamine, or N-acetyl-galactos-
amine (from Sigma), followed by addition of the mixture to the plates. Saccharides 
were applied at a concentration of 100 mM unless otherwise indicated. Additional 
inhibition studies were performed using purifi ed mouse mAb directed against MBL 
(1C10 and 3F8 (23)), which were incubated together with MBL at concentrations 
between 2 and 20 µg/ml. 
Analysis of complement activation by MBL
Activation of complement via MBL was assessed as follows. Plates were coated with 
IgA, mannan, or BSA, blocked by BSA and, in some cases, incubated with MBL as 
described above. Subsequently, plates were incubated with 2% NHS as a comple-
ment source, diluted in BVB/MgEGTA, for one hour at 37°C. Deposition of C3 was 
detected by dig-conjugated RFK22 (mAb anti-human C3 (mouse IgG1) produced 
at the laboratory of Nephrology, Leiden, the Netherlands). Alternatively, C4 activa-
tion was assessed using a method adapted from Vorup-Jensen et al. (24). For these 
experiments, MBL, diluted in BVB++, was incubated for one hour at 37°C and for 
16 hours at 4°C. Plates were washed with PBS / 5 mM CaCl
2 
/ 0.05% Tween-20, 
and C4 was added (1 µg/ml, diluted in BVB++ containing 1 mM MgCl
2
 and 2 mM 
CaCl
2
). C4 binding was detected with affi nity-purifi ed goat anti-human C4 antibodies 
conjugated to dig, or with dig-conjugated C4-4A (mAb anti-C4, kindly provided by 
Dr. C.E. Hack, Amsterdam, the Netherlands). In some experiments, activation of C4 
was assessed directly in human serum. For this assay, all washing and incubation 
steps were performed in the absence of Tween 20, which reduced non-specifi c stain-
ing. Plates were coated with IgA, mannan, IgG (5 µg/ml) or IgM (5 µg/ml), washed 
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with PBS, and blocked by 1% gelatin in PBS. Serum was diluted in VBS containing 
2 mM CaCl
2
, 0.5 mM MgCl
2
, and 0.1% gelatin and incubated for 1 hour at 37°C. 
Subsequently, C4 binding was detected, using PBS / 1% BSA as a dilution buffer for 
antibody conjugates.
Statistical analysis
Differences in C4 activation between sera from two groups of donors (i.e. either 
MBL-wildtype or MBL-mutant genotype) were analyzed using a t test and are consid-
ered statistically signifi cant when p values are less than 0.05.
RESULTS
Interaction of MBL with IgA
The binding of MBL to IgA was studied using microtiterplates coated with purifi ed 
human IgA. Addition of MBL resulted in a dose-dependent binding to IgA, but not 
to a control coating with BSA only (Fig. 1A). Binding was clearly detectable at an 
MBL concentration of 20 ng/ml. Coating of different concentrations of IgA followed 
by incubation with a fi xed concentration of MBL revealed that MBL binding was 
maximal at an IgA coating concentration of 5 µg/ml (Fig. 1B). 
The characteristics of the interaction between MBL and IgA were studied by pre-
incubating MBL in the presence of various inhibitors. Pre-incubation with D-man-
nose, L-fucose, or N-acetyl-glucosamine (GlcNAc), but not N-acetyl-galactosamine 
(GalNAc) blocked the binding of MBL to IgA and to its major ligand mannan (Fig. 
1C). This inhibition by saccharides was dose-dependent: IC50 values for mannose 
and GlcNAc were between 5 and 10 mM for binding of MBL to IgA (Fig. 1D) and 
to mannan (not shown). Furthermore, incubation of MBL in a calcium-free buffer 
containing MgEGTA prevented binding of MBL to IgA and to mannan (Fig. 1C). 
Binding of MBL to IgA is calcium-dependent and reaches a plateau at 1 mM CaCl
2
 
(Fig. 1E). This concentration was chosen for further assays. These results indicate a 
calcium-dependent interaction of the CRD of MBL with human IgA. 
IgA activates the complement system via the lectin pathway
In order to assess whether the interaction of MBL with IgA induces complement 
activation, activation of C4 and C3 was studied by ELISA. For experiments studying 
activation of C3, NHS diluted in a MgEGTA-containing buffer was used as a comple-
ment source. The use of MgEGTA prevented activation of the classical pathway and 
the lectin pathway in the complement source that may occur irrespective of the 
MBL that was previously bound to the coating, resulting in low background levels. 
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Figure 1. Binding of MBL to immobilized IgA. Microtiterplates were coated with either IgA or BSA, as indicated. MBL binding 
was detected by ELISA. A, MBL was added to coated IgA (5 µg/ml) or BSA at concentrations as indicated. Data represent mean 
± SD from 4 independent experiments. B, IgA was coated at various concentrations, and binding of a ﬁ xed concentration 
of MBL (2 µg/ml) was detected. Data represent mean ± SD from two independent experiments. C, Wells were coated with 
mannan or IgA, and incubated with MBL (0.1 µg/ml on mannan; 1 µg/ml on IgA) either under standard assay conditions 
(control) or in the presence of MgEGTA, D-mannose, L-fucose, N-acetyl-glucosamine (GlcNAc) or N-acetyl-galactosamine 
(GalNAc) as indicated in Materials and Methods. The percentage inhibition of MBL binding to IgA or mannan was calculated 
using the following formula: 100 – (100 * (MBL binding (+ inhibitor) – MBL binding to BSA) / (MBL binding (control) - MBL 
binding to BSA)), using OD values measured at 415 nm. None of the inhibitors aﬀ ected the background binding of MBL to 
BSA. Mean and SD are shown of triplicate wells of a representative experiment. Similar results were obtained in 5 independent 
experiments. D, Similar experiment as shown in C, but the inhibitors were applied at diﬀ erent concentrations, as indicated 
(mean ± SD from two independent experiments). E, Wells were incubated with MBL (1 µg/ml) in the presence or absence of 
diﬀ erent concentrations of CaCl
2
, as indicated. Data represent mean ± SD from two out of three similar experiments. 
C
ha
p
te
r 2
.3
82
0.0
0.2
0.4
0.6
0.8
0.01 0.1 1 10
IgA
MBL (µg/ml)
M
BL
 b
in
di
ng
 (O
D
41
5)
BSA
0
A
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.001 0.01 0.1 1
Mannan
MBL (µg/ml)
M
BL
 b
in
di
ng
 (O
D
41
5)
BSA
0
B
0.0
0.5
1.0
1.5
0.01 0.1 1 10
IgA
BSA
0
MBL (µg/ml)
C
3 
de
po
si
tio
n 
(O
D
41
5)
C
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.001 0.01 0.1 1
Mannan
MBL (µg/ml)
C
3 
de
po
si
tio
n 
(O
D
41
5)
BSA
0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.1 1 10 100
IgA
BSA
0
MBL (ng/ml)
C
4 
de
po
si
tio
n 
(O
D
41
5)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.001 0.01 0.1 1
Mannan
BSA
0
MBL (ng/ml)
C
4 
de
po
si
tio
n 
(O
D
41
5)
D
E F
Figure 2. Binding of MBL to IgA induces complement activation. Wells were coated with IgA, mannan or BSA and in the ﬁ rst 
step incubated with MBL-MASP complexes in various concentrations, as indicated, followed by addition of a complement 
source in the second step. For A-D, the second step consisted of NHS (2% in VBS/BSA/Tween/MgEGTA), which was followed by 
detection of binding of MBL (A, B) or deposition of C3 (C, D). Alternatively, puriﬁ ed C4 was added in the second step, followed 
by detection of C4 binding (E, F). Please note that MBL concentrations on the X-axis in E and F are in nanogram per ml. The 
results are representative for at least three independent experiments.
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Binding of MBL to IgA and to mannan, which was fi rst achieved in the presence 
of calcium, was clearly detectable after a one-hour incubation with serum in the 
presence of MgEGTA (Fig. 2A, B), as has been previously reported for the bind-
ing of MBL to mannan-coated erythrocytes (25). Using these conditions, binding of 
purifi ed MBL-MASP complexes induced a concentration-dependent deposition of C3 
on coated IgA (Fig. 2C) and on coated mannan (Fig. 2D) upon addition of serum. 
Coated mannan requires about 10 times less MBL than coated IgA to induce the same 
level of MBL binding and C3 deposition (Fig. 2A, C versus 2B, D).
MBL binding to IgA and mannan also resulted in activation of C4. After binding of 
MBL-MASP complexes to either IgA (Fig. 2E) or mannan (Fig. 2F), addition of puri-
fi ed C4 resulted in a dose-dependent deposition of C4 on the coating. C4 activation 
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Figure 3. Complement activation is dependent on MBL binding. Plates were coated with mannan or IgA, followed by incubation 
with MBL in the presence of inhibitors as described at ﬁ gure 1C. A, MBL was incubated at 1 µg/ml and 0.1 µg/ml on IgA and 
mannan, respectively, followed by addition of NHS (2% in VBS/BSA/Tween/MgEGTA) and assessment of C3 deposition. B, MBL 
was incubated at 2 ng/ml and 0.1 ng/ml on IgA and mannan, respectively, followed by addition of C4 and assessment of C4 
binding. Results in A and B are mean ± SD of one out of two or three triplicate experiments. C, Similar experiment as shown in 
ﬁ g. 3B, but the saccharides were applied at diﬀ erent concentrations, as indicated. D, MBL was incubated on IgA and mannan 
in the presence or absence of mAb anti-MBL (3F8 and 1C10), as indicated. Binding of MBL and activation of C3 and C4 was 
assessed as described at ﬁ g. 1 and at ﬁ g. 3A and B, respectively. Anti-MBL antibodies were used at 20 µg/ml (MBL binding 
experiments) or at 2 µg/ml (complement activation experiments). Results represent the mean ± SD of triplicate experiments. 
Inhibition was calculated as described at ﬁ g. 1C. 
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was detectable at MBL concentrations between 0.01 and 1 ng/ml, depending on the 
coating used. MASP enzymes required for activation of C4 are present in the MBL 
preparation as demonstrated by its direct ability to induce C4 consumption in the 
fl uid phase (not shown).
The results presented above strongly suggest that activation of C3 and C4 is in-
duced by the binding of MBL and associated MASPs to IgA or mannan. To further 
establish this, the MBL preparation was pre-incubated on coated IgA or mannan 
in the presence of inhibitors, followed by addition of a complement source and 
analysis of deposition of C3 (Fig. 3A) and C4 (Fig. 3B, C). As expected for an MBL-
dependent mechanism, pre-incubation of MBL with mannose, fucose and GlcNAc, 
but not GalNAc, blocked the activation of C3 and C4, both on IgA and mannan. 
Inhibition of C4 activation by mannose and GlcNAc was dose-dependent, and 50% 
inhibition was reached at saccharide concentrations between 5 and 10 mM, both on 
IgA (Fig. 3C) and on mannan (not shown). Similar dose-response relationships were 
observed for saccharide inhibition of C3 activation (not shown). 
Incubation of MBL on mannan performed in the presence of MgEGTA completely 
inhibited subsequent C3 and C4 activation (Fig. 3A, B). On IgA, similar results were 
obtained for C4 deposition (Fig. 3B), whereas deposition of C3 was inhibited for a 
major part, but not completely (Fig. 3A).
To further prove the MBL-dependence of C3 and C4 activation on IgA and man-
nan, additional blocking studies were performed using mAb anti-MBL. Two different 
MBL-specifi c mAb were used (Fig. 3D): 3F8 that blocks MBL-mediated complement 
activation and, as a control, 1C10 that binds to MBL but does not block its function 
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Figure 4. Lectin pathway activation is mainly a function of di- and polymeric IgA. Plates were coated with monomeric, dimeric, 
and polymeric IgA. MBL in diﬀ erent concentrations and NHS (2% in VBS/BSA/Tween/MgEGTA) were successively incubated 
and C3 binding was detected. One out of two similar experiments is shown.
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(23). The mAb 3F8 totally inhibited the binding of MBL as well as the activation of 
C3 and C4 on IgA and on mannan, whereas mAb 1C10 did not have any effect. 
Complement activation is known to be predominantly a function of polymeric IgA 
(26). We tested the different molecular sizes of IgA for their ability to activate the 
lectin pathway. Polymeric IgA is superior to dimeric IgA in activation of the lectin 
pathway (Fig. 4). No signifi cant activation could be detected by monomeric IgA. 
Previous studies have shown that IgA can activate the alternative pathway in se-
rum in the presence of MgEGTA (16). Only the alternative pathway, but not the 
classical pathway nor the lectin pathway, can proceed in the absence of Ca2+. To 
examine the combined contribution of the lectin pathway and the alternative path-
way to activation of C3 by IgA, complement activation was studied with or without 
a pre-incubation with MBL. Serum incubated in the presence of MgEGTA, but in 
the absence of MBL, induced a clear deposition of C3 on IgA (Fig. 5), in agreement 
with previously published data (27). Pre-incubation with MBL in a calcium-contain-
ing buffer enhanced the deposition of C3 dose-dependently. Deposition of C3 was 
reduced to background levels when EDTA was present in the complement source 
(not shown).
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Figure 5. IgA activates both the lectin pathway and the alternative pathway. Plates were coated with IgA or BSA, as indicated, 
and incubated in the presence or absence of MBL, followed by NHS in diﬀ erent concentrations in VBS/BSA/Tween/MgEGTA. C3 
deposition was detected. Similar results were obtained in two experiments.
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Serum containing mutated MBL has a partial defect in the activation of C4 by mannan and by IgA
MBL derived from individuals with mutations in exon 1 of the MBL gene has an 
impaired ability to activate the complement system (7). In order to examine whether 
this defect also hampers complement activation by IgA, serum from MBL wildtype 
donors (n = 5) was compared with that from donors with a mutant genotype (homo-
zygous (n=2) or heterozygous (n=4) point mutations at codon 54) in a C4 activation 
assay. In comparison to the control group, serum from donors having MBL gene 
mutations induced signifi cantly less C4 activation both on IgA (p = 0.015) and on 
mannan (p = 0.001) (Fig. 6). However, when plates were coated with human IgG of 
IgM, as activators of the classical complement pathway, both groups of sera induced 
a similar level of C4 activation.
DISCUSSION
The present study demonstrates that the CRD of MBL can bind to IgA and thereby 
activate the complement system via the lectin pathway. We propose that this inter-
action between the lectin pathway and IgA may function as a novel link between 
the innate and the adaptive immune system. Furthermore, the interaction between 
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Figure 6. C4 activation in serum with wildtype or mutated MBL. Plates were coated with IgA, mannan, IgG or IgM. Sera 
obtained from donors with a wildtype (N = 5) or mutant MBL genotype (heterozygous (N = 4; circles) or homozygous (N = 
2; squares)) were incubated in a calcium and magnesium-containing buﬀ er (dilution 1/80 (IgA, mannan), 1/160 (IgG) or 1/40 
(IgM)), and C4 activation was assessed. Background OD values obtained in the absence of serum were subtracted. The mean 
of each group is indicated by a horizontal line. Diﬀ erences between mutant and wildtype sera were evaluated by a t test. * 
P= 0.015; ** p= 0.001. 
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MBL and IgA is expected to contribute to mesangial complement deposition in IgA 
nephropathy.
Our results demonstrate a calcium-dependent interaction of the CRD of MBL with 
IgA. This binding was evident at concentrations well below the mean MBL plasma 
concentration in healthy individuals, which is approximately 1.5 µg/ml. The carbo-
hydrate specifi city of the MBL-IgA interaction is similar to that of the interaction of 
MBL with mannan, and is consistent with the known specifi city of MBL (1). Binding 
of MBL to IgA induced lectin pathway activation, as demonstrated by activation of 
C4 and C3. Complement activation on mannan and IgA-coated plates was inhibited 
by incubating the MBL preparation in the presence of mannose, in the absence of 
calcium, or in the presence of an MBL-blocking mAb, which is fully consistent with 
an MBL-dependent mechanism.
Although it has been demonstrated that MASP-1 can directly activate C3 in the 
fl uid phase (5), we could not detect deposition of activated C3 when mannan-coated 
plates were incubated consecutively with MBL/MASP complexes and purifi ed C3 
(not shown), in agreement with data reported by Vorup-Jensen et al (24). This dis-
crepancy is most likely due to differences in the experimental settings, including the 
method of detection of C3 activation and the concentration and activity of MASP-1 
present. In contrast, activation of C4 was readily detectable after incubation with 
purifi ed C4 under similar conditions, both on IgA and on mannan. Activation of C3 
was demonstrated when NHS was used as a complement source. In the latter experi-
ment, we show that MBL binding to plate-coated IgA or mannan is preserved during 
a one-hour incubation step with a calcium-free buffer, although calcium is required 
to establish the primary interaction of MBL with its ligands. Similar characteristics are 
known for the binding of MBL to mannan-coated erythrocytes (25). The MBL-MASP 
interaction, which is required for complement activation, is also stable in a calcium-
free environment (24). 
C3 activation by IgA was also demonstrated when serum was used as a comple-
ment source in the absence of calcium and without pre-incubation with MBL. Calci-
um-independent C3 activation is consistent with activation of the alternative pathway 
by IgA, which is in agreement with previously published data (16; 27). Apparently, 
different complement activation pathways cooperate to induce activation of C3 by 
IgA. 
To further establish a role for the lectin pathway in complement activation by IgA 
in whole serum, we compared sera obtained from donors having either a wildtype 
or a mutant MBL genotype for their ability to activate C4. Our data indicate that sera 
from donors having heterozygous or homozygous mutations in the fi rst exon of the 
MBL gene are partially defi cient in activation of C4 both by IgA and by mannan. 
Since C4 activation by the classical pathway is similar in both groups, the observed 
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differences in mannan and IgA-induced C4 activation can not be based on differ-
ences in the classical pathway activity or the concentration of active C4. Therefore, 
these data are strongly suggestive for the involvement of the lectin pathway in C4 
activation by IgA in whole serum.
Complement activation by IgA has been subject of investigation already during 
several decades. It is generally agreed that IgA cannot activate the classical comple-
ment pathway (14). Activation of the alternative complement pathway by IgA is 
supported by both in vitro (27-29) and in vivo observations (30), as well as by the 
present study. It has been argued that complement activation by IgA has to rely 
on studies using artifi cially modifi ed or presented IgA (14). However, complement 
activation has also been demonstrated upon binding of IgA to its natural antigen. 
For example, xenoreactive human IgA antibodies can induce complement-mediated 
lysis of pig endothelial cells in a calcium-independent way (28). Furthermore, bind-
ing of human serum IgA to Streptococcus pneumonia induces neutrophil-mediated 
bacterial killing which was complement-dependent and proceeded in the presence 
of MgEGTA (29).
A strong suggestion for the activation of complement by human IgA in vivo is 
present in patients with IgA nephropathy. IgA nephropathy is a common glomerular 
disease characterized by mesangial deposition of IgA and complement components 
(31). Furthermore, deposition of C4 and C4-binding protein was shown in 30% and 
60% of cases, respectively, whereas only 6% showed the presence of C1q (31). 
Alternative pathway activation by IgA may explain the deposition of C3 but not that 
of C4 in IgA nephropathy. Therefore, activation of C4 by IgA via the lectin pathway, 
as demonstrated in the present study, may very well be the mechanism of C4 activa-
tion in IgA nephropathy. This hypothesis is strongly supported by the deposition of 
MBL in association with IgA in the mesangial area of patients with IgA nephropathy 
(19; 20) and patients with Henoch-Schönlein purpura (32). The latter disease is also 
characterized by mesangial deposition of IgA and complement. 
Lectin pathway activation by IgA was most prominent for polymeric IgA, followed 
by dimeric IgA and monomeric IgA. Similar differences have been previously re-
ported for activation of the alternative pathway by rat and human IgA (16; 26; 29). In 
addition, polymeric IgA shows enhanced binding to the phagocytic IgA Fc receptor 
CD89 (33) and to human mesangial cells (34). The stronger effector functions of 
polymeric IgA have a benefi cial role for the defense functions of IgA (29; 35; 36). 
In accordance, circulating antigen-specifi c IgA produced upon primary pathogen 
contact predominantly consists of polymers (29). The polymeric nature of mesangial 
IgA in IgA nephropathy (37) will most likely contribute to the development of renal 
damage, involving complement activation and mesangial cell activation.
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At present it is unknown which part of the IgA molecule is involved in binding to 
the CRD of MBL. IgA is a heavily glycosylated molecule (reviewed in (15)). Several 
variants in the sugar composition have been described, among which high mannose 
type N-linked glycan chains (38). Especially the latter glycosylation variant may 
be a likely candidate to serve as a ligand for MBL. Interestingly, circulatory IgA in 
patients with IgA nephropathy shows an abnormal glycosylation, characterized by a 
decreased galactosylation of O-linked sugar chains (39). Patients with rheumatoid ar-
thritis produce increased levels of a certain glycoform of IgG that lacks the terminal 
galactose moieties on the N-terminal glycan chains. This so-called G0-IgG has been 
shown to bind MBL (40). The hypothesis that altered glycosylation of IgA contributes 
to complement activation in IgA nephropathy is presently under investigation. 
Binding of IgA to microorganisms enables its interaction with phagocytes via the 
phagocytic Fcα receptor CD89 (29). Together with complement activation, this may 
result in pathogen elimination, involving CD89 and complement receptors. MBL 
binding may directly contribute to phagocytosis via MBL receptors (41; 42). In this 
respect it is conceivable that complement receptors and IgA receptors act together 
in pathogen elimination (29). In a similar way, classical pathway activation via IgG 
antibodies works in concert with Fcγ receptors (43).
Based on a number of studies in individuals with MBL gene mutations, the promi-
nent role of MBL in innate immunity has been well appreciated. The protective role 
of MBL against infection can be explained by the direct binding of MBL to micro-
organisms (1; 13). MBL binding to IgA may be an additional protective mechanism 
against microorganisms to which MBL does not bind directly. In situations in which 
pre-exposure to a pathogen has taken place, such as after vaccination or during 
chronic infection, MBL may act in concert with IgA to maintain host integrity. Such 
a mechanism is conceivable for example in cystic fi brosis, in which chronic lung in-
fections often lead to irreversible pulmonary damage and death. Expression of MBL 
variant alleles in patients with cystic fi brosis is associated with a severely reduced 
life span (12).
Although MBL is an important defense factor of the immune system, it may also 
play an unfavorable role in disease progression. This is proposed for rheumatoid 
arthritis, and is suggested by the presence of MBL in renal biopsies from patients 
with IgA nephropathy, Henoch-Schönlein purpura, SLE, and post-streptococcal glo-
merulonephritis (19; 20; 32; 40; 44). IgA nephropathy is the leading cause of end 
stage renal disease worldwide. Therefore, the IgA-binding function of MBL described 
in the present study is also likely to play a dual role in immunity. On the one hand, 
it may link the innate and the adaptive immune system and thereby protect the in-
dividual against invading pathogens. In this respect, antibody-mediated complement 
activation can be considered as an additional parallel between MBL and C1q. On 
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the other hand, it may enhance the pro-infl ammatory effects of IgA deposition in the 
glomerulus, ultimately leading to renal injury. 
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CHAPTER 3
MBL and type I diabetes
Elevated Levels of Mannose Binding Lectin at Clinical 
Manifestation of Type 1 Diabetes in Juveniles
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ABSTRACT
Mannose Binding Lectin (MBL) is a recognition molecule of the lectin pathway of 
complement and a key component of innate immunity. MBL polymorphisms have 
been described which are associated with MBL serum concentration, impaired 
function and diabetic complications. We investigated 86 new-onset juvenile type 1 
diabetic patients and compared these with their non-diabetic siblings and healthy 
unrelated control subjects. Polymorphisms of MBL exon 1 and promoter were de-
termined and serum concentration and MBL-complex activity were measured. While 
the genetic polymorphisms of MBL were not different between patients and controls, 
MBL serum concentration as well as MBL complex activity was signifi cantly higher 
in new onset diabetic patients compared to their siblings matched for high produc-
ing MBL genotypes (p=0.0018 and p=0.0005, respectively). The increase in MBL 
complex activity in high MBL producing patients could only partially be explained 
by high MBL production as demonstrated by an increased MBL complex activity/
MBL concentration ratio (p=0.004). We conclude that MBL serum concentration and 
complex activity is increased in early onset diabetic patients upon manifestation 
independently of genetic predisposition to high MBL production, indicating a pos-
sible role in the immunopathogenesis of type 1 diabetes, in addition to the adaptive 
islet autoimmunity.
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INTRODUCTION
Type 1 (insulin dependent) diabetes mellitus (T1D) is an autoimmune disease char-
acterized by the specifi c destruction of beta cells in the pancreas. The etiology of 
T1D is multifactorial, consisting of genetic predisposition and environmental factors 
including a variety of viruses and dietary components (1;2). The role of the adap-
tive immune system in the autoimmune process leading to type 1 diabetes is well 
established. Presently the interest for the innate immune system in the immuno-
pathogenesis of T1D is mounting (3-5). It is generally proposed that the recognition 
of self-determinants is confi ned to the adaptive immune system, diminishing the role 
of the innate immune system in auto-immunity. However evidence is growing that 
changes in the innate immune system could lead to autoimmunity, either by priming 
or promoting aggressive immune responses (6).
Mannose Binding Lectin (MBL) is a key molecule of the innate immune system 
and is able to bind common carbohydrate structures of a variety of microorganisms 
(including bacteria, viruses and fungi), resulting in direct opsonophagocytosis and 
complement activation. In plasma, MBL is associated with MBL-associated serine 
proteases (MASP). Upon binding of MBL to its ligand, the subsequent MASP-2 activa-
tion is responsible for complement activation via the lectin pathway (7). Exon 1 of 
the mbl-2 gene, contains three known single nucleotide polymorphisms (SNPs) at 
codons 52, referred to as allele ‘D’, codon 54 (allele ‘B’) and codon 57 (allele ‘C’) (8). 
These SNPs are associated with low serum concentrations, disturbed polymerization 
and impaired function of MBL (9;10). Dependent on ethnicity, the allele frequency 
of variant alleles B, C and D, commonly referred to as O-alleles, may be above 40% 
(wildtype = A/A). In addition to the three SNPs in exon 1, there are several other 
polymorphic sites located in the MBL promoter region, including SNPs located at 
positions -550 (H/L variant), and -221 (X/Y variant). The common allele A of exon 
1 is associated with the following haplotypes: HYA, LYA and LXA, exhibiting re-
spectively high, intermediate and low promoter activity and serum MBL levels. The 
structural alleles carry the following haplotypes: LYB, LYC and HYD (11;12). Low 
MBL serum levels and genetic polymorphisms associated with impaired MBL func-
tion have been shown to be associated with different autoimmune diseases including 
celiac disease and systemic lupus erythematosis (13;14). Although the complement 
system has been studied in diabetes(15), the association between MBL and the im-
munopathogenesis of diabetes has not yet been investigated to any extent. MBL has 
been associated with vascular complications in diabetic patients. High MBL geno-
types are signifi cantly more frequent in diabetic patients with nephropathy than in 
normoalbuminuric diabetic patients. Furthermore, comparing patients with identical 
MBL genotypes, serum MBL levels were higher in patients with nephropathy than 
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those with normoalbuminuria (16;17). Recently, high MBL levels in the early course 
of type 1 diabetes were shown to be associated with development of albuminuria, 
indicating that MBL may be involved in the pathogenesis of diabetic microvascular 
complications(18).
We decided to address the possible association between MBL and the pathogenesis 
of T1D. We hypothesize that, as the insulin production diminishes during insulitis, 
MBL serum concentration will rise as a consequence of the infl ammation process. 
MBL in turn, could promote the adaptive immune response, either via enhanced 
complement activation or increased opsonophagocytosis of auto-antigens, inter-
weaving MBL in the complex autoimmune process of T1D. 
To test our hypothesis, we studied 86 juvenile type 1 diabetic patients at clinical 
presentation. With the intention to match for age, genetic background, municipality 
of residence and other environmental factors, an unaffected sibling was included of 
every diabetic patient as control. For genetic analysis a healthy, unrelated control 
group was included in the study of 69 voluntary healthy blood donors. MBL geno-
type, concentration and complex activity were further correlated with diagnostic and 
predictive parameters as serum fructosamine levels, the presence of islet autoanti-
bodies, and HLA type.
PATIENTS AND METHODS
Patients
Meeting all legal and ethical criteria set out by the local and ethical committees, fresh 
peripheral blood samples were obtained from 86 juvenile type 1 diabetic patients 
at diagnosis (mean ± SD; age 9.3 ± 3.5 years; 34 females). Diabetes was diagnosed 
according to the criteria set out by the World Health Association (19). Of every 
patient, a sibling control was included as control for serological assessment of MBL 
concentration and MBL complex activity (age 10.3 ± 4.8 years; 36 females). In order 
to avoid a parental selection bias, a control group of 69 healthy blood donors was 
included for allele frequency analysis. Serum was immediately aliquotted and frozen 
at -70°C. DNA was routinely isolated from heparinized blood.
MBL genotyping
MBL SNPs at codon 52, codon 54 and codon 57 of the mbl2 gene were typed by py-
rosequencing. The MBL genotype of carriers of one or two variant allele(s) (B, C, or 
D alleles) was designated as A/O and O/O, respectively, whereas the MBL genotype 
of only wildtype allele carriers at all three positions were designated as A/A. 
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Promoter SNPs located at positions H/L (-550) and Y/X (-221) were typed by 
polymerase chain reaction (PCR) using sequence-specifi c priming (SSP). PCR’s were 
performed in a total volume of 10 µl, containing 10 ng genomic DNA, 3 pmol of each 
primer, 200 µM dNTPs (Amersham Biosciences), 5% glycerol (Gibco), and 0.5 units 
of Taq DNA polymerase (Promega Life Science). The amplifi cation buffer consisted 
of 50 mM KCl (Merck), 10 mM Tris-HCl (USB) pH 8.4, 1.5 mM MgCl
2
 (Promega Life 
Science), and 0.06 mg/ml bovine serum albumin (BSA; Promega Life Science). We 
included a PCR accounting for a growth hormone-1 gene fragment as an internal 
positive control using 2 pmol of each primer. The primer sequences for the MBL 
promoter genotyping and internal control are shown in table 1. PCR’s were carried 
out in a Peltier Thermal Cycler (PTC-200; MJ Research). After an initial denaturation 
step at 95°C for 5 min, touchdown PCR was used to increase the specifi city of primer 
annealing during the fi rst fi ve cycles, consisting of denaturation at 94°C for 30 s, an-
nealing at 65°C→60°C for 30 s and extension at 72°C for 20 s, followed by 30 cycles 
with an annealing step at 60°C for 30 s. Finally, a 2 min extension was performed 
at 72°C. For visualization, the amplifi cation products were run on a 1.5% (w/v) 
agarose MP gel (Boehringer Mannheim) prestained with ethidium bromide. Primer 
sequences are described in table 1.
The conditions for PCR amplifi cation and primer sets that are used in this study are 
available on the journal’s website (online appendix available from http://diabetes.
diabetesjournals.org). For analysis, MBL genotypes HYA/HYA, HYA/LYA, LYA/LYA, 
HYA/LXA and LYA/LXA were considered high MBL producing genotypes (HP). Low 
MBL producing genotypes (LP) were defi ned as LXA/LXA, HYA/O and LYA/O. Geno-
types LXA/O and O/O were considered MBL defi cient (DF).
Table 1: Primers of Mannose Binding Lectin (MBL) promoter polymerase chain reaction (PCR) sequence speciﬁ c priming
SNP Forward primer Reverse primer PCR product (bp)
-550
H 5’-AGGCTGCTGAGGTTTCTTAG-3’ 5’-GCTTCCCCTTGGTGTTTTAC-3’ 253
L 5’-GCTTCCCCTTGGTGTTTTAG-3’ 253
-221
Y 5’-CATTTGTTCTCACTGCCACG-3’ 5’-CTACAATCTGGGTGCAGGC-3’ 228
X 5’-CATTTGTTCTCACTGCCACC-3’ 228
Control 5’-CAGTGCCTTCCCAACCATTCCCTTA-3’ 5’-ATCCACTCACGGATTTCTGTTGTGTTTC-3’ 485
H: G variant of the SNP at position -550 of the MBL promoter. 
L: C variant of the SNP at position -550 of the MBL promoter.
Y: G variant of the SNP at position -221 of the MBL promoter.
X: C variant of the SNP at position -221 of the MBL promoter.
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MBL concentration
MBL serum concentrations were measured blinded in all serum samples by sand-
wich ELISA essentially as previously described with some modifi cations (10). Briefl y, 
plates were coated with mAb 3E7 (anti-MBL mAb kindly provided by Dr. T. Fujita, 
Fukushima, Japan) at 5 µg/ml. Sera were diluted in PBS containing 0.05% Tween-20 
and 1% BSA. MBL was detected using dig-conjugated mAb 3E7, followed by HRP-
conjugated sheep anti-dig antibodies (Boehringer).
MBL complex activity
MBL complex activity was measured blinded in all serum samples as previously 
described (20). Briefl y, mannan-coated plates were incubated with human serum 
diluted in GVB++, containing 1M NaCl, for 16 hours at 4°C. Plates were washed 
with PBS/Tween containing 5 mM CaCl
2
 , followed by incubation with purifi ed C4 
(1µg/ml), diluted in GVB++ for 1 hour at 37°C. Activation of C4 was assessed.
HLA typing
All subjects were HLA typed at class 1 using a PCR-sequence-specifi c oligonucleotide 
probe (Dynal Biotech) and typed at HLA class 2 using standard PCR for sequence-
specifi c polymorphisms.
Autoantibody typing
Glutamic acid decarboxylase (GAD) and insulinoma antigen 2 (IA2) antibodies were 
determined in all serum samples by radiobinding assay as described in great detail 
(21).
C-reactive protein concentration
C-reactive protein was measured by use of a sandwich enzyme immunoassay (Kor-
dia) that was based on two polyclonal rabbit antibodies against C-reactive protein. 
The between-assay coeffi cient of variation was 5.3% at 0.82 mg/L and 5.1% at 8.9 
mg/L. The sensitivity of the assay was 1.1 µg/L in our laboratory. All samples were 
assayed in 1 batch. Normal values are <20 mg/L.
Fructosamine concentration
In 53 patients, suffi cient amounts of serum were available for routine fructosamine 
serum concentration quantifi cation. Fructosamine was determined on a Roche In-
tegra analyzer, using Nitrobluetetrazolium reagent (Roche Diagnostics, Mannheim, 
Germany).
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Statistical analysis
Statistical analysis for group comparison was performed using a Mann-Whitney test. 
Allele frequency distribution was analyzed using Chi-square analyses with Fisher 
exact tests, and corrected for the number of comparisons. Correlation was evalu-
ated using the Spearman rank correlation coeffi cient (r). All statistical analyses were 
performed using GraphPad Prism (GraphPad Software), and P<0.05 was considered 
signifi cant.
RESULTS
MBL genotype
The allele frequency of SNPs located in exon 1 and the promoter region of the mbl-2 
gene were compared between patients and healthy controls. No signifi cant differ-
ence in allele frequency of the promoter SNPs could be observed between patients 
and healthy controls (table 2). Allele C located at position 57 of exon 1 of the MBL 
gene showed a borderline signifi cant increase in frequency in T1D patients before 
correction (p=0.05, Fisher’s exact test, table 2), that was lost after correction for 
the number of comparisons. We did not observe any signifi cant difference in allele 
frequencies of the other polymorphic sites of exon 1. Comparing high MBL produc-
ing (HP) genotypes, low MBL producing (LP) genotypes and MBL defi cient (DF) 
genotypes between patients and healthy controls, no dissimilarity was observed. 
MBL serum concentration
MBL serum concentration was compared between patients and sibling controls. 
Groups not stratifi ed according to MBL genotype, showed no signifi cant differences 
(p=0.25, Mann-Whitney test, fi gure 1). When patients and sibling controls were di-
vided according to HP, LP and DF genotypes, patients in the high MBL producing 
group had a signifi cantly higher serum MBL level (p=0.0018, Mann-Whitney test, 
fi gure 1).
MBL complex activity
Next to the MBL concentration, we also examined MBL function by measuring MBL 
complex activity. When we compared MBL complex activity between patients and 
sibling controls, MBL complex activity was strongly elevated in diabetic patients 
(p=0.01, Mann-Whitney test, fi gure 2). Stratifying both patients and sibling controls 
according to HP, LP and DF genotypes, revealed that MBL complex activity is strong-
ly dependent on MBL genotype in both patients and in sibling controls (p<0.0001, 
ANOVA). However, MBL complex activity was approximately 2-fold higher in dia-
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betic patients with a high producing MBL genotype than in the sibling controls 
(p<0.00005, Mann-Whitney test, fi gure 1). No difference between patients and sibling 
controls was observed for the LP and DF genotypes.
Table 2: Frequency, phenotype and nomenclature of MBL Single nucleotide Polymorphisms. 
Haplotype Common
reference
Phenotype
(MBL production)
Haplotype frequency
     Patients (n=86)     Controls (n=69)
n (%) n % p
HYA A High 53 (30.8) 42 (30.4) 1.00
LYA A High/intermediate 46 (26.7) 46 (33.3) 0.21
LXA A Low 32 (18.6) 23 (16.7) 0.77
HYD O Deﬁ cient 12 (7.0) 8 (5.8) 0.82
LYB O Deﬁ cient 21 (12.2) 18 (13.0) 0.86
LYC O Deﬁ cient 8 (4.7) 1 (0.7) 0.05
Genotype Common
reference
Phenotype
(MBL production)
Genotype frequency
     Patients (n=86)    Controls (n=69)
n (%) n % p
HYA/HYA
HYA/LYA
LYA/LYA HP High 46 (53.4) 41 (59.4) 0.63
HYA/LXA
LYA/LXA
LXA/LXA
HYA/O LP Low 26 (30.2) 22 (31.9) 0.86
LYA/O
LXA/O DF Deﬁ cient 14 (16.3) 6 (8.7) 0.23
O/O
A: MBL wildtype for SNPs located in exon 1 of the mbl-2 gene
O: Varient for SNPs located in exon 1 of the mbl-2 gene
HP: High producing MBL genotype
LP: Low producing MBL genotype
DF: Deﬁ cient MBL genotype
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Comparing MBL concentration and MBL complex activity
The MBL concentration was related to the MBL complex activity in both diabetic 
patients and the sibling controls. MBL concentration was strongly correlated to MBL 
complex activity in both groups (p<0.0001, R = 0.87, Spearman test, fi gure 3). Since 
the MBL complex activity shows a stronger elevation in patients as compared to sibling 
controls than the MBL concentration (fi gure 1), we normalized the amount of MBL, by 
calculating a ratio. The MBL complex activity/MBL concentration ratio was compared 
between patients and sibling controls in accordance to the MBL genotype. Patients 
with a HP producing genotype showed a signifi cantly increased ratio (mean: 1.6) as 
compared to sibling controls (mean: 1.1) (p=0.004, Mann-Whitney test, fi gure 2A).
HLA, autoantibodies and fructosamine concentration
No signifi cant relation was observed between MBL genotype, MBL serum concentra-
tion and MBL complex activity when comparing to the presence of autoantibodies or 
high risk HLA types (22) (data not shown). Fructosamine serum concentration cor-
related with MBL complex activity but not MBL serum levels (overall MBL producers 
(HP and LP) p=0.0075, r=0.66; HP: p=0.03, r=0.40; LP: p=0.0076, r=0.66, Spearman 
test, fi gure 2B).
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Figure 1. MBL serum concentration in the total group of diabetic patients (A) and diabetic patients with high producing MBL 
genotypes (HP) (B). Patients with an HP genotype showed an increased MBL serum concentration compared to their sibling 
controls (p=0.0018, Mann-Whitney test). 
MBL complex activity in the total group of diabetic patients (C) and diabetic high producing MBL genotypes (HP) (D). When 
analyzed as total group, diabetic patients displayed an increased MBL complex activity (p=0.01, Mann-Whitney test), which 
after stratiﬁ cation according to MBL genotype could be attributed entirely to patients in the HP group (p=0.00005, Mann-
Whitney test).
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Figure 2. A: Ratio MBL complex activity / MBL serum concentration. Patients displayed a signiﬁ cantly increased ratio 
compared to sibling controls, signifying greater activity per molecule MBL (p=0.004, Mann-Whitney test). B: Correlation 
between MBL complex activity and serum fructosamine level, stratiﬁ ed according to MBL genotype. Diabetic patients with 
an MBL producing genotype (HP and LP) showed a signiﬁ cant correlation (p=0.0075, r=0.66). The HP and LP subgroups 
individually showed a signiﬁ cant correlation (p=0.03, r=0.40; p=0.0076, r=0.66, respectively). Linear regression analysis 
showed signiﬁ cance in both HP group (solid line) and LP group of diabetic patients (dotted line) (r2=0.24, p=0.007; r2=0.52, 
p=0.003, respectively).
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Figure 3. Correlation of MBL complex activity and MBL serum concentration.
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C-reactive protein
In all but two diabetic patients, CRP levels were within the normal range (mean: 
1.67 mg/L, SD: 4.73 mg/L; normal range below 20 mg/L). There was no correlation 
between CRP and either MBL concentration or MBL complex activity (total patient 
group: CRP vs. MBL concentration: p=0.82, r=-0.024, CRP vs. MBL complex activity 
p=0.97, r=-0.004; HP: CRP vs. MBL concentration: p=0.32, r=0.150, CRP vs. MBL 
complex activity p=0.76, r=0.046, Spearman test).
DISCUSSION
Our study demonstrates that serum MBL levels and MBL complex activity are el-
evated at clinical manifestation in juvenile type 1 diabetic patients with HP MBL 
genotype compared to sibling controls. The complex activity was higher within the 
group of HP genotypes of T1D patients, suggesting that the increase was associated 
with the immunopathogenesis of type 1 diabetes, rather than genetic variation. In-
terestingly, the ratio between MBL concentration and MBL complex activity was also 
signifi cantly higher in the HP patient group, signifying a greater activity per molecule 
MBL. This indicates that MBL function in new onset diabetic patients is increased in 
addition to elevated MBL protein concentration. 
The increase in functional MBL activity in diabetic patients could be a result of 
immune hyperactivity. Although MBL has been suggested to act as an acute phase 
protein (23), several studies have been unable to show an association between MBL 
and CRP as acute phase reactant (16;17;24). Our studies confi rm the absence of an 
association between both MBL concentration and MBL complex activity and CRP. 
This renders acute phase reactivity as an unlikely explanation for the increased MBL 
levels and activity in new onset type 1 diabetes. Alternatively, it could be argued that 
the signifi cant association of MBL complex activity, but not MBL serum concentra-
tion, with fructosamine serum levels implies that this is a consequence of poor gly-
cemic control, rather than a surrogate of immune hyperactivity. Nonetheless, in view 
of a lack of association of MBL serum levels in either subpopulation of patients with 
fructosamine levels, we favor the interpretation that the increased serum levels are 
associated with the immunopathogenesis of type 1 diabetes, while the actual MBL 
complex activity is affected by glycemic control. Elevated glucose levels resulting 
in high MBL complex activity could facilitate the adaptive autoimmune response by 
means of direct opsonophagocytosis of aberrantly glycosilated autoantigens. Finally, 
it should be appreciated that in plasma, MBL function is dependent of its association 
with serine proteases (MASPs). Currently, there are three known MASPs, MASP-1, 
MASP-2 and MASP-3, all of which have a different function. Among these, MASP-2 is 
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responsible for cleavage of C4 and C2, and generation of the C3 convertase C4bC2a 
(25). It could be hypothesized that an increase in the MBL complex activity on top of 
an increased MBL serum concentration is a result of preferential binding of MASP-2 
to MBL, resulting in a higher C4 splicing ability. Furthermore, in addition to increased 
MBL serum concentration in HP genotypes, MASP-2 levels could be elevated and re-
sult in more prominent MBL complex activity. Finally, it could be hypothesized that 
the increase in MBL complex activity could be the result of reduced inhibition. Fluid 
phase complement inhibitors like C1 esterase inhibitor have been shown to inhibit 
MASP activity (26). Impairment of complement inhibitors as a result of increasing 
hyperglycemia could clarify an increased complement activating capacity of MBL 
with poor glycemic control. 
The observation that serum concentration and complex activity were not increased 
in either the LP or DF genotypes of MBL in T1D patients confi rmed our expectation 
that these genotypes are unable to facilitate a suffi cient MBL response both in T1D 
patients and non-diabetic control subjects. In concurrence with our conclusion, pre-
vious studies have shown a lack of association between MBL serum levels in diabetic 
patients and poor glycemic control (27). Interestingly, it has been suggested that an 
increase in MBL serum concentration as an acute phase response can be suppressed 
by intensive insulin therapy, which fortifi es our conclusion of the contribution of 
MBL in the pathogenesis of T1D (24). A direct implication would be that LP and 
DF MBL genotypes could have a benefi cial effect on T1D, as the onset may be less 
fulminant. In any case, low MBL producing genotypes and MBL defi cient genotypes 
are favorable for diabetic patients, in addition to a potential role of MBL in the 
pathogenesis, as high MBL serum levels have been shown to be associated with 
vascular complications (17).
In conclusion, we suggest that elevated MBL levels, resulting in increased comple-
ment activation, could assist the autoimmune process of insulitis, pathognomonic for 
early stages of T1D and act as a marker for ongoing insulitis. This effect may be en-
hanced by an increased MBL complex activity as a result of poor glycemic control.
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ABSTRACT
Background & Aim: Infection is the primary cause of death after liver transplanta-
tion. Mannose Binding Lectin (MBL) is a recognition molecule of the lectin pathway 
of complement and a key component of innate immunity. MBL variant alleles have 
been described in the coding region of the MBL gene, which are associated with 
low MBL serum concentration and impaired MBL structure and function. The aims of 
our study were to establish the role of the liver in production of serum MBL and to 
evaluate the effect of MBL variant alleles on the susceptibility to infection after liver 
transplantation. 
Methods: We investigated 49 patients undergoing orthotopic liver transplantation. 
MBL exon 1 and promoter polymorphisms were determined in patients and in liver 
donors. MBL serum concentration was determined before and during one year after 
transplantation. The incidence of clinically signifi cant infections during this period 
was assessed. 
Results: Transplantation of MBL-wildtype recipients with donor livers carrying MBL-
variant alleles resulted in a rapid and pronounced decrease of serum MBL levels. 
This serum conversion was associated with the disappearance of high molecular 
weight MBL. No indication for extrahepatic production of serum MBL could be ob-
tained. The presence of MBL variant alleles in the MBL gene of the donor liver, but 
not in the recipient, was associated with a strongly increased incidence of clinically 
signifi cant infections following transplantation. 
Conclusions: Serum MBL is produced by the liver under strong genetic control. 
Following liver transplantation, the MBL genotype of the donor liver is a major risk 
determinant for life-threatening infections.
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INTRODUCTION
Infection is the Achilles heel in liver transplantation constituting the most common 
cause of death at all time points, representing 28.4% of all deaths (1). Immune 
suppressive drugs causing inhibition of the adaptive cellular immune system are 
generally considered to be the primary cause of high infection rates in this patient 
group. This notion underscores the signifi cance of the innate immune system in liver 
transplant patients. 
Mannose Binding Lectin (MBL) is a key molecule of the innate immune system. 
The MBL molecule is composed of homotrimers, containing collagenous domains 
and C-type lectin domains that are organized into higher order multimers. Via its 
lectin domains, MBL is able to bind common carbohydrate structures of a variety of 
micro-organisms (including bacteria, viruses and fungi) resulting in direct opsono-
phagocytosis and complement activation via the lectin pathway (2). 
Exon 1 of the mbl-2 gene, which is located at chromosome 10, contains three 
known single nucleotide polymorphisms (SNPs) at codons 52 (Arg→Cys), referred to 
as allele 'D', codon 54 (Gly→Asp, allele 'B') and codon 57 (Gly→Glu, allele 'C') (3). 
These SNPs are associated with low serum concentrations, disturbed polymerization 
and impaired function of MBL (2, 4). Dependent on ethnicity, the allele frequency 
of variant alleles B, C and D, commonly referred to as O-alleles, may be above 40% 
(wildtype = A/A). In addition to the three SNPs in exon 1, there are several other 
polymorphic sites located in the MBL promoter region, including SNPs located at 
positions -550 (H/L variant), and -221 (X/Y variant), both G to C nucleotide substitu-
tions. The common allele A of exon 1 is associated with the following haplotypes: 
HYA, LYA and LXA, exhibiting respectively high, intermediate and low promoter 
activity and serum MBL levels. The structural alleles carry the following haplotypes: 
LYB, LYC and HXD (5, 6). 
The clinical implication of low MBL serum levels in relation to infection has been 
shown in children and immune-compromised patients (2, 7-9). Variant alleles confer-
ring low MBL concentrations are associated with a doubling of the risk of acquir-
ing infection in early childhood when the adaptive immune system is not yet fully 
developed (10-12). 
Based upon animal models and tissue studies, it is generally assumed that the liver 
is the main producer of MBL, however direct evidence is lacking (2, 13, 14). Produc-
tion of MBL by the liver implies that liver transplantation is distinguished from other 
solid organ transplantations, since it determines functionality of the innate immune 
system after transplantation. We postulate that MBL defi ciency as a result of the liver 
donor’s MBL genotype, contributes to the risk for developing life-threatening infec-
tions in liver transplant patients.
112
C
ha
p
te
r 4
PATIENTS AND METHODS
Patients
Meeting all legal and ethical criteria set out by the local and ethical committees, we 
investigated 49 patients undergoing orthotopic liver transplantation (OLT) in our 
transplant center for cirrhosis or hepatocellular carcinoma. All patients received de-
ceased donor whole orthotopic liver transplantations and standard immune suppres-
sive therapy consisting of corticosteroids, cyclosporine or tacrolimus with or without 
mofetil mycophenolate or azathioprine. Furthermore, all patients received 24 hours 
i.v. antibiotics and 3 weeks of selective bowel decontamination after OLT. To study 
the correlation between MBL genotype and serum concentration, serum samples 
were collected of 25 patients at eight time points: twice prior to transplantation (I/II) 
and at 2 days (III), 1 week (IV), 1 month (V), 3 months (VI), 6 months (VII) and 1 
year after OLT (VIII). 
MBL genotyping
DNA from all 49 liver donors and from 25 recipients was routinely isolated from 
blood or tissue samples. MBL SNPs at codon 52, codon 54 and codon 57 of the mbl2 
gene were typed by pyrosequencing (P. de Knijff and A. Roos, submitted). The MBL 
genotype of carriers of one or two variant allele(s) (B, C, or D alleles) was desig-
nated as A/O and O/O, respectively, whereas the MBL genotype of only wildtype 
allele carriers at all three positions were designated as A/A. For analysis, carriers of 
A/O and O/O MBL genotypes were considered as one group (MBL-variant).
Promoter SNPs located at positions H/L (-550) and Y/X (-221) were typed by poly-
merase chain reaction (PCR) using sequence-specifi c priming (SSP). PCR’s were per-
formed in a total volume of 10 µl, containing 10 ng genomic DNA, 3 pmol of each 
primer, 200 µM dNTPs (Amersham Biosciences), 5% glycerol (Gibco), and 0.5 units 
of Taq DNA polymerase (Promega Life Science). The amplifi cation buffer consisted 
of 50 mM KCl (Merck), 10 mM Tris-HCl (USB) pH 8.4, 1.5 mM MgCl
2
 (Promega Life 
Science), and 0.06 mg/ml bovine serum albumin (BSA; Promega Life Science). We 
included a PCR accounting for a growth hormone-1 gene fragment as an internal 
positive control using 2 pmol of each primer. The primer sequences for the MBL 
promoter genotyping and internal control are shown in table 1. PCR’s were carried 
out in a Peltier Thermal Cycler (PTC-200; MJ Research). After an initial denaturation 
step at 95°C for 5 min, touchdown PCR was used to increase the specifi city of primer 
annealing during the fi rst fi ve cycles, consisting of denaturation at 94°C for 30 s, an-
nealing at 65°C→60°C for 30 s and extension at 72°C for 20 s, followed by 30 cycles 
with an annealing step at 60°C for 30 s. Finally, a 2 min extension was performed at 
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72°C. For visualization, the amplifi cation products were run on a 1.5% (w/v) agarose 
MP gel (Boehringer Mannheim) prestained with ethidium bromide.
MBL concentration
MBL serum concentrations were measured blinded in all serum samples by sand-
wich ELISA essentially as previously described with some modifi cations (4). Briefl y, 
plates were coated with mAb 3E7 (anti-MBL mAb kindly provided by Dr. T. Fujita, 
Fukushima, Japan) at 5 µg/ml. Sera were diluted in PBS containing 0.05% Tween-20 
and 1% BSA. MBL was detected using dig-conjugated mAb 3E7, followed by HRP-
conjugated sheep anti-dig antibodies (Boehringer).
Western blotting
The molecular structure of MBL was examined by Western blotting, essentially as pre-
viously described (4). Human serum (1.2 µl) was subjected to SDS-PAGE using a 6% 
polyacrylamide gradient gel under nonreducing conditions. Proteins were transferred 
to polyvinyldene fl uoride membranes (Immobilon; Millipore, Bedford, MA) using a 
semi-dryblotting procedure. Membranes were blocked with PBS/0.05% Tween-20/2% 
Casein followed by incubation with mAb 3E7 (1 µg/ml) for 16 h at 4°C and HRP-con-
jugated goat anti-mouse IgG (Dako, Glostrup, Denmark) for 2 h at room temperature. 
Development of blots was performed with Supersignal (Pierce Chemical Co., Rock-
ford, Il) and exposed to Hyperfi lms (Amersham Pharmacia Biotech).
Cholinesterase concentration
Cholinesterase was routinely measured in all sera with a fully automated Cobas 
Integra 800 (Roche, Almere, The Netherlands).
Clinical data
Patients who contracted clinically signifi cant infections (CSI) within the fi rst year 
after transplantation were identifi ed using a retrospective computer search of the 
Table 1: Primers of Mannose Binding Lectin (MBL) promoter polymerase chain reaction (PCR) sequence speciﬁ c priming 
SNP Forward primer Reverse primer PCR product (bp)
-550
H 5’-AGGCTGCTGAGGTTTCTTAG-3’ 5’-GCTTCCCCTTGGTGTTTTAC-3’ 253
L 5’-GCTTCCCCTTGGTGTTTTAG-3’ 253
-221
Y 5’-CATTTGTTCTCACTGCCACG-3’ 5’-CTACAATCTGGGTGCAGGC-3’ 228
X 5’-CATTTGTTCTCACTGCCACC-3’ 228
Control 5’-CAGTGCCTTCCCAACCATTCCCTTA-3’ 5’-ATCCACTCACGGATTTCTGTTGTGTTTC-3’ 485
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general patient database. CSI was defi ned as bacteremia, peritonitis or pneumonia 
(i.e. positive blood, ascites or sputum culture with accompanying symptoms). 
Statistical analysis
Statistical analysis for group comparison of MBL serum concentration between pa-
tients receiving an MBL wildtype liver and patients receiving an MBL variant liver 
was performed using a Mann-Whitney test. Differences in the occurrence of CSI in 
patients receiving either an MBL wildtype or an MBL variant liver were analyzed 
using Chi-square analyses with Fisher exact tests. Statistical signifi cance was defi ned 
as P < 0.05.
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Figure 1: Hepatic production of serum MBL.
A. MBL serum concentration in liver transplant recipients 
stratiﬁ ed according to the MBL genotype of the liver [W: 
MBL wildtype (A/A); V: MBL-variant (A/0 or 0/0)]. Error 
bars show the standard error of the mean. (W→W: 
Recipients with wildtype MBL genotype transplanted 
with an MBL wildtype liver, n=10; V→V: Recipients 
with MBL-variant genotype transplanted with an MBL 
variant liver, n=5; W→V: Recipients with wildtype 
MBL genotype transplanted with an MBL variant liver, 
n=9; V→W: Recipient with MBL variant genotype 
transplanted with an MBL wildtype liver, n=1)
B. Serum samples before and 1 year following 
transplantation from liver transplant patients with 
serum conversion were subjected to SDS-PAGE (6% non-
reducing conditions) followed by Western Blotting using 
mAb 3E7. The MBL genotype of the liver pre and post 
transplantation is indicated.
A
B
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RESULTS
MBL serum concentrations were compared with the MBL genotype combination of 
liver donor and recipient (fi gure 1A). Patients receiving a liver with an MBL genotype 
equivalent to their own, showed similar MBL serum concentrations prior and post 
transplantation. However, MBL genotype mismatches between liver donor and recipi-
ent, resulted in a rapid and pronounced serum concentration change that was com-
patible with the MBL genotype of the liver. Reduction in MBL serum levels was seen 
in recipients with wildtype MBL genotype transplanted with a liver of donors with 
MBL-variant genotype, as rapid as 2 days post transplantation. Conversely, in a recipi-
ent with MBL-variant genotype receiving a liver with wildtype MBL genotype, the MBL 
serum concentration increased strongly following transplantation (fi gure 1 A).
Serum MBL from patients before and one year after transplantation was further 
characterized by Western blotting. Conversion of serum MBL could be observed from 
wildtype high molecular weight oligomers to variant low molecular weight mono- 
and multimers and vice versa, depending on the genetic background of the liver 
donor and recipient (fi gure 1B). Serum MBL with a molecular weight above 250 kD 
was only detectable in carriers of a liver expressing one or two wildtype alleles, also 
after prolonged exposure of the fi lm (fi gure 1B and data not shown). No evidence 
was obtained for extra-hepatic production of serum MBL.
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Figure 2: Donor MBL genotype determines MBL serum concentration after transplantation.
MBL serum concentration at 1 year following transplantation in patients stratiﬁ ed according to the MBL genotype of the 
donor liver. Patients with clinically signiﬁ cant infections (CSI) are represented by black dots. 
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Patients receiving an MBL wildtype liver
number Haplotype
donor liver
CSI Micro-organism Weeks
after Tx
1 HYA/HYA Sepsis Escherichia coli, Enterococcus faecalis 28
2 HYA/LYA
3 HYA/LYA
4 HYA/LYA
5 HYA/LYA
6 HYA/LYA
7 HYA/LYA
8 HYA/LYA
9 HYA/LYA
10 HYA/LYA
11 HYA/LYA
12 HYA/LYA
13 HYA/LXA
14 HYA/LXA
15 HYA/LXA
16 HYA/LXA
17 LYA/LXA
18 LYA/LYA
19 LYA/LYA
20 LYA/LYA
21 LYA/LYA
22 LYA/LYA Sepsis Escherichia coli, Enterococcus faecalis 6
23 LYA/LXA
24 LYA/LXA
25 LYA/LXA Pneumonia Streptococcus pneumoniae, Haemophilus inﬂ uenzae 12
Patients receiving an MBL variant liver
26 LXA/LYB Sepsis Klebsiella oxytoca 10
27 LYA/LYB Pneumonia Streptococcus pneumoniae 19
28 HYA/LYB Sepsis
Sepsis
Streptococcus mutans, Klebsiella oxytoca
Gram-negative coccobacilus, Group D streptococci
8
20
29 LYA/LYB
30 LXA/LYB Sepsis Escherichia coli
Enterococcus faecalis
11
31 LYA/LYB
32 LXA/LYB
33 LYA/LYB
34 HYA/LYB
35 HYA/LYB
36 LXA/LYB
37 HYA/LYB
38 HYA/LYC
39 LYA/HYD Peritonitis Coagulase-negative staphylococci 1
40 LXA/HYD Peritonitis Coagulase-negative staphylococci 4
41 LYA/HYD
42 LYA/HYD Sepsis/peritonitis Enterococcus faecalis 3
43 LXA/HYD
44 LYB/LYB Sepsis/peritonitis Coagulase-negative staphylococci, Pseudomonas aeruginosa 4
45 LYB/LYB Sepsis Enterococcus faecalis
Lysteria monocytogenes
16
46 LYB/LYC Sepsis Streptococcus oralis 3
47 LYB/HYD Sepsis Enterococcus faecalis 7
48 HYD/HYD
49 HYD/HYD
Table 2: Occurrence of clinically signiﬁ cant infections (CSI) in 49 liver transplant patients, stratiﬁ ed according to donor liver 
MBL haplotype 
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One year following liver transplantation, recipients of an MBL wildtype liver showed 
up to 40-fold higher MBL serum concentrations than recipients from an MBL-variant 
liver (p<0.0001, Mann-Whitney test, fi gure 2). The function of the liver was evaluated 
at all time points using cholinesterase as a common marker. In all patients, with the 
exception of one, serum cholinesterase concentration increased after transplanta-
tion to normal levels, indicating good graft function (normal range 5.3-13 U/ml). 
The patient that did not sustain normal cholinesterase levels, was an MBL wildtype 
patient who received a donor liver with an MBL variant genotype. This patient died 
shortly after the follow-up period of a sepsis. No difference in liver function could 
be observed between patients receiving a wildtype or an MBL variant genotype liver 
(fi gure 3).
Clinical evaluation of all 49 patients showed that the incidence of clinical signifi cant 
infections was 3.8-fold higher in the recipients of MBL-variant livers, as compared to 
recipients of MBL-wildtype livers (p=0.01, Fisher’s exact test; table 2). The incidence 
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Figure 3: Cholinesterase as a marker for liver function.
Cholinesterase serum concentration in liver transplant recipients stratiﬁ ed according to the MBL genotype of the liver [W: 
MBL wildtype (A/A); V: MBL-variant (A/0 or 0/0)]. Error bars indicate the standard error of the mean. (W to W: Recipients 
with wildtype MBL genotype transplanted with an MBL wildtype liver, n=10; V to V: Recipients with MBL-variant genotype 
transplanted with an MBL variant liver, n=5; W to V: Recipients with wildtype MBL genotype transplanted with an MBL 
variant liver, n=9; V to W: Recipient with MBL variant genotype transplanted with an MBL wildtype liver, n=1)
Figure 4: Donor MBL genotype is a risk factor for clinically signiﬁ cant infections (CSI).
Percentage of CSI in patients stratiﬁ ed according to the genotype of the donor liver.
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of CSI was highest in recipients of livers with an O/O MBL genotype (4/6), fol-
lowed by recipients of livers with an A/O MBL genotype (7/18). Patients receiving a 
MBL wildtype liver had the lowest incidence of CSI (3/25), (p=0.01, Chi-square test, 
fi gure 4). We could not detect an association between recipient MBL genotype and 
incidence of CSI (p=0.34, Fisher’s exact test). No signifi cant relation was observed 
between the different MBL promoter SNPs and the occurrence of clinically signifi cant 
infections.
DISCUSSION
The present study is the fi rst to investigate directly a change of MBL status in liver 
transplant patients. We describe 49 liver transplant patients receiving standard im-
mune suppressive therapy. As the cellular adaptive immune system is suppressed, 
the role of the innate immune system is essential in preventing life-threatening infec-
tions. Moreover, surveys of bacteria have shown that MBL binds to a wide range of 
microbes, including microorganisms that cause severe infections in liver transplant 
patients (15). 
We conclude that the liver is the pivotal source of serum MBL, whereas extrahepat-
ic production is undetectable. After liver transplantation, the donor liver determines 
the MBL serum concentration and molecular size, as evidenced by rapid MBL serum 
conversion. Moreover, the MBL genotype of the donor, not the recipient, determines 
the risk for potential life-threatening infections. Therefore, hepatic production of 
functional MBL is of major importance for the host defense against infection follow-
ing liver transplantation. Accordingly, liver MBL genotypes resulting in low levels 
of serum MBL as well as predominance of low molecular weight oligomers, was 
associated with a strongly increased risk for infection following liver transplantation. 
The increase in CSI appeared to be gene dose-dependent, being most prominent in 
recipients of livers with two MBL-variant alleles. However, as the number of patients 
in the latter group was limited, further studies are warranted.
A recent study showed that a wildtype MBL genotype of the donor strongly pro-
tects against infections in recipients of haemopoietic stem cell transplants, suggesting 
production of MBL by bone marrow-derived cells (8). However, successful haemo-
poietic stem cell transplantation from MBL-suffi cient donors does not result into a 
detectable reconstitution of serum MBL in MBL-defi cient recipients ((16) and R.G. 
Bredius and A. Roos et al. unpublished results). Although the present study clearly 
indicates that serum MBL is produced by the liver, it is conceivable that MBL-produc-
tion by extrahepatic cells may play a local role in host defense.
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The ability to unambiguously identify a group of patients severely prone to infec-
tion post transplantation is of signifi cant clinical value. In an era of donor shortage, 
donor selection based upon MBL genotype is inconceivable. However, our study 
suggests that patients receiving an ‘MBL-variant’ liver could benefi t from MBL re-
placement therapy similar to that presently being studied in phase I/II and III studies 
(17, 18). Furthermore, prophylactic approaches including intensifi ed clinical follow-
up, preemptive antimicrobal therapy and prolonged selective digestive decontamina-
tion could be considered dependent on the MBL genotype of the liver donor.
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CHAPTER 5
Adaptive immunity in pancreatic islet 
transplantation
HLA Incompatibility and Immunogenicity of Human 
Pancreatic Islet Preparations Co-Cultured with Blood 
Cells of Healthy Donors 
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ABSTRACT
Type 1 Diabetes Mellitus (T1D) is a T-cell mediated autoimmune disease character-
ized by the destruction of beta cells in the pancreas. An attractive novel therapy 
for type 1 diabetes is pancreatic islet transplantation, provided that recurrent islet 
autoimmunity and allograft rejection can be prevented.
We analysed the response of peripheral blood mononuclear cells (PBMC) from 
healthy blood donors to human islet-cell preparations with a composition similar 
to that of islet grafts used in clinical transplantation trials. It was examined whether 
the degree of MHC incompatibility between PBMC and donor islet cells is related to 
the degree of proliferative T-cell responses during co-culture of HLA-matched and 
mismatched PBMC with human islet cell-preparations [i.e. mixed islet lymphocyte 
reaction (MILR)]. 
Prominent T-cell responses were observed in the vast majority of cases of double 
HLA class II-mismatches. Intermediate T-cell responsiveness was observed in single 
HLA class II mismatches, whereas HLA-matches did not induce a T-cell response. 
Our results identify the potential immunogenicity of islet preparations transplanted 
between HLA-DR incompatible subjects regardless of an autoimmune background 
of the recipient.
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INTRODUCTION
Since the major histocompatibility complex (MHC) molecule plays an essential role 
in the activation of T cell responses, the genes encoding these molecules have been 
implicated in susceptibility to serve T cell mediated autoimmune diseases. Several 
HLA alleles have been shown to be major genetic risk factors in development of type 
1 diabetes. Vulnerability for type 1 diabetes is genetically dominated by the HLA 
gene region accounting for 42% of the familial inheritance of type 1 diabetes[1].
Type 1 (Insulin Dependent) Diabetes Mellitus (T1D) is an autoimmune disease 
characterized by the specifi c destruction of beta cells in the pancreas. The etiol-
ogy of T1D is multifactorial, consisting of genetic predisposition and environmental 
factors including a variety of viruses and dietary components[2]. It has long been 
acknowledged that T-cells play a crucial role in the immunopathogenesis of type 
1 diabetes, the hallmark of autoimmune diabetes being lymphocytic invasion of 
pancreatic islets[3-10]. 
A potential therapy for diabetes is transplantation of insulin-producing beta-cells 
of isolated pancreatic islets, provided that recurrence of T-cell autoreactivity against 
islet determinants, as well as induction of alloimmunity to donor antigens, is pre-
vented[11-13]. This attractive and recently successful therapy for T1D is overshad-
owed by the need for permanent immune suppression. Without the administration 
of these non-specifi c and potentially harmful immunosuppressive drugs, graft failure 
seems inevitable. Islet transplantation is thus limited to diabetic patients already 
receiving immune suppression for a previous organ transplant, or to patients with se-
vere hypoglycemia unawareness or uncontrollable hyperglycemia. The introduction 
of a new glucocorticoid free immunosuppressive regime, the so-called Edmonton 
protocol, has improved the outcome of islet transplantation considerably[14]. This 
protocol includes sirolimus, tacrolimus and dacluzimab. All these immunosuppres-
sive drugs share the same basic quality that they all inhibit T-cell stimulation and 
proliferation, identifying once again T-cells as key-players in this rejection process.
Prediction and prevention of ongoing beta-cell destruction after islet transplanta-
tion, resulting in long-term graft survival is of utmost importance. In order to be able 
to optimise the current islet transplantation, it is essential to study the reaction of 
T-cells to islets. 
In rat studies, it has been shown that T-cells obtained prior to islet transplantation 
can react against islet allografts in a mixed islet-leukocyte culture [15]. This reactivity 
was similar to that of T-cells isolated after grafting. We have previously demonstrated 
a marked increase in T-cell alloreactivity in immune suppressed type 1 diabetes pa-
tients rapidly upon implantation of human islet allografts from multiple donors[11]. 
This rise was exclusive to patients that acutely rejected the islet allograft, and absent 
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in cases of successful restoration of beta-cell function. The contribution of HLA class 
II to immunogenicity of islets was further underscored by our recent observation 
that islet autoantigens are processed and presented by vascular endothelial cells 
expressing MHC class II leading to activation of autoreactive T-cells [16], implying 
that MHC class II could be important in human islet graft-failure by autoreactivity[17]. 
Little is known about the extent that human islet preparations could be target of 
alloreactivity in relation with the degree of HLA mismatching with human healthy 
blood donors.
To evaluate the potential immunogenicity of human islet preparations under im-
munocompetent conditions, we investigated the ability of peripheral blood mono-
nuclear cells (PBMC), isolated from immunologically uncompromised healthy blood 
donors, to react human islet preparations in relation with the degree of HLA-DR 
incompatibility. Mixed islets lymphocyte cultures [18,19] were performed with a 
panel of HLA-DR matched and mismatched healthy blood donors. For comparison, 
mixed lymphocyte reactions (MLR) using PBMC of blood donors with PBMC of the 
islet donor, were carried out and analysed in relationship to the pattern of reactivity 
found in the MILR.
MATERIAL AND METHODS
Human islet isolation and culture
Human pancreata, were obtained from organ donors (eleven preparations from 
10 donors, age 2-60 years) at European hospitals affi liated with ß-Cell Transplant, 
a European Concerted Action on islet cell transplantation in diabetes. Islets were 
Figure 1: Representative image of human pancreatic cell preparations immunostained for HLA-DR. Positive cells (arrow) were 
present at a low percentage (<1%) and occurred usually as single units. The scale bar represents 50µm. 
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prepared in the Central Unit of this multicenter program (Medical Campus, Vrije 
Universiteit Brussel) [12]. Detailed description of methods of isolation, phenotypic 
and functional characterization of the islet preparations is available elsewhere [12]. 
This study was conducted with cultured Islet cell preparations that were comparable 
to those incorporated in grafts that are implanted in patients. They are composed of 
endocrine and non-endocrine duct cells with, in average, 48 percent insulin-positive 
cells (Table 1). Their content in MHC-II expressing cells is consistently lower than 1 
percent (Figure 1). The available beta cell mass was too low for inclusion in grafts so 
that the preparations became available for approved research projects if they fulfi lled 
the legal and ethical criteria that were set for such use. The isolated islet preparations 
were cultured in Ham’s F10 medium[12] for 1-5 days before transfer to Leiden, where 
they were processed immediately for immunological studies. 
Table 1: Characterization of human islet preparations.
Donors Age Sex HLA-DR Culture 
Time
(days)
Cellular composition (% total)
Exocrine Non-
granulated
Endocrine Dead Insulin 
positive
1 17 M DR4 DR6(13) 5 0 40 58 2 58
2 22 M DR2(15) DR6(13) 1 15 31 50 4 42
3 40 F DR2(16) DR3(17) 5 0 58 32 10 28
4 20 M DR4 8 0 46 50 4 42
5 12 M DR8 DR12 5 0 50 42 8 44
6 2 M DR2 DR4 4 0 28 62 10 57
7 52 M DR6 DR13 3 2 28 64 6 49
8 42 F DR1 6 0 12 82 6 61
9 48 F DR2 DR6 3 0 8 76 16 63
10a 60 M DR4 DR6 4 0 31 66 3 54
10b 60 M DR4 DR6 4 0 66 30 4 30
Peripheral Blood mononuclear cells (PBMC) isolation
PBMC were obtained from healthy blood donors visiting the blood bank in Leiden, 
the Netherlands by Ficoll separation after obtaining informed consent. 
HLA-DR typing
The HLA-DR genotypes of both blood- and pancreas-donors were determined by 
conventional genotyping in the vast majority of cases as described in detail [20]. Inci-
dentally, pancreata were HLA typed by serology only. Therefore, all HLA genotypes 
were translated to serotype to allow comparison.
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Mixed islet lymphocyte reaction (MILR)
Islet preparations in a concentration range (10.000 to 150.000 endocrine cells per 
well) were co-cultured with 150.000 PBMC per well, in micro well tissue plates (Gri-
ener) for 5 days at 37°C, 5% carbon dioxide in air. Islet preparations and PMBC were 
HLA-DR matched or mismatched. RPMI culture medium was used containing 10% 
fetal calf serum and 100 units/ml penicillin and 100 µg/ml streptomycin. Samples 
were incubated in triplo. On day 5 [H3]-Thymidine was added to each well for 16 
hours in an end concentration of 1µCi/ml. The MILR response was measured by 
incorporation of [H3]-Thymidine in proliferating lymphocytes using a liquid scintilla-
tion counter (LKB Wallac, Croydon UK). Dose-response curves differed between islet 
preparations, and optimal responses were determined individually. For standardiza-
tion and comparison between islet preparations, the MILR was considered positive 
when the signal exceeded the average signal of stimulatory cells alone plus three 
times the standard deviation.
Furthermore, in two cases a double mismatched MILR was performed, in the pres-
ence and absence of monoclonal antibodies directed against HLA-DR (B8.11.2), 
HLA-DQ (SPV-L3) and HLA class 1 (W6.32). The human islet preparations were 
incubated in the presence of 10 µg/ml of monoclonal antibodies directed against 
HLA-DR (B8.11.2), HLA-DQ (SPV-L3) and HLA class 1 (W6.32).
Mixed lymphocyte reaction (MLR)
In the MLR, PBMC of both blood donors and islet donors were used. γ-irradiated 
PBMC (3000 R) of the islet donor were incubated with blood donor PMBC in a 1:1 
ratio, 200.000 cells per well (Griener). Samples were incubated in triplicate for 5 days 
at 37°C, 5% carbon dioxide in air. On day 5 [H3]-Thymidine was added to each well 
for 16 hours in an end concentration of 1 µCi/ml. The MLR response was measured 
by incorporation of [H3]-Thymidine in proliferating lymphocytes. The MLR responses 
were considered positive when the signal exceeded the average signal of stimulatory 
cells alone plus 3 times the standard deviation. 
Statistical analysis
Statistical analysis for group comparison was performed using Chi-square analyses 
with two-sided Fisher exact tests. Statistical signifi cance was achieved if the P value 
was less than 0.05. Frequencies of both positive and negative MILR and MLR were 
compared with the chi-square test or the Fisher’s exact probability test.
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RESULTS
Comparison between MILR and HLA-DR haplotype
Mixed islet lymphocyte reactions (MILR) were performed with islet and PBMC prep-
arations that were HLA-DR matched, single mismatched and doubled mismatched 
(Table 2). T cell responses were exclusively seen in HLA mismatch combinations 
(p=0.0004). In the group of double HLA-DR mismatches, 12/13 resulted in potent T 
cell proliferative responsiveness (double mismatched vs. matched: p=0.0003). The one 
combination without reactivity involved the islet preparation with the highest percent 
endocrine cells (82%). Intermediate T cell responses were observed in 6/9 tested 
combinations with a single HLA-DR mismatch (single mismatch vs. matched: p=0.017), 
whereas none of the 6 HLA-DR matched combinations induced a T cell response. In 
rare cases, suffi cient numbers of islets were available to allow HLA blocking studies. 
The observed T cell proliferative responses were to a large extent suppressed when 
the mixed islet lymphocyte reactions were performed in presence of a monoclonal 
antibody directed against HLA-DR, whereas no inhibition was seen with monoclonal 
antibodies directed against HLA-DQ and HLA class 1 (data not shown). 
Table 2: MILR in relation with HLA-DR matching. Indicated are positive or negative proliferative responses of HLA- 
matched, single or double mismatched PBMC of healthy donors against human islet-preparations, tested in the MILR 
(“nr.” refers to the donor number indicated in Table 1). 
MILR HLA-DR mismatches
2 1 0
POS
DR3,3 x DR4,6 (nr.1)*
DR3,3 x DR2,6 (nr.2)
DR4,10 x DR 2,3(nr.3)
DR1,8 x DR4,4(nr.4)
DR6,13 x DR2,4(nr.6)
DR3,3 x DR6,13(nr.7)
DR2,6 x DR 1,1(nr.8)
DR1,7 x DR2,6 (nr. 9)
DR 15,15 x DR 4,6 (nr.10a)
DR 1,1 x DR 4,6 (nr.10a)
DR 16,11 x DR 4,6 (nr.10b)
DR 3,7 x DR 4,6 (nr.10b)
DR6,6 x DR4,6(nr.1)*
DR 2,6(14) x DR 2,6(13)(nr.2)
DR2,2 x DR2,3(nr.3)
DR1,8 x DR8,12(nr.5)
DR2,6 x DR6,13(nr.7)
DR1,8 x DR1,1(nr.8)
NEG DR 3,7 x 1,1(nr.8) DR3,3 x DR2,3(nr.3)
DR2,6 x DR2,4(nr.6)
DR1,6 x DR 1,1(nr.8)
DR2,6 x DR2,6(nr.2)
DR2,3 x DR2,3(nr.3)
DR6,13 x DR6,13(nr.7)
DR1,1 x DR1,1(nr.8)
DR 4,6 x DR 4,6 (nr.10a)
DR 4,6 x DR 4,6 (nr.10b)
Mismatch vs. Match:  p = 0,0004
Double mismatch vs. Match: p = 0,0003
Single mismatch vs. Match: p = 0,017
* No MLR done
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Comparison between MILR and MLR
The lymphocyte reactivity to allogeneic islet cell preparations (MILR) was compared 
to that measured against lymphocytes (MLR) that were isolated from the islet cell 
donor (table 2). The MLR tests were positive for 15/16 cases where a positive MILR 
had been measured; the one MLR negative/ MILR positive case related to the only 
child (2y) that was tested as islet donor (Table 3). In the group of negative MILR 
tests, 3/10 exhibited a positive MLR. Overall, a signifi cant relation was seen between 
recognition of islet donor PBMC and islet preparations by healthy donor derived 
PBMC (p=0.0013; Table 3). When the analysis was restricted to the 12 to 60 year old 
donor group the correlation between MILR and MLR was even stronger (p=0.0003).
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Figure 2: Representative comparison between MILR and MLR. Raw counts per minute (cpm) are indicated to illustrate 
background responses of islet preparations, stimulator or responder PBMC alone as well as the amplitude of the proliferative 
response to . (n.d.: not done)
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Table 3: The correlation between the presence (POS) and absence (NEG) of proliferative T-cell responses in co-cultures of PBMC 
isolated from healthy blood donors with human islet preparation. Responsiveness was signiﬁ cantly concordant between MILR 
and MLR (p=0.0013).
MILR MLR
POS NEG
POS
DR 3,3 x DR 2,6
DR 4,10 x DR 2,3
DR 1,8 x DR 4,4
DR 3,3 x DR 6,13
DR 2,6 x DR 1,1
DR 1,7 x DR 2,6
DR 15,15 x DR 4,6
DR 1,1 x DR 4,6
DR 16,11 x DR 4,6
DR 3,7 x DR 4,6
DR 2,6(13) x DR 2,6(14)
DR 2,2 x DR 2,3
DR 1,8 x DR 8,12
DR 2,6 x DR 6,13
DR 1,8 x DR 1,1
DR 3,7 x DR 1,1
DR 6,13 x DR 2,4
DR 2,6 x DR 2,4
NEG DR 3,3 x DR 2,3
DR 1,6 x DR 1,1
DR 2,6 x DR 2,6 
DR 2,3 x DR 2,3
DR 6,13 x DR 6,13
DR 1,1 x DR 1,1
DR 4,6 x DR 4,6
DR 4,6 x DR 4,6
DISCUSSION
Our study demonstrates that cultured human islet cell preparations with a composi-
tion similar to that used in our clinical trial, have a strong immunogenic potential 
dependent of the degree of their HLA incompatibility with responder leukocytes. 
Importantly, matched islet preparation persistently led to absence of alloreactivity in 
vitro. This may bear implications for clinical islet cell transplantation. Human islet 
transplantation has been considered to be a promising therapy for T1D patients 
for the last 31 years[21,22]. A major obstacle that remains to be tackled in allograft 
islet transplantation, is the rejection process resulting in graft failure. The current 
knowledge of the immunogenesis of the rejection process is at best incomplete. This 
might be due to the fact that graft tissue is inaccessible after transplantation, making 
clinical and histological studies very diffi cult and demanding. Hence, most studies 
addressing the specifi c allogeneic rejection response are murine based and cannot 
be extrapolated directly to the human situation. Clinical trials studying the rejection 
process rely upon the presence of C-peptide, indicating beta cell function. The 
immunological status of the islet-transplantation however remains concealed[23]. 
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Multiple donor islet grafts further cloud the different roles of involved actors in this 
immunological play. In the present study we selectively studied the degree of allore-
activity in PBMC of immunocompetent healthy blood donors against allogeneic islet 
preparation with different degrees of HLA incompatibility and composition.
HLA has long been recognized to be of clinical importance in solid organ transplan-
tation as one of the primary causes of Th1/HLA class II antigen-rejection. However 
the importance of HLA in islet transplantation and rejection has been disputed. One 
study showed low or even absent T-cell response directed against pancreatic islets in 
vitro [23]. The authors hypothesized that low T-cell proliferative responses could be 
a direct result of the inhibitory effects of exocrine enzymes upon lymphocytes, utiliz-
ing the role of class II MHC. However, we have demonstrated that alloreactivity in 
type 1 diabetes patients transplanted with human islet allografts strongly correlated 
with acute rejection and loss of graft function in vivo [11]. Moreover, it has been sug-
gested that HLA mismatching could provide better allograft survival of transplanted 
pancreatic islets in autoimmune diabetes, as was shown in mice. It has also been 
argued that avoidance of MHC class II sharing between donor and recipient, could 
avoid the recurrence of autoimmunity and subsequently the destruction of beta 
cells[24]. However, there is little evidence from clinical trials on islet transplanta-
tion that islet allografts benefi t from mismatching with the recipient. Moreover, our 
present data clearly demonstrate that HLA matching signifi cantly reduces the risk for 
alloreactivity, while induction of alloreactivity appears to be the most pronounced 
cause of graft failure[11]. We appreciate that in an era of donor shortage and multiple 
donors being required to obtain a suffi cient islet load for transplantation, donor 
selection based upon HLA is inconceivable. Therefore, tailored immune suppresion 
is of utmost importance in order to optimize the outcome of islet transplantation.
In order to address the involvement of HLA in human islet transplantation, we 
studied the response of peripheral blood mononuclear cells (PBMC) from healthy 
blood donors to human islet-preparations. Healthy donors were chosen, rather than 
diabetic patients, to evaluate the primary T-cell response and exclude recurrent islet 
autoimmunity. Contrary to a previous report [23], a T-cell proliferative reaction could 
be invoked upon stimulation of healthy donor T-cells with double HLA-mismatched 
islet preparations in all but one mixed islet lymphocyte reactions. In contrast, none 
of MILR performed with HLA-DR matched T-cells and islet preparations displayed 
any T-cell responsiveness. Partial HLA-DR mismatching could invoke an intermedi-
ate T-cell response in the majority of cases, which accorded with the MLR.
As previously mentioned, there was only one exception where a positive MLR did 
not correlate with a positive MILR despite a complete HLA class II disparity. This 
occurred in the case of an islet preparation from a 2 year-old pancreas donor, sug-
gesting that donor age may be a factor related to immunogenicity.
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In conclusion, our data clearly demonstrate the immunogenic nature of islet prepa-
rations of clinical norm, even in healthy donors lacking auto-reactive islet T-cells.
The immunogenicity is dependent largely on the degree of HLA matching with 
responder leukocytes. HLA-DR matching is accompanied by lack of immune re-
activity against the islet preparation. Our fi ndings underscore the diffi culty of islet 
allotransplantation, but provide leads to reduce the extent of alloreactivity in clinical 
islet transplantation. 
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SUMMARY AND GENERAL DISCUSSION
The aim of the thesis was to obtain insight in the immunological aspects of trans-
plantation and diabetes, with the emphasis on mannose binding lectin (MBL) as a 
crucial part of the innate immune system. The results of this thesis underscore the 
Jekyll-and-Hyde character of MBL as it is shown that MBL defi ciency is detrimental 
in liver transplantation patients wheras it could be benefi cial in type 1 diabetes. In 
order to fully appreciate the genetic, functional and serological impact of MBL under 
discrete pathological conditions, novel assays were required and designed. As op-
posed to the vast majority of groups studying MBL in relation to disease, presently 
it was opted to expand the focus of the current research by tallying not only MBL 
genetics and MBL serum levels but also MBL function. By doing so, a discrepancy 
was identifi ed between MBL serum levels and functional MBL activity under specifi c 
circumstances, underlining the necessity to study all dimensions of MBL when cor-
relating the lectin pathway (LP) to disease. Furthermore, being capable to study MBL 
in transplantation and diabetes resulted in ability to link specifi c parts of innate and 
adaptive immunity. 
Mannose binding lectin, as a key player of natural immunity, is capable of bind-
ing common carbohydrate structures of a diversity of microorganisms (including 
bacteria, viruses and fungi) and facilitates elimination of these pathogens (1). In the 
general population there is a wide variety in MBL serum concentrations as well as 
functional MBL activity (2). This great diversity in concentration and function has 
been shown to be determined by single nucleotide polymorphisms in exon 1 of the 
mbl2 gene and its promoter(3; 4). Currently, it has well been acknowledged that an 
impaired MBL function signifi cantly increases the risk for infections in individuals 
who largely depend on their innate immune system for anti-microbial defense, like 
immune-compromised patients and young children (5-9). It is therefore intriguing 
that the frequency of variant alleles, resulting in low MBL production, is above 40% 
depending on ethnicity. This percentage is even higher when promoter SNPs are tak-
en into account (3). The high frequency of variant genotypes resulting in low levels 
of high molecular MBL weight and decreased MBL function indicate that in particular 
cases impaired MBL function and low serum concentrations may be benefi cial. This 
has been suggested to be the case for mycobacterial infections, infl ammatory bowel 
disease like ulcerative colitis, and transplantation (1; 10; 11). 
Molecular and immunological characteristics of MBL
Chapter 2 is build up of three parts and shows the close interaction between the 
different complement pathways. The fi rst part of this chapter discusses the functional 
characterization of the lectin pathway in human serum. Here, a novel functional as-
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say is described that enables quantifi cation of autologous complement activation via 
the LP in full human serum up to the formation of the membrane attack complex. 
This assay offers novel possibilities for both patient diagnostics and research.
The second part of this chapter is continuation of the observation shown in the 
previous section, that normal human serum contains IgG, IgA and IgM antibodies 
against mannan. The high frequency of MBL defi ciency suggests that MBL-mediated 
innate immunity can be compensated by alternative defense strategies. To examine 
this hypothesis, complement activation by MBL-binding ligands was studied. The 
results show that the prototypic MBL ligand mannan can induce complement activa-
tion via both the LP and the classical pathway (CP). Furthermore, antibody binding 
to mannan restored complement activation in MBL-defi cient serum in a C1q-depen-
dent manner. Cooperation between the CP and the LP was also observed for comple-
ment activation by the protein 60 from Listeria monocytogenes. It is concluded that 
antibody-mediated CP activation can compensate for impaired target opsonisation 
via the LP in MBL-defi cient individuals. 
The last part of this chapter describes binding of MBL to polymeric serum IgA as a 
novel mechanism for activation of the lectin pathway. Furthermore, it is shown that 
MBL binding to IgA results in complement activation and propose that this leads to a 
synergistic action of MBL and IgA in antimicrobial defense, especially in the mucosal 
immune system. 
It is concluded that the LP of the complement system as a part of the innate immu-
nity is interwoven with the adaptive immune system, a characteristic that previously 
was only allocated to the CP within the complement system.
MBL and type I diabetes
Type 1 (insulin-dependent) diabetes mellitus (T1D) is an autoimmune disease char-
acterized by the specifi c destruction of beta cells in the pancreas. The role of the 
adaptive immune system in the autoimmune process leading to type 1 diabetes is 
well established (12). Presently the interest for the innate immune system in the im-
munopathogenesis of T1D is mounting (13-15). Having previously shown that MBL 
is able to meticulously link the adaptive and innate immune system, it is speculated 
that MBL could be involved in the pathogenesis of type 1 diabetes. It could be 
hypothesized that low MBL serum levels could result in an impaired clearance and 
inactivation of pathogens responsible for beta cell destruction. Contrarily, insulitis 
resulting in tissue damage could activate the lectin pathway via MBL, facilitating ad-
ditional beta cell damage and a more fulminant insulitis. Chapter 3 describes MBL 
in relationship to type 1 diabetes at clinical presentation. In this study new-onset ju-
venile type 1 diabetic patients are investigated in comparison with their non-diabetic 
siblings and healthy unrelated control subjects. The polymorphisms of MBL exon 
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1 and promoter were determined and serum MBL concentration and MBL-complex 
activity were measured. Initially, the genetic MBL constitution did not account for 
disease predisposition, since the genetic epidemiology did not show pronounced 
differences between patient and unrelated control subjects. However, genetic strati-
fi cation based upon MBL polymorphisms in both the coding exon 1 and promoter 
region, proved to be essential to reveal T1D associated differential MBL functionality. 
MBL serum concentration as well as MBL complex activity was signifi cantly higher 
in new onset diabetic patients compared to their siblings matched for high produc-
ing MBL genotypes. The increase in MBL complex activity in high MBL producing 
patients could only partially be explained by high MBL production as demonstrated 
by an increased MBL complex activity/MBL concentration ratio. It is concluded that 
MBL serum concentration and complex activity are increased in early onset diabetic 
patients upon manifestation independently of genetic predisposition to high MBL 
production, indicating a possible role in the immunopathogenesis of type 1 diabetes. 
The study described in this chapter is the fi rst to show an association between MBL 
and the onset of T1D. Although MBL is a major recognition molecule of the lectin 
pathway, it should be appreciated that various other molecules are involved, includ-
ing MBL-associated serine protease and fl uid phase complement inhibitors like C1 
esterase inhibitor. In order to be able to fully comprehend the involvement of the 
lectin pathway in the onset of T1D, further extension of research is required and 
should include all relevant players. However, with our present knowledge it can 
be hypothesized that high MBL levels and MBL activity could facilitate an immune 
response by infl icting or maintaining damage during the insulitis phase of T1D. In 
accordance with the danger model of the immune system (16), the presence of dam-
age is essential for an (auto)immune response 
MBL and liver transplantation
Infection is the primary cause of death after liver transplantation. As transplant pa-
tients require immune suppressive drugs in order to insure graft survival, they rely 
to a great extent on their innate immunity to counteract infections. Studying MBL as 
a major component of the innate immune system, the effect of MBL gene polymor-
phisms on the susceptibility to infection after liver transplantation was evaluated in 
chapter 4. Furthermore, although it is generally assumed that MBL is hepatically 
produced, it was sought to establish the role of the liver in production of serum 
MBL. Patients undergoing orthotopic liver transplantation were investigated. MBL 
promoter and exon 1 polymorphisms were determined in both patients and in liver 
donors. MBL serum concentration was monitored shortly before and during one 
year after transplantation. MBL defi ciency was evaluated in association to the oc-
currence of clinically signifi cant infections during this period. This study shows that 
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transplantation of MBL-wildtype recipients with donor livers carrying MBL-variant 
alleles resulted in a rapid and pronounced decrease of serum MBL levels. This 
serum conversion was associated with the disappearance of high molecular weight 
MBL. No indication for extrahepatic production of serum MBL could be obtained. 
The presence of MBL variant alleles in the MBL gene of the donor liver, but not in 
the recipient, was associated with a strongly increased incidence of clinically sig-
nifi cant infections following transplantation in a gene-dose-dependent way. It was 
concluded that serum MBL is produced by the liver under strong genetic control, 
and established that the liver is the primary producer of serum MBL. Following liver 
transplantation, the MBL genotype of the donor liver is a major risk determinant for 
life-threatening infections.
The ability to unambiguously identify a group of patients severely prone to infec-
tion post transplantation is of signifi cant clinical value. In an era of donor short-
age, donor selection based upon MBL genotype is inconceivable. However, this 
study suggests that patients receiving an ‘MBL-variant’ liver could benefi t from MBL 
replacement therapy similar to that presently being studied in phase I/II and III 
studies (17; 18). Furthermore, prophylactic approaches including intensifi ed clini-
cal follow-up, preemptive antimicrobal therapy, and prolonged selective digestive 
decontamination could be considered dependent on the MBL genotype of the liver 
donor. Moreover, administering intravenous immunoglobulins (IVIg) should be con-
sidered. By administering a diverse repertoire of immunoglobulins that possess the 
same wide spectrum of antibacterial, antiviral and antifungal specifi cities as MBL, 
IVIg could compensate MBL defi ciency via the CP. As clearly shown in chapter 2, 
complement activation by prototypic MBL ligands can be achieved in MBL-defi cient 
serum via the antibody-mediated activation of the classical pathway, thus compen-
sating MBL defi ciency. 
Having shown the direct implications of MBL defi ciency in liver transplantation, 
randomized clinical intervention studies should be set up in transplant patients re-
ceiving an MBL variant liver in order to diminish the increased susceptibility to 
life-threatening infections.
Adaptive immunity in pancreatic islet transplantation
As shown and discussed in chapter 3, type 1 diabetes is an autoimmune disease in 
which both adaptive and innate immune processes are involved, ultimately leading 
to beta cell destruction. An attractive novel therapy for type 1 diabetes is pancreatic 
islet transplantation. In order to successfully apply islet transplantation as a treatment 
for diabetes, two distinct tribulations have to be resolved. Primary, the recurrence 
of islet autoimmunity, a process theoretically equivalent to the pathogeneses of 
T1D (chapter 3), should be prevented. It is conceivable that MBL is also involved 
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in this process as implied in chapter 3, however this topic remains subject to future 
investigation. Secondly, to assure pancreatic islet graft survival, it is fundamental 
to prevent alloimmunity resulting in allograft rejection. In order to optimise the 
current islet transplantation, it is essential to study the reaction of T-cells to islets. 
Chapter 5 describes the effect of HLA incompatibility and immunogenicity of hu-
man pancreatic islet preparations and peripheral blood mononuclear cells (PBMC) 
of healthy blood donors. The aim of this study was to examine whether the degree 
of MHC incompatibility between PBMC and donor islet cells is related to the degree 
of proliferative T-cell responses. The experiments included co-culturing of PBMC 
with human islet-cell preparations with a composition similar to that of islet grafts 
used in clinical transplantation trials [i.e. mixed islet lymphocyte reaction (MILR)]. 
PBMCs isolated from immunologically uncompromised healthy blood donors were 
used to exclusively study alloreactivity independently of recurrence of autoreactivity. 
Prominent T-cell responses were observed in the vast majority of cases of complete 
HLA class II-mismatches. Intermediate T-cell responsiveness was observed in single 
HLA class II mismatches, whereas HLA-matches islet preparations did not induce a 
T-cell response. 
These results identify the potential immunogenicity of islet preparations trans-
planted between HLA-DR incompatible subjects regardless of an autoimmune back-
ground of the recipient. These fi ndings underscore the diffi culty of islet allotrans-
plantation, but provide leads to reduce the extent of alloreactivity in clinical islet 
transplantation. 
CONCLUDING REMARKS
The interplay between innate and adaptive immunity is complex and multifaceted 
as chapters 2 and 3 of this thesis show. The benefi cial effect of high MBL serum 
levels in liver transplant patients stand in vast contrast to the potential harmful effect 
of elevated serum MBL levels in diabetic patients emphasizing the pluripotency of 
mannose binding lectin. This paradox is refl ected in chapters 3 and 4. Since the fi rst 
report of the clinical implication of MBL defi ciency somewhat four decades ago (19), 
our knowledge of the lectin pathway has expanded tremendously. Strikingly how-
ever, clinical implementation of our current knowledge occurs tediously lethargic. 
Presently, MBL replacement therapy is being studied in phase I/II and III studies (17; 
18). However several other therapeutic interventions can be put forward to compen-
sate for MBL defi ciency in immunocompromised patients, including intensifi ed clini-
cal follow-up and preemptive antimicrobal therapy. Intravenous and subcutaneous 
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immunoglobulin administration might also be an alternative therapy to counterweigh 
a malfunctioning lectin pathway (20; 21).
Finally, pancreatic islet transplantation as a potential therapy for diabetes currently 
remains an immunological pitfall. Major hurdles include the occurrence of alloim-
munity and the recurrence of autoimmunity. Further complicating immunological 
disentanglement is the fact that both innate and adaptive immunity appear to be 
involved. Presently islet graft rejection can only be counteracted by pharmacological 
immune suppression. The substitution of insulin replacement therapy by immune 
suppressive drugs is a debatable issue, which should be evaluated conscientiously 
by physicians and patients, taking both short and long term perils into account. 
Currently, diabetic patients appear to be stuck between a rock and a hard place. 
Therefore studies aimed to identify immunological aspects of islet transplantation are 
of eminent importance in order to optimalize immune suppressive therapy and to 
reduce morbidity and mortality.
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De term immuniteit is afgeleid van het Latijnse woord immunitas, dat refereert 
aan de vrijstelling die Romeinse senatoren hadden van civiele verplichtingen, zoals 
bijvoorbeeld dienstplicht en wettelijk vastgelegde vervolging. Sinds het Romeinse 
tijdperk heeft de term immuniteit meer de betekenis gekregen van het resistent zijn 
tegen infecties. Het immuunsysteem is een complexe verzameling van cellen en 
moleculen, die het lichaam laat functioneren in een habitat vol ziekteverwekkers 
(pathogenen), zoals bacteriën en virussen. 
Het immuunsysteem kan worden ingedeeld in natuurlijke en specifi eke immu-
niteit. Deze indeling is gebaseerd op het vermogen van het specifi eke deel van 
het immuunsysteem om bij herhaalde infecties een versterkte immuunrespons te 
genereren. Natuurlijke immuniteit is het deel van het immuunsysteem dat reeds bij 
de geboorte aanwezig is en continu is qua intensiteit bij herhaalde infecties.
Er zijn situaties waarin een te hard werkend immuunsysteem nadelig kan zijn. 
Twee voorbeelden waarin excessieve immuunrespons negatieve gevolgen heeft 
zijn auto-immuunziekten (bijvoorbeeld type 1 diabetes) en transplantatie. Het on-
vermogen om lichaamseigen cellen en eiwitten te onderscheiden van pathogene 
eiwitten en micro-organismen kan resulteren in auto-immuunziekten, welke leiden 
tot weefsel- en/of orgaanschade. Na een transplantatie kan het immuunsysteem het 
getransplanteerde orgaan als pathogeen herkennen en een immuunrespons initiëren, 
hetgeen kan leiden tot zowel acute- als chronische afstoting.
Het doel van dit proefschrift is om inzicht te verkrijgen in immunologische aspec-
ten van transplantatie en diabetes. De nadruk ligt op Mannose Binding Lectin (MBL) 
als cruciaal onderdeel van de natuurlijke immuniteit.
Hoofdstuk 1 beschrijft de verschillende moleculaire en immunologische eigen-
schappen van Mannose Binding Lectin als onderdeel van het complementsysteem.
Het complementsysteem bestaat uit drie verschillende routes: de klassieke route, 
de alternatieve route en de lectine route. Hoewel alle drie routes van het comple-
ment systeem op verschillende wijzen worden geactiveerd, resulteren ze alle in akti-
vatie van het complement systeem. De vijf biologische functies van het complement 
systeem zijn 1) complement-gemedieerde cytolysis (celdood); 2) opsonisatie van 
lichaamsvreemde organismen; 3) activatie van ontsteking; 4) klaren van lichaamsei-
gen- en lichaamsvreemde débris; 5) versterken van de specifi eke immuunrespons 
(fi guur 1, hoofdstuk 1).
De lectine route wordt geactiveerd wanneer MBL bindt aan koolhydraatstructuren 
welke aanwezig zijn op een groot aantal micro-organismen. In de algemene popu-
latie bestaat er een grote variatie aan MBL-concentratie in het bloed. Dit concentra-
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tieverschil is erfelijke bepaald door verschillende variante genen die leiden tot een 
lage MBL-productie en gestoorde MBL-functie.
Een defi ciënte lectine route door een gestoorde MBL-functie dan wel een te lage 
MBL-concentratie, resulteert in vatbaarheid voor infectie. Een overdreven lectine 
route gemedieerde complementactivatie zou kunnen leiden tot weefsel- en orgaan-
schade. Deze bipolaire verhouding wordt in hoofdstuk 1 besproken aan de hand van 
een overzicht van verschillende ziekten, geassocieerd met een hoge dan wel lage 
MBL concentratie.
Moleculaire en immunologische karakteristieken van MBL
In hoofdstuk 2 worden in drie delen functionele karakteristieken van MBL be-
schreven. Het eerste deel van dit hoofdstuk beschrijft de functionele karakterisatie 
van de lectine route in normaal humaan bloed. Een nieuwe techniek wordt be-
schreven waarmee complementactivatie via de lectine route kan worden gemeten. 
Het tweede deel beschrijft de relatie tussen MBL-genotype en MBL-functionaliteit. 
Verder wordt er in dit deel ingegaan op de observatie, dat humaan bloed antili-
chamen bevat die gericht zijn tegen mannan, een koolhydraat dat typisch door 
MBL wordt gebonden. De hoge frequentie aan variante MBL genen in de populatie 
zou een aanwijzing kunnen zijn, dat er een alternatief immuun mechanisme is, dat 
compenseert voor MBL defi ciëntie. Om deze hypothese te staven werd complement 
activatie bestudeerd door middel van moleculen welke typisch worden gebonden 
door MBL (MBL-liganden). Hieruit bleek dat het prototypische MBL-ligand, mannan, 
complementactivatie kan bewerkstelligen via zowel de lectine route als de klassieke 
route. Verder kan ook het eiwit “protein 60” van de bacterie Listeria monocytogenes, 
zowel via de lectine route als via de klassieke route het complementsysteem acti-
veren. Er kan geconcludeerd worden dat, tot op zekere hoogte, de klassieke route 
van het complement systeem kan compenseren voor een defi ciëntie van de lectine 
route in MBL-defi ciënte individuen.
Het laatste deel van dit hoofdstuk beschrijft de binding van MBL aan polymeer 
serum IgA als nieuw mechanisme van complement activatie via de lectine route. 
Deze vorm van complement activatie zou kunnen leiden tot een synergistisch effect 
op de antimicrobiële werking van MBL en IgA, met name in het mucosale immuun-
systeem.
MBL en type I diabetes
Type 1 (insuline afhankelijke) diabetes mellitus (T1D) is een auto-immuunziekte, 
die gekarakteriseerd wordt door de specifi eke destructie van insuline producerende 
bètacellen in het pancreas (alvleesklier). De rol van het specifi eke immuunsysteem 
in het complexe auto-immuun dat resulteert in T1D is alom geaccepteerd. Er zijn 
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echter steeds meer aanwijzingen, dat ook de natuurlijke immuniteit betrokken is bij 
het ontstaan van T1D. Hoofdstuk 3 beschrijft MBL in relatie tot type 1 diabetes. In 
deze studie werden juveniele type 1 diabetische patiënten bij de klinische presenta-
tie van hun ziekte bestudeerd. Patiënten werden vergeleken met hun gezonde (niet-
diabetische) broers of zussen (“familie controles”) en met gezonde bloeddonoren. 
Zowel MBL-bloedconcentratie als MBL-activiteit werden bepaald, alsook het MBL-
genotype. Genetisch werden er geen verschillen aangetoond tussen de patiënten en 
de gezonde bloeddonoren. Echter, nadat zowel patiënten als hun familiecontroles 
ingedeeld waren aan de hand van hun genetische MBL achtergrond, bleken diabe-
tische patiënten zowel een hogere MBL-bloedconcentratie te hebben als een hogere 
MBL-activiteit. Verder bleek de MBL-activiteit meer verhoogd te zijn dan verklaard 
kon worden aan de hand van MBL-concentratiestijging. Geconcludeerd wordt dat 
MBL-concentratie en activiteit verhoogd is bij T1D patiënten bij klinische presentatie, 
hetgeen een mogelijke rol voor MBL weglegt in de pathogenese (wijze waarop een 
ziekte ontstaat) van type 1 diabetes. 
MBL en levertransplantatie
Infectie is de primaire doodsoorzaak na levertransplantatie. Om geen afstotingsreac-
tie tegen het getransplanteerde orgaan te ontwikkelen, moeten transplantatiepatiënt-
en geneesmiddelen innemen die het immuunsysteem onderdrukken. Omdat deze 
geneesmiddelen de specifi eke immuniteit onderdrukken, vallen de patiënten voor 
een groot deel terug op hun natuurlijke immuniteit om infecties te voorkomen. In 
hoofdstuk 4 wordt het effect beschreven van MBL-defi ciënte genotypen op de 
vatbaarheid van infecties na levertransplantatie. Verder wordt getoetst of de lever 
de voornaamste producent is van MBL, zoals wordt aangenomen. Negenenveertig 
levertransplantatiepatiënten werden bestudeerd. MBL-concentratie in het bloed werd 
kort voor transplantatie en gedurende 1 jaar na transplantatie gemeten. Van zowel de 
donorlever als van de patiënt werd het volledig MBL-genotype bepaald. Gedurende 
een periode van 1 jaar na transplantatie werden levensbedreigende infecties gecor-
releerd aan het MBL-genotype van de ontvanger en aan het MBL-genotype van de 
donorlever. De in dit hoofdstuk beschreven studie laat zien dat na transplantatie, 
de donorlever de MBL-serumconcentratie bepaalt, onafhankelijk van het genotype 
van de ontvanger. Verder toont deze studie dat patiënten die een MBL-defi ciënte 
donorlever ontvangen een bijna viermaal hoger risico hebben op levensbedreigende 
infecties in het eerste jaar na transplantatie.
Speciﬁ eke immuniteit bij transplantatie van eilandjes van Langerhans 
Zoals reeds besproken in hoofdstuk 3 is type 1 diabetes een auto-immuunziekte 
waarbij zowel specifi eke- als natuurlijke immuniteit betrokken zijn, die uiteindelijk 
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resulteert in destructie van insuline-producerende bètacellen in het pancreas. Een 
nieuwe en hoopgevende therapie voor T1D is het transplanteren van bètacellen in 
eilandjes van Langerhans. Echter, om een dergelijke transplantatie succesvol te laten 
zijn moeten twee grote obstakels worden overwonnen. Ten eerste moet de terug-
keer van het auto-immuunproces, leidend tot bètaceldestructie, worden voorkómen 
(hoofdstuk 3). Ten tweede moet worden voorkómen dat er afstoting plaats vindt van 
de getransplanteerde eilandjes. Hoofdrolspelers in de specifi eke immuniteit en in 
afstootreacties zijn de T-cellen van het immuunsysteem. Om een goede overleving 
van de getransplanteerde eilandjes te krijgen is het van groot belang de reactie van 
T-cellen te bestuderen, om zo gericht geneesmiddelen te kunnen ontwikkelen om 
de afstootreactie tegen te kunnen gaan.
De werking van T-cellen berust op het herkennen van HLA-moleculen. Dit zijn 
moleculen die op (bijna) alle cellen van het lichaam aanwezig zijn en aangeven 
of een cel lichaamseigen, dan wel lichaamsvreemd is. In Hoofdstuk 5 wordt het 
onderzoek beschreven waarin de immuunreactie van T-cellen wordt onderzocht aan 
de hand van het verschil van HLA-moleculen tussen T-cellen en eilandjes. Gecon-
cludeerd wordt dat reeds bij geringe verschillen van HLA tussen T-cellen van de 
ontvanger en donoreilandjes een T-cel immuunrespons waarneembaar is. Deze im-
muunrespons treedt niet op wanneer T-cellen van de ontvanger HLA-identiek zijn 
aan de donoreilandjes.
In de klinische praktijk is implementatie van basaal wetenschappelijke onder-
zoeksresultaten een zeer moeizame onderneming. In dit proefschrift is getracht de 
consequenties van basaal wetenschappelijke bevindingen voor de kliniek in kaart te 
brengen. De toekomst moet leren of deze vertaalslag van fundamentele wetenschap 
naar klinische praktijk waardevol is gebleken.
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